#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=In cocaine dependence, neural prediction errors during loss avoidance are increased with cocaine deprivation and predict drug use
#Text=Background:
#Text=In substance dependent individuals, drug-deprivation and drug-use trigger divergent behavioral responses to environmental cues.
1-1	0-2	In	_	
1-2	3-10	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-3	11-21	dependence	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[1]	
1-4	21-22	,	_	
1-5	23-29	neural	_	
1-6	30-40	prediction	_	
1-7	41-47	errors	_	
1-8	48-54	during	_	
1-9	55-59	loss	_	
1-10	60-69	avoidance	_	
1-11	70-73	are	_	
1-12	74-83	increased	_	
1-13	84-88	with	_	
1-14	89-96	cocaine	_	
1-15	97-108	deprivation	_	
1-16	109-112	and	_	
1-17	113-120	predict	_	
1-18	121-125	drug	_	
1-19	126-129	use	_	
1-20	130-140	Background	_	
1-21	140-141	:	_	
1-22	142-144	In	_	
1-23	145-154	substance	_	
1-24	155-164	dependent	_	
1-25	165-176	individuals	_	
1-26	176-177	,	_	
1-27	178-194	drug-deprivation	_	
1-28	195-198	and	_	
1-29	199-207	drug-use	_	
1-30	208-215	trigger	_	
1-31	216-225	divergent	_	
1-32	226-236	behavioral	_	
1-33	237-246	responses	_	
1-34	247-249	to	_	
1-35	250-263	environmental	_	
1-36	264-268	cues	_	
1-37	268-269	.	_	

#Text=These divergent responses are consonant with data showing that short- and long-term adaptations in dopamine signaling are similarly sensitive to state of drug-use.
2-1	270-275	These	_	
2-2	276-285	divergent	_	
2-3	286-295	responses	_	
2-4	296-299	are	_	
2-5	300-309	consonant	_	
2-6	310-314	with	_	
2-7	315-319	data	_	
2-8	320-327	showing	_	
2-9	328-332	that	_	
2-10	333-338	short	_	
2-11	338-339	-	_	
2-12	340-343	and	_	
2-13	344-353	long-term	_	
2-14	354-365	adaptations	_	
2-15	366-368	in	_	
2-16	369-377	dopamine	_	
2-17	378-387	signaling	_	
2-18	388-391	are	_	
2-19	392-401	similarly	_	
2-20	402-411	sensitive	_	
2-21	412-414	to	_	
2-22	415-420	state	_	
2-23	421-423	of	_	
2-24	424-432	drug-use	_	
2-25	432-433	.	_	

#Text=These literatures suggest a drug-state dependent role of learning in maintaining substance use; evidence linking dopamine to both reinforcement learning and addiction provides a framework to test this possibility.
3-1	434-439	These	_	
3-2	440-451	literatures	_	
3-3	452-459	suggest	_	
3-4	460-461	a	_	
3-5	462-472	drug-state	_	
3-6	473-482	dependent	_	
3-7	483-487	role	_	
3-8	488-490	of	_	
3-9	491-499	learning	_	
3-10	500-502	in	_	
3-11	503-514	maintaining	_	
3-12	515-524	substance	_	
3-13	525-528	use	_	
3-14	528-529	;	_	
3-15	530-538	evidence	_	
3-16	539-546	linking	_	
3-17	547-555	dopamine	_	
3-18	556-558	to	_	
3-19	559-563	both	_	
3-20	564-577	reinforcement	_	
3-21	578-586	learning	_	
3-22	587-590	and	_	
3-23	591-600	addiction	_	
3-24	601-609	provides	_	
3-25	610-611	a	_	
3-26	612-621	framework	_	
3-27	622-624	to	_	
3-28	625-629	test	_	
3-29	630-634	this	_	
3-30	635-646	possibility	_	
3-31	646-647	.	_	

#Text=Methods:
#Text=In a randomized crossover design, 22 participants with current cocaine use disorder completed a probabilistic loss-learning task during functional MRI while on- and off-cocaine (44 sessions). 54 participants without Axis-I psychopathology served as a secondary reference group.
4-1	648-655	Methods	_	
4-2	655-656	:	_	
4-3	657-659	In	_	
4-4	660-661	a	_	
4-5	662-672	randomized	_	
4-6	673-682	crossover	_	
4-7	683-689	design	_	
4-8	689-690	,	_	
4-9	691-693	22	_	
4-10	694-706	participants	_	
4-11	707-711	with	_	
4-12	712-719	current	_	
4-13	720-727	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
4-14	728-731	use	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
4-15	732-740	disorder	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[2]	
4-16	741-750	completed	_	
4-17	751-752	a	_	
4-18	753-766	probabilistic	_	
4-19	767-780	loss-learning	_	
4-20	781-785	task	_	
4-21	786-792	during	_	
4-22	793-803	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-23	804-807	MRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[3]	
4-24	808-813	while	_	
4-25	814-816	on	_	
4-26	816-817	-	_	
4-27	818-821	and	_	
4-28	822-833	off-cocaine	_	
4-29	834-835	(	_	
4-30	835-837	44	_	
4-31	838-846	sessions	_	
4-32	846-847	)	_	
4-33	847-848	.	_	
4-34	849-851	54	_	
4-35	852-864	participants	_	
4-36	865-872	without	_	
4-37	873-879	Axis-I	_	
4-38	880-895	psychopathology	_	
4-39	896-902	served	_	
4-40	903-905	as	_	
4-41	906-907	a	_	
4-42	908-917	secondary	_	
4-43	918-927	reference	_	
4-44	928-933	group	_	
4-45	933-934	.	_	

#Text=Within-drug state and paired-subjects’ learning effects were assessed with computational-model derived individual learning parameters.
5-1	935-946	Within-drug	_	
5-2	947-952	state	_	
5-3	953-956	and	_	
5-4	957-972	paired-subjects	_	
5-5	972-973	’	_	
5-6	974-982	learning	_	
5-7	983-990	effects	_	
5-8	991-995	were	_	
5-9	996-1004	assessed	_	
5-10	1005-1009	with	_	
5-11	1010-1029	computational-model	_	
5-12	1030-1037	derived	_	
5-13	1038-1048	individual	_	
5-14	1049-1057	learning	_	
5-15	1058-1068	parameters	_	
5-16	1068-1069	.	_	

#Text=Model-based neuroimaging analyses evaluated effects of drug-use state on neural learning signals.
6-1	1070-1081	Model-based	_	
6-2	1082-1094	neuroimaging	_	
6-3	1095-1103	analyses	_	
6-4	1104-1113	evaluated	_	
6-5	1114-1121	effects	_	
6-6	1122-1124	of	_	
6-7	1125-1133	drug-use	_	
6-8	1134-1139	state	_	
6-9	1140-1142	on	_	
6-10	1143-1149	neural	_	
6-11	1150-1158	learning	_	
6-12	1159-1166	signals	_	
6-13	1166-1167	.	_	

#Text=Relationships among model-derived behavioral learning rates (α+, α-), neural prediction error signals (δ+, δ-), cocaine use, and desire to use were assessed.
7-1	1168-1181	Relationships	_	
7-2	1182-1187	among	_	
7-3	1188-1201	model-derived	_	
7-4	1202-1212	behavioral	_	
7-5	1213-1221	learning	_	
7-6	1222-1227	rates	_	
7-7	1228-1229	(	_	
7-8	1229-1230	α	_	
7-9	1230-1231	+	_	
7-10	1231-1232	,	_	
7-11	1233-1234	α	_	
7-12	1234-1235	-	_	
7-13	1235-1236	)	_	
7-14	1236-1237	,	_	
7-15	1238-1244	neural	_	
7-16	1245-1255	prediction	_	
7-17	1256-1261	error	_	
7-18	1262-1269	signals	_	
7-19	1270-1271	(	_	
7-20	1271-1272	δ	_	
7-21	1272-1273	+	_	
7-22	1273-1274	,	_	
7-23	1275-1276	δ	_	
7-24	1276-1277	-	_	
7-25	1277-1278	)	_	
7-26	1278-1279	,	_	
7-27	1280-1287	cocaine	_	
7-28	1288-1291	use	_	
7-29	1291-1292	,	_	
7-30	1293-1296	and	_	
7-31	1297-1303	desire	_	
7-32	1304-1306	to	_	
7-33	1307-1310	use	_	
7-34	1311-1315	were	_	
7-35	1316-1324	assessed	_	
7-36	1324-1325	.	_	

#Text=Results:
#Text=During cocaine-deprivation, cocaine dependent individuals exhibited heightened positive learning rates (α+), heightened neural positive prediction error (δ+) responses, and heightened association of α+ with neural δ+ responses.
8-1	1326-1333	Results	_	
8-2	1333-1334	:	_	
8-3	1335-1341	During	_	
8-4	1342-1361	cocaine-deprivation	_	
8-5	1361-1362	,	_	
8-6	1363-1370	cocaine	_	
8-7	1371-1380	dependent	_	
8-8	1381-1392	individuals	_	
8-9	1393-1402	exhibited	_	
8-10	1403-1413	heightened	_	
8-11	1414-1422	positive	_	
8-12	1423-1431	learning	_	
8-13	1432-1437	rates	_	
8-14	1438-1439	(	_	
8-15	1439-1440	α	_	
8-16	1440-1441	+	_	
8-17	1441-1442	)	_	
8-18	1442-1443	,	_	
8-19	1444-1454	heightened	_	
8-20	1455-1461	neural	_	
8-21	1462-1470	positive	_	
8-22	1471-1481	prediction	_	
8-23	1482-1487	error	_	
8-24	1488-1489	(	_	
8-25	1489-1490	δ	_	
8-26	1490-1491	+	_	
8-27	1491-1492	)	_	
8-28	1493-1502	responses	_	
8-29	1502-1503	,	_	
8-30	1504-1507	and	_	
8-31	1508-1518	heightened	_	
8-32	1519-1530	association	_	
8-33	1531-1533	of	_	
8-34	1534-1535	α	_	
8-35	1535-1536	+	_	
8-36	1537-1541	with	_	
8-37	1542-1548	neural	_	
8-38	1549-1550	δ	_	
8-39	1550-1551	+	_	
8-40	1552-1561	responses	_	
8-41	1561-1562	.	_	

#Text=The deprivation-enhanced neural learning signals were specific to successful loss avoidance, comparable to non-psychiatric participants, and mediated a relationship between chronicity of drug use and desire to use cocaine.
9-1	1563-1566	The	_	
9-2	1567-1587	deprivation-enhanced	_	
9-3	1588-1594	neural	_	
9-4	1595-1603	learning	_	
9-5	1604-1611	signals	_	
9-6	1612-1616	were	_	
9-7	1617-1625	specific	_	
9-8	1626-1628	to	_	
9-9	1629-1639	successful	_	
9-10	1640-1644	loss	_	
9-11	1645-1654	avoidance	_	
9-12	1654-1655	,	_	
9-13	1656-1666	comparable	_	
9-14	1667-1669	to	_	
9-15	1670-1685	non-psychiatric	_	
9-16	1686-1698	participants	_	
9-17	1698-1699	,	_	
9-18	1700-1703	and	_	
9-19	1704-1712	mediated	_	
9-20	1713-1714	a	_	
9-21	1715-1727	relationship	_	
9-22	1728-1735	between	_	
9-23	1736-1746	chronicity	_	
9-24	1747-1749	of	_	
9-25	1750-1754	drug	_	
9-26	1755-1758	use	_	
9-27	1759-1762	and	_	
9-28	1763-1769	desire	_	
9-29	1770-1772	to	_	
9-30	1773-1776	use	_	
9-31	1777-1784	cocaine	_	
9-32	1784-1785	.	_	

#Text=Conclusions:
#Text=Neurocomputational learning signals are sensitive to drug-use status and suggest that heightened reinforcement by successful avoidance of negative outcomes may contribute to drug seeking during deprivation.
10-1	1786-1797	Conclusions	_	
10-2	1797-1798	:	_	
10-3	1799-1817	Neurocomputational	_	
10-4	1818-1826	learning	_	
10-5	1827-1834	signals	_	
10-6	1835-1838	are	_	
10-7	1839-1848	sensitive	_	
10-8	1849-1851	to	_	
10-9	1852-1860	drug-use	_	
10-10	1861-1867	status	_	
10-11	1868-1871	and	_	
10-12	1872-1879	suggest	_	
10-13	1880-1884	that	_	
10-14	1885-1895	heightened	_	
10-15	1896-1909	reinforcement	_	
10-16	1910-1912	by	_	
10-17	1913-1923	successful	_	
10-18	1924-1933	avoidance	_	
10-19	1934-1936	of	_	
10-20	1937-1945	negative	_	
10-21	1946-1954	outcomes	_	
10-22	1955-1958	may	_	
10-23	1959-1969	contribute	_	
10-24	1970-1972	to	_	
10-25	1973-1977	drug	_	
10-26	1978-1985	seeking	_	
10-27	1986-1992	during	_	
10-28	1993-2004	deprivation	_	
10-29	2004-2005	.	_	

#Text=More generally, attention to drug-use state is important for delineating substrates of addiction.
11-1	2006-2010	More	_	
11-2	2011-2020	generally	_	
11-3	2020-2021	,	_	
11-4	2022-2031	attention	_	
11-5	2032-2034	to	_	
11-6	2035-2043	drug-use	_	
11-7	2044-2049	state	_	
11-8	2050-2052	is	_	
11-9	2053-2062	important	_	
11-10	2063-2066	for	_	
11-11	2067-2078	delineating	_	
11-12	2079-2089	substrates	_	
11-13	2090-2092	of	_	
11-14	2093-2102	addiction	_	
11-15	2102-2103	.	_	

#Text=Introduction
#Text=In substance dependent individuals, responses to negative environmental cues appear to both vary with state of drug use and contribute to continued drug seeking.
12-1	2104-2116	Introduction	_	
12-2	2117-2119	In	_	
12-3	2120-2129	substance	_	
12-4	2130-2139	dependent	_	
12-5	2140-2151	individuals	_	
12-6	2151-2152	,	_	
12-7	2153-2162	responses	_	
12-8	2163-2165	to	_	
12-9	2166-2174	negative	_	
12-10	2175-2188	environmental	_	
12-11	2189-2193	cues	_	
12-12	2194-2200	appear	_	
12-13	2201-2203	to	_	
12-14	2204-2208	both	_	
12-15	2209-2213	vary	_	
12-16	2214-2218	with	_	
12-17	2219-2224	state	_	
12-18	2225-2227	of	_	
12-19	2228-2232	drug	_	
12-20	2233-2236	use	_	
12-21	2237-2240	and	_	
12-22	2241-2251	contribute	_	
12-23	2252-2254	to	_	
12-24	2255-2264	continued	_	
12-25	2265-2269	drug	_	
12-26	2270-2277	seeking	_	
12-27	2277-2278	.	_	

#Text=Specifically, when drug deprived, substance dependent individuals are adept at avoiding negative states, such as withdrawal and isolation, through drug use.
13-1	2279-2291	Specifically	_	
13-2	2291-2292	,	_	
13-3	2293-2297	when	_	
13-4	2298-2302	drug	_	
13-5	2303-2311	deprived	_	
13-6	2311-2312	,	_	
13-7	2313-2322	substance	_	
13-8	2323-2332	dependent	_	
13-9	2333-2344	individuals	_	
13-10	2345-2348	are	_	
13-11	2349-2354	adept	_	
13-12	2355-2357	at	_	
13-13	2358-2366	avoiding	_	
13-14	2367-2375	negative	_	
13-15	2376-2382	states	_	
13-16	2382-2383	,	_	
13-17	2384-2388	such	_	
13-18	2389-2391	as	_	
13-19	2392-2402	withdrawal	_	
13-20	2403-2406	and	_	
13-21	2407-2416	isolation	_	
13-22	2416-2417	,	_	
13-23	2418-2425	through	_	
13-24	2426-2430	drug	_	
13-25	2431-2434	use	_	
13-26	2434-2435	.	_	

#Text=At the same time, when drug using, dependent individuals ignore negative outcomes, including serious social, health, and economic costs.
14-1	2436-2438	At	_	
14-2	2439-2442	the	_	
14-3	2443-2447	same	_	
14-4	2448-2452	time	_	
14-5	2452-2453	,	_	
14-6	2454-2458	when	_	
14-7	2459-2463	drug	_	
14-8	2464-2469	using	_	
14-9	2469-2470	,	_	
14-10	2471-2480	dependent	_	
14-11	2481-2492	individuals	_	
14-12	2493-2499	ignore	_	
14-13	2500-2508	negative	_	
14-14	2509-2517	outcomes	_	
14-15	2517-2518	,	_	
14-16	2519-2528	including	_	
14-17	2529-2536	serious	_	
14-18	2537-2543	social	_	
14-19	2543-2544	,	_	
14-20	2545-2551	health	_	
14-21	2551-2552	,	_	
14-22	2553-2556	and	_	
14-23	2557-2565	economic	_	
14-24	2566-2571	costs	_	
14-25	2571-2572	.	_	

#Text=The divergence between these behavioral responses to negative consequences suggests a drug-state dependent role for loss-learning (i.e., learning about negative outcomes) in maintaining substance use.
15-1	2573-2576	The	_	
15-2	2577-2587	divergence	_	
15-3	2588-2595	between	_	
15-4	2596-2601	these	_	
15-5	2602-2612	behavioral	_	
15-6	2613-2622	responses	_	
15-7	2623-2625	to	_	
15-8	2626-2634	negative	_	
15-9	2635-2647	consequences	_	
15-10	2648-2656	suggests	_	
15-11	2657-2658	a	_	
15-12	2659-2669	drug-state	_	
15-13	2670-2679	dependent	_	
15-14	2680-2684	role	_	
15-15	2685-2688	for	_	
15-16	2689-2702	loss-learning	_	
15-17	2703-2704	(	_	
15-18	2704-2707	i.e	_	
15-19	2707-2708	.	_	
15-20	2708-2709	,	_	
15-21	2710-2718	learning	_	
15-22	2719-2724	about	_	
15-23	2725-2733	negative	_	
15-24	2734-2742	outcomes	_	
15-25	2742-2743	)	_	
15-26	2744-2746	in	_	
15-27	2747-2758	maintaining	_	
15-28	2759-2768	substance	_	
15-29	2769-2772	use	_	
15-30	2772-2773	.	_	

#Text=In particular, these clinical and behavioral data suggest the hypothesis that heightened reinforcement from avoiding negative states may facilitate drug seeking during deprivation, relative to during substance use.
16-1	2774-2776	In	_	
16-2	2777-2787	particular	_	
16-3	2787-2788	,	_	
16-4	2789-2794	these	_	
16-5	2795-2803	clinical	_	
16-6	2804-2807	and	_	
16-7	2808-2818	behavioral	_	
16-8	2819-2823	data	_	
16-9	2824-2831	suggest	_	
16-10	2832-2835	the	_	
16-11	2836-2846	hypothesis	_	
16-12	2847-2851	that	_	
16-13	2852-2862	heightened	_	
16-14	2863-2876	reinforcement	_	
16-15	2877-2881	from	_	
16-16	2882-2890	avoiding	_	
16-17	2891-2899	negative	_	
16-18	2900-2906	states	_	
16-19	2907-2910	may	_	
16-20	2911-2921	facilitate	_	
16-21	2922-2926	drug	_	
16-22	2927-2934	seeking	_	
16-23	2935-2941	during	_	
16-24	2942-2953	deprivation	_	
16-25	2953-2954	,	_	
16-26	2955-2963	relative	_	
16-27	2964-2966	to	_	
16-28	2967-2973	during	_	
16-29	2974-2983	substance	_	
16-30	2984-2987	use	_	
16-31	2987-2988	.	_	

#Text=A largely parallel but related literature linking neural dopamine (DA) systems in reinforcement learning and cocaine addiction provides a framework within which to examine this possibility.
17-1	2989-2990	A	_	
17-2	2991-2998	largely	_	
17-3	2999-3007	parallel	_	
17-4	3008-3011	but	_	
17-5	3012-3019	related	_	
17-6	3020-3030	literature	_	
17-7	3031-3038	linking	_	
17-8	3039-3045	neural	_	
17-9	3046-3054	dopamine	_	
17-10	3055-3056	(	_	
17-11	3056-3058	DA	_	
17-12	3058-3059	)	_	
17-13	3060-3067	systems	_	
17-14	3068-3070	in	_	
17-15	3071-3084	reinforcement	_	
17-16	3085-3093	learning	_	
17-17	3094-3097	and	_	
17-18	3098-3105	cocaine	_	
17-19	3106-3115	addiction	_	
17-20	3116-3124	provides	_	
17-21	3125-3126	a	_	
17-22	3127-3136	framework	_	
17-23	3137-3143	within	_	
17-24	3144-3149	which	_	
17-25	3150-3152	to	_	
17-26	3153-3160	examine	_	
17-27	3161-3165	this	_	
17-28	3166-3177	possibility	_	
17-29	3177-3178	.	_	

#Text=Extant data show that while acute cocaine use increases striatal DA, chronic cocaine use decreases postsynaptic DA receptor availability.
18-1	3179-3185	Extant	_	
18-2	3186-3190	data	_	
18-3	3191-3195	show	_	
18-4	3196-3200	that	_	
18-5	3201-3206	while	_	
18-6	3207-3212	acute	_	
18-7	3213-3220	cocaine	_	
18-8	3221-3224	use	_	
18-9	3225-3234	increases	_	
18-10	3235-3243	striatal	_	
18-11	3244-3246	DA	_	
18-12	3246-3247	,	_	
18-13	3248-3255	chronic	_	
18-14	3256-3263	cocaine	_	
18-15	3264-3267	use	_	
18-16	3268-3277	decreases	_	
18-17	3278-3290	postsynaptic	_	
18-18	3291-3293	DA	_	
18-19	3294-3302	receptor	_	
18-20	3303-3315	availability	_	
18-21	3315-3316	.	_	

#Text=These short- and long-term neurophysiological adaptations together contribute to changes in DA signaling and detection that are sensitive to state of drug use; for reviews, see.
19-1	3317-3322	These	_	
19-2	3323-3328	short	_	
19-3	3328-3329	-	_	
19-4	3330-3333	and	_	
19-5	3334-3343	long-term	_	
19-6	3344-3362	neurophysiological	_	
19-7	3363-3374	adaptations	_	
19-8	3375-3383	together	_	
19-9	3384-3394	contribute	_	
19-10	3395-3397	to	_	
19-11	3398-3405	changes	_	
19-12	3406-3408	in	_	
19-13	3409-3411	DA	_	
19-14	3412-3421	signaling	_	
19-15	3422-3425	and	_	
19-16	3426-3435	detection	_	
19-17	3436-3440	that	_	
19-18	3441-3444	are	_	
19-19	3445-3454	sensitive	_	
19-20	3455-3457	to	_	
19-21	3458-3463	state	_	
19-22	3464-3466	of	_	
19-23	3467-3471	drug	_	
19-24	3472-3475	use	_	
19-25	3475-3476	;	_	
19-26	3477-3480	for	_	
19-27	3481-3488	reviews	_	
19-28	3488-3489	,	_	
19-29	3490-3493	see	_	
19-30	3493-3494	.	_	

#Text=In addition, related evidence indicates that during healthy reinforcement learning, DA release encodes prediction errors (δ; signaling ‘better’ or ‘worse’ than expected) which have detectable correlates in human striatum.
20-1	3495-3497	In	_	
20-2	3498-3506	addition	_	
20-3	3506-3507	,	_	
20-4	3508-3515	related	_	
20-5	3516-3524	evidence	_	
20-6	3525-3534	indicates	_	
20-7	3535-3539	that	_	
20-8	3540-3546	during	_	
20-9	3547-3554	healthy	_	
20-10	3555-3568	reinforcement	_	
20-11	3569-3577	learning	_	
20-12	3577-3578	,	_	
20-13	3579-3581	DA	_	
20-14	3582-3589	release	_	
20-15	3590-3597	encodes	_	
20-16	3598-3608	prediction	_	
20-17	3609-3615	errors	_	
20-18	3616-3617	(	_	
20-19	3617-3618	δ	_	
20-20	3618-3619	;	_	
20-21	3620-3629	signaling	_	
20-22	3630-3631	‘	_	
20-23	3631-3637	better	_	
20-24	3637-3638	’	_	
20-25	3639-3641	or	_	
20-26	3642-3643	‘	_	
20-27	3643-3648	worse	_	
20-28	3648-3649	’	_	
20-29	3650-3654	than	_	
20-30	3655-3663	expected	_	
20-31	3663-3664	)	_	
20-32	3665-3670	which	_	
20-33	3671-3675	have	_	
20-34	3676-3686	detectable	_	
20-35	3687-3697	correlates	_	
20-36	3698-3700	in	_	
20-37	3701-3706	human	_	
20-38	3707-3715	striatum	_	
20-39	3715-3716	.	_	

#Text=Together, these literatures suggest that in the case of substance dependence, DA-related learning signals are likely to be enhanced with drug deprivation, as DA receptors are relatively freed, allowing the detection of prediction errors.
21-1	3717-3725	Together	_	
21-2	3725-3726	,	_	
21-3	3727-3732	these	_	
21-4	3733-3744	literatures	_	
21-5	3745-3752	suggest	_	
21-6	3753-3757	that	_	
21-7	3758-3760	in	_	
21-8	3761-3764	the	_	
21-9	3765-3769	case	_	
21-10	3770-3772	of	_	
21-11	3773-3782	substance	_	
21-12	3783-3793	dependence	_	
21-13	3793-3794	,	_	
21-14	3795-3805	DA-related	_	
21-15	3806-3814	learning	_	
21-16	3815-3822	signals	_	
21-17	3823-3826	are	_	
21-18	3827-3833	likely	_	
21-19	3834-3836	to	_	
21-20	3837-3839	be	_	
21-21	3840-3848	enhanced	_	
21-22	3849-3853	with	_	
21-23	3854-3858	drug	_	
21-24	3859-3870	deprivation	_	
21-25	3870-3871	,	_	
21-26	3872-3874	as	_	
21-27	3875-3877	DA	_	
21-28	3878-3887	receptors	_	
21-29	3888-3891	are	_	
21-30	3892-3902	relatively	_	
21-31	3903-3908	freed	_	
21-32	3908-3909	,	_	
21-33	3910-3918	allowing	_	
21-34	3919-3922	the	_	
21-35	3923-3932	detection	_	
21-36	3933-3935	of	_	
21-37	3936-3946	prediction	_	
21-38	3947-3953	errors	_	
21-39	3953-3954	.	_	

#Text=A few previous studies that have examined neural substrates of contingency learning in cocaine dependence have primarily focused on reward-learning and found decreased prediction error signaling in cocaine dependent individuals compared with controls (; see who report greater baseline neural win responses in successful future abstainers)
#Text=To evaluate cocaine-state modulation of learning signals and assess the potential drug-state dependent role of loss-learning mechanisms in maintaining substance dependence, we tested cocaine-dependent individuals in a loss-learning task both during cocaine deprivation and when using cocaine as usual.
22-1	3955-3956	A	_	
22-2	3957-3960	few	_	
22-3	3961-3969	previous	_	
22-4	3970-3977	studies	_	
22-5	3978-3982	that	_	
22-6	3983-3987	have	_	
22-7	3988-3996	examined	_	
22-8	3997-4003	neural	_	
22-9	4004-4014	substrates	_	
22-10	4015-4017	of	_	
22-11	4018-4029	contingency	_	
22-12	4030-4038	learning	_	
22-13	4039-4041	in	_	
22-14	4042-4049	cocaine	_	
22-15	4050-4060	dependence	_	
22-16	4061-4065	have	_	
22-17	4066-4075	primarily	_	
22-18	4076-4083	focused	_	
22-19	4084-4086	on	_	
22-20	4087-4102	reward-learning	_	
22-21	4103-4106	and	_	
22-22	4107-4112	found	_	
22-23	4113-4122	decreased	_	
22-24	4123-4133	prediction	_	
22-25	4134-4139	error	_	
22-26	4140-4149	signaling	_	
22-27	4150-4152	in	_	
22-28	4153-4160	cocaine	_	
22-29	4161-4170	dependent	_	
22-30	4171-4182	individuals	_	
22-31	4183-4191	compared	_	
22-32	4192-4196	with	_	
22-33	4197-4205	controls	_	
22-34	4206-4207	(	_	
22-35	4207-4208	;	_	
22-36	4209-4212	see	_	
22-37	4213-4216	who	_	
22-38	4217-4223	report	_	
22-39	4224-4231	greater	_	
22-40	4232-4240	baseline	_	
22-41	4241-4247	neural	_	
22-42	4248-4251	win	_	
22-43	4252-4261	responses	_	
22-44	4262-4264	in	_	
22-45	4265-4275	successful	_	
22-46	4276-4282	future	_	
22-47	4283-4293	abstainers	_	
22-48	4293-4294	)	_	
22-49	4295-4297	To	_	
22-50	4298-4306	evaluate	_	
22-51	4307-4320	cocaine-state	_	
22-52	4321-4331	modulation	_	
22-53	4332-4334	of	_	
22-54	4335-4343	learning	_	
22-55	4344-4351	signals	_	
22-56	4352-4355	and	_	
22-57	4356-4362	assess	_	
22-58	4363-4366	the	_	
22-59	4367-4376	potential	_	
22-60	4377-4387	drug-state	_	
22-61	4388-4397	dependent	_	
22-62	4398-4402	role	_	
22-63	4403-4405	of	_	
22-64	4406-4419	loss-learning	_	
22-65	4420-4430	mechanisms	_	
22-66	4431-4433	in	_	
22-67	4434-4445	maintaining	_	
22-68	4446-4455	substance	_	
22-69	4456-4466	dependence	_	
22-70	4466-4467	,	_	
22-71	4468-4470	we	_	
22-72	4471-4477	tested	_	
22-73	4478-4495	cocaine-dependent	_	
22-74	4496-4507	individuals	_	
22-75	4508-4510	in	_	
22-76	4511-4512	a	_	
22-77	4513-4526	loss-learning	_	
22-78	4527-4531	task	_	
22-79	4532-4536	both	_	
22-80	4537-4543	during	_	
22-81	4544-4551	cocaine	_	
22-82	4552-4563	deprivation	_	
22-83	4564-4567	and	_	
22-84	4568-4572	when	_	
22-85	4573-4578	using	_	
22-86	4579-4586	cocaine	_	
22-87	4587-4589	as	_	
22-88	4590-4595	usual	_	
22-89	4595-4596	.	_	

#Text=Using a computational psychiatry approach, we assessed behavioral and neural learning substrates, in the form of model-derived learning rate parameters and striatal encoding of prediction errors, respectively, and tested the relationship of neural learning signals to measures of drug use and dependence.
23-1	4597-4602	Using	_	
23-2	4603-4604	a	_	
23-3	4605-4618	computational	_	
23-4	4619-4629	psychiatry	_	
23-5	4630-4638	approach	_	
23-6	4638-4639	,	_	
23-7	4640-4642	we	_	
23-8	4643-4651	assessed	_	
23-9	4652-4662	behavioral	_	
23-10	4663-4666	and	_	
23-11	4667-4673	neural	_	
23-12	4674-4682	learning	_	
23-13	4683-4693	substrates	_	
23-14	4693-4694	,	_	
23-15	4695-4697	in	_	
23-16	4698-4701	the	_	
23-17	4702-4706	form	_	
23-18	4707-4709	of	_	
23-19	4710-4723	model-derived	_	
23-20	4724-4732	learning	_	
23-21	4733-4737	rate	_	
23-22	4738-4748	parameters	_	
23-23	4749-4752	and	_	
23-24	4753-4761	striatal	_	
23-25	4762-4770	encoding	_	
23-26	4771-4773	of	_	
23-27	4774-4784	prediction	_	
23-28	4785-4791	errors	_	
23-29	4791-4792	,	_	
23-30	4793-4805	respectively	_	
23-31	4805-4806	,	_	
23-32	4807-4810	and	_	
23-33	4811-4817	tested	_	
23-34	4818-4821	the	_	
23-35	4822-4834	relationship	_	
23-36	4835-4837	of	_	
23-37	4838-4844	neural	_	
23-38	4845-4853	learning	_	
23-39	4854-4861	signals	_	
23-40	4862-4864	to	_	
23-41	4865-4873	measures	_	
23-42	4874-4876	of	_	
23-43	4877-4881	drug	_	
23-44	4882-4885	use	_	
23-45	4886-4889	and	_	
23-46	4890-4900	dependence	_	
23-47	4900-4901	.	_	

#Text=Methods and Materials
#Text=Participants and Experimental Design
#Text=Twenty-two right handed, non-treatment seeking male individuals who met criteria only for current cocaine use disorder without other substance dependencies or comorbid Axis-I psychopathology were enrolled from a larger study on biomarkers of substance use (see Table 1 for demographic information and Supplemental Methods for inclusion/exclusion criteria).
24-1	4902-4909	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
24-2	4910-4913	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
24-3	4914-4923	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[4]	
24-4	4924-4936	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-5	4937-4940	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-6	4941-4953	Experimental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-7	4954-4960	Design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-8	4961-4971	Twenty-two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-9	4972-4977	right	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-10	4978-4984	handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-11	4984-4985	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-12	4986-4999	non-treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-13	5000-5007	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-14	5008-5012	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-15	5013-5024	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-16	5025-5028	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-17	5029-5032	met	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-18	5033-5041	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-19	5042-5046	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-20	5047-5050	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-21	5051-5058	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-22	5059-5066	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
24-23	5067-5070	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
24-24	5071-5079	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]|http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse[6]	
24-25	5080-5087	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-26	5088-5093	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-27	5094-5103	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-28	5104-5116	dependencies	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-29	5117-5119	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-30	5120-5128	comorbid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-31	5129-5135	Axis-I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-32	5136-5151	psychopathology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-33	5152-5156	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-34	5157-5165	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-35	5166-5170	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-36	5171-5172	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-37	5173-5179	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-38	5180-5185	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-39	5186-5188	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-40	5189-5199	biomarkers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-41	5200-5202	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-42	5203-5212	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-43	5213-5216	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-44	5217-5218	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-45	5218-5221	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-46	5222-5227	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-47	5228-5229	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-48	5230-5233	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-49	5234-5245	demographic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-50	5246-5257	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-51	5258-5261	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-52	5262-5274	Supplemental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-53	5275-5282	Methods	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-54	5283-5286	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-55	5287-5296	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-56	5296-5297	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-57	5297-5306	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-58	5307-5315	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-59	5315-5316	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
24-60	5316-5317	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Following an initial lab visit to assess cocaine use and entrance criteria, eligible individuals participated in two subsequent scanning sessions in a within-subject design: In one session, participants were instructed to use cocaine as usual (C+), and in a second session, participants were instructed to abstain from cocaine use for at least 72 hours (C-).
25-1	5318-5327	Following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-2	5328-5330	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-3	5331-5338	initial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-4	5339-5342	lab	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-5	5343-5348	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-6	5349-5351	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-7	5352-5358	assess	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-8	5359-5366	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-9	5367-5370	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-10	5371-5374	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-11	5375-5383	entrance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-12	5384-5392	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-13	5392-5393	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-14	5394-5402	eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-15	5403-5414	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-16	5415-5427	participated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-17	5428-5430	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-18	5431-5434	two	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-19	5435-5445	subsequent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-20	5446-5454	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-21	5455-5463	sessions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-22	5464-5466	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-23	5467-5468	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-24	5469-5483	within-subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-25	5484-5490	design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-26	5490-5491	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-27	5492-5494	In	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-28	5495-5498	one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-29	5499-5506	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-30	5506-5507	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-31	5508-5520	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-32	5521-5525	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-33	5526-5536	instructed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-34	5537-5539	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-35	5540-5543	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-36	5544-5551	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-37	5552-5554	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-38	5555-5560	usual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-39	5561-5562	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-40	5562-5563	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-41	5563-5564	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-42	5564-5565	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-43	5565-5566	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-44	5567-5570	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-45	5571-5573	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-46	5574-5575	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-47	5576-5582	second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-48	5583-5590	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-49	5590-5591	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-50	5592-5604	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-51	5605-5609	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-52	5610-5620	instructed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-53	5621-5623	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-54	5624-5631	abstain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-55	5632-5636	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-56	5637-5644	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-57	5645-5648	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-58	5649-5652	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-59	5653-5655	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-60	5656-5661	least	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-61	5662-5664	72	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-62	5665-5670	hours	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-63	5671-5672	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-64	5672-5673	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-65	5673-5674	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-66	5674-5675	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
25-67	5675-5676	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=Cocaine-use state was verified at each lab visit with urine testing for cocaine metabolites (NIDA 5-panel drug test; Alere, Inc.); C+ and C- sessions were counterbalanced for order.
26-1	5677-5688	Cocaine-use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-2	5689-5694	state	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-3	5695-5698	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-4	5699-5707	verified	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-5	5708-5710	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-6	5711-5715	each	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-7	5716-5719	lab	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-8	5720-5725	visit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-9	5726-5730	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-10	5731-5736	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-11	5737-5744	testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-12	5745-5748	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-13	5749-5756	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-14	5757-5768	metabolites	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-15	5769-5770	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-16	5770-5774	NIDA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-17	5775-5776	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-18	5776-5777	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-19	5777-5782	panel	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-20	5783-5787	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-21	5788-5792	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-22	5792-5793	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-23	5794-5799	Alere	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-24	5799-5800	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-25	5801-5804	Inc	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-26	5804-5805	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-27	5805-5806	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-28	5806-5807	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-29	5808-5809	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-30	5809-5810	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-31	5811-5814	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-32	5815-5816	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-33	5816-5817	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-34	5818-5826	sessions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-35	5827-5831	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-36	5832-5847	counterbalanced	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-37	5848-5851	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-38	5852-5857	order	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
26-39	5857-5858	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	

#Text=All participants provided informed consent and all procedures were approved by the Institutional Review Boards of Baylor College of Medicine and Virginia Tech.
27-1	5859-5862	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-2	5863-5875	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-3	5876-5884	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-4	5885-5893	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-5	5894-5901	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-6	5902-5905	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-7	5906-5909	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-8	5910-5920	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-9	5921-5925	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-10	5926-5934	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-11	5935-5937	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-12	5938-5941	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-13	5942-5955	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-14	5956-5962	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-15	5963-5969	Boards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-16	5970-5972	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-17	5973-5979	Baylor	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-18	5980-5987	College	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-19	5988-5990	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-20	5991-5999	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-21	6000-6003	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-22	6004-6012	Virginia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-23	6013-6017	Tech	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[5]	
27-24	6017-6018	.	_	

#Text=Participants completed a probabilistic loss-learning task (Figure 1A) during fMRI scanning in two separate lab sessions (N = 22, each scanned in both states of cocaine use; see Supplemental Methods for scanning parameters and preprocessing procedures).
28-1	6019-6031	Participants	_	
28-2	6032-6041	completed	_	
28-3	6042-6043	a	_	
28-4	6044-6057	probabilistic	_	
28-5	6058-6071	loss-learning	_	
28-6	6072-6076	task	_	
28-7	6077-6078	(	_	
28-8	6078-6084	Figure	_	
28-9	6085-6087	1A	_	
28-10	6087-6088	)	_	
28-11	6089-6095	during	_	
28-12	6096-6100	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
28-13	6101-6109	scanning	_	
28-14	6110-6112	in	_	
28-15	6113-6116	two	_	
28-16	6117-6125	separate	_	
28-17	6126-6129	lab	_	
28-18	6130-6138	sessions	_	
28-19	6139-6140	(	_	
28-20	6140-6141	N	_	
28-21	6142-6143	=	_	
28-22	6144-6146	22	_	
28-23	6146-6147	,	_	
28-24	6148-6152	each	_	
28-25	6153-6160	scanned	_	
28-26	6161-6163	in	_	
28-27	6164-6168	both	_	
28-28	6169-6175	states	_	
28-29	6176-6178	of	_	
28-30	6179-6186	cocaine	_	
28-31	6187-6190	use	_	
28-32	6190-6191	;	_	
28-33	6192-6195	see	_	
28-34	6196-6208	Supplemental	_	
28-35	6209-6216	Methods	_	
28-36	6217-6220	for	_	
28-37	6221-6229	scanning	_	
28-38	6230-6240	parameters	_	
28-39	6241-6244	and	_	
28-40	6245-6258	preprocessing	_	
28-41	6259-6269	procedures	_	
28-42	6269-6270	)	_	
28-43	6270-6271	.	_	

#Text=The task entailed learning from repeated choices between two losing options (two-arm bandit in the loss domain; see details in Supplemental Methods; adapted from 7, 20), with one having a higher probability of producing the better outcome (i.e., smaller loss).
29-1	6272-6275	The	_	
29-2	6276-6280	task	_	
29-3	6281-6289	entailed	_	
29-4	6290-6298	learning	_	
29-5	6299-6303	from	_	
29-6	6304-6312	repeated	_	
29-7	6313-6320	choices	_	
29-8	6321-6328	between	_	
29-9	6329-6332	two	_	
29-10	6333-6339	losing	_	
29-11	6340-6347	options	_	
29-12	6348-6349	(	_	
29-13	6349-6356	two-arm	_	
29-14	6357-6363	bandit	_	
29-15	6364-6366	in	_	
29-16	6367-6370	the	_	
29-17	6371-6375	loss	_	
29-18	6376-6382	domain	_	
29-19	6382-6383	;	_	
29-20	6384-6387	see	_	
29-21	6388-6395	details	_	
29-22	6396-6398	in	_	
29-23	6399-6411	Supplemental	_	
29-24	6412-6419	Methods	_	
29-25	6419-6420	;	_	
29-26	6421-6428	adapted	_	
29-27	6429-6433	from	_	
29-28	6434-6435	7	_	
29-29	6435-6436	,	_	
29-30	6437-6439	20	_	
29-31	6439-6440	)	_	
29-32	6440-6441	,	_	
29-33	6442-6446	with	_	
29-34	6447-6450	one	_	
29-35	6451-6457	having	_	
29-36	6458-6459	a	_	
29-37	6460-6466	higher	_	
29-38	6467-6478	probability	_	
29-39	6479-6481	of	_	
29-40	6482-6491	producing	_	
29-41	6492-6495	the	_	
29-42	6496-6502	better	_	
29-43	6503-6510	outcome	_	
29-44	6511-6512	(	_	
29-45	6512-6515	i.e	_	
29-46	6515-6516	.	_	
29-47	6516-6517	,	_	
29-48	6518-6525	smaller	_	
29-49	6526-6530	loss	_	
29-50	6530-6531	)	_	
29-51	6531-6532	.	_	

#Text=On each trial, subjects chose between two abstract stimuli and subsequently observed the outcome (Figure 1A).
30-1	6533-6535	On	_	
30-2	6536-6540	each	_	
30-3	6541-6546	trial	_	
30-4	6546-6547	,	_	
30-5	6548-6556	subjects	_	
30-6	6557-6562	chose	_	
30-7	6563-6570	between	_	
30-8	6571-6574	two	_	
30-9	6575-6583	abstract	_	
30-10	6584-6591	stimuli	_	
30-11	6592-6595	and	_	
30-12	6596-6608	subsequently	_	
30-13	6609-6617	observed	_	
30-14	6618-6621	the	_	
30-15	6622-6629	outcome	_	
30-16	6630-6631	(	_	
30-17	6631-6637	Figure	_	
30-18	6638-6640	1A	_	
30-19	6640-6641	)	_	
30-20	6641-6642	.	_	

#Text=Participants were instructed that one option was better than the other and that payment was related to their choices but were not explicitly informed of the outcome probabilities or loss framework.
31-1	6643-6655	Participants	_	
31-2	6656-6660	were	_	
31-3	6661-6671	instructed	_	
31-4	6672-6676	that	_	
31-5	6677-6680	one	_	
31-6	6681-6687	option	_	
31-7	6688-6691	was	_	
31-8	6692-6698	better	_	
31-9	6699-6703	than	_	
31-10	6704-6707	the	_	
31-11	6708-6713	other	_	
31-12	6714-6717	and	_	
31-13	6718-6722	that	_	
31-14	6723-6730	payment	_	
31-15	6731-6734	was	_	
31-16	6735-6742	related	_	
31-17	6743-6745	to	_	
31-18	6746-6751	their	_	
31-19	6752-6759	choices	_	
31-20	6760-6763	but	_	
31-21	6764-6768	were	_	
31-22	6769-6772	not	_	
31-23	6773-6783	explicitly	_	
31-24	6784-6792	informed	_	
31-25	6793-6795	of	_	
31-26	6796-6799	the	_	
31-27	6800-6807	outcome	_	
31-28	6808-6821	probabilities	_	
31-29	6822-6824	or	_	
31-30	6825-6829	loss	_	
31-31	6830-6839	framework	_	
31-32	6839-6840	.	_	

#Text=Trials were presented for a maximum of 36 trials per block or when sufficient learning occurred (see Supplemental Methods for learning criteria).
32-1	6841-6847	Trials	_	
32-2	6848-6852	were	_	
32-3	6853-6862	presented	_	
32-4	6863-6866	for	_	
32-5	6867-6868	a	_	
32-6	6869-6876	maximum	_	
32-7	6877-6879	of	_	
32-8	6880-6882	36	_	
32-9	6883-6889	trials	_	
32-10	6890-6893	per	_	
32-11	6894-6899	block	_	
32-12	6900-6902	or	_	
32-13	6903-6907	when	_	
32-14	6908-6918	sufficient	_	
32-15	6919-6927	learning	_	
32-16	6928-6936	occurred	_	
32-17	6937-6938	(	_	
32-18	6938-6941	see	_	
32-19	6942-6954	Supplemental	_	
32-20	6955-6962	Methods	_	
32-21	6963-6966	for	_	
32-22	6967-6975	learning	_	
32-23	6976-6984	criteria	_	
32-24	6984-6985	)	_	
32-25	6985-6986	.	_	

#Text=Each block consisted of novel stimuli, which required participants to learn the contingencies between stimuli and outcomes within each block.
33-1	6987-6991	Each	_	
33-2	6992-6997	block	_	
33-3	6998-7007	consisted	_	
33-4	7008-7010	of	_	
33-5	7011-7016	novel	_	
33-6	7017-7024	stimuli	_	
33-7	7024-7025	,	_	
33-8	7026-7031	which	_	
33-9	7032-7040	required	_	
33-10	7041-7053	participants	_	
33-11	7054-7056	to	_	
33-12	7057-7062	learn	_	
33-13	7063-7066	the	_	
33-14	7067-7080	contingencies	_	
33-15	7081-7088	between	_	
33-16	7089-7096	stimuli	_	
33-17	7097-7100	and	_	
33-18	7101-7109	outcomes	_	
33-19	7110-7116	within	_	
33-20	7117-7121	each	_	
33-21	7122-7127	block	_	
33-22	7127-7128	.	_	

#Text=An additional group of fifty-four males (see Table S1A for demographics) with no history of Axis-I psychopathology were used as an independent non-psychiatric control sample to identity learning-related striatum activation that could be used as a reference against which to interpret any neural effects observed in the CUD individuals, and to compute non-psychiatric individual parameter estimates for model validation and parameter recovery.
34-1	7129-7131	An	_	
34-2	7132-7142	additional	_	
34-3	7143-7148	group	_	
34-4	7149-7151	of	_	
34-5	7152-7162	fifty-four	_	
34-6	7163-7168	males	_	
34-7	7169-7170	(	_	
34-8	7170-7173	see	_	
34-9	7174-7179	Table	_	
34-10	7180-7183	S1A	_	
34-11	7184-7187	for	_	
34-12	7188-7200	demographics	_	
34-13	7200-7201	)	_	
34-14	7202-7206	with	_	
34-15	7207-7209	no	_	
34-16	7210-7217	history	_	
34-17	7218-7220	of	_	
34-18	7221-7227	Axis-I	_	
34-19	7228-7243	psychopathology	_	
34-20	7244-7248	were	_	
34-21	7249-7253	used	_	
34-22	7254-7256	as	_	
34-23	7257-7259	an	_	
34-24	7260-7271	independent	_	
34-25	7272-7287	non-psychiatric	_	
34-26	7288-7295	control	_	
34-27	7296-7302	sample	_	
34-28	7303-7305	to	_	
34-29	7306-7314	identity	_	
34-30	7315-7331	learning-related	_	
34-31	7332-7340	striatum	_	
34-32	7341-7351	activation	_	
34-33	7352-7356	that	_	
34-34	7357-7362	could	_	
34-35	7363-7365	be	_	
34-36	7366-7370	used	_	
34-37	7371-7373	as	_	
34-38	7374-7375	a	_	
34-39	7376-7385	reference	_	
34-40	7386-7393	against	_	
34-41	7394-7399	which	_	
34-42	7400-7402	to	_	
34-43	7403-7412	interpret	_	
34-44	7413-7416	any	_	
34-45	7417-7423	neural	_	
34-46	7424-7431	effects	_	
34-47	7432-7440	observed	_	
34-48	7441-7443	in	_	
34-49	7444-7447	the	_	
34-50	7448-7451	CUD	http://maven.renci.org/NeuroBridge/neurobridge#CocaineAbuse	
34-51	7452-7463	individuals	_	
34-52	7463-7464	,	_	
34-53	7465-7468	and	_	
34-54	7469-7471	to	_	
34-55	7472-7479	compute	_	
34-56	7480-7495	non-psychiatric	_	
34-57	7496-7506	individual	_	
34-58	7507-7516	parameter	_	
34-59	7517-7526	estimates	_	
34-60	7527-7530	for	_	
34-61	7531-7536	model	_	
34-62	7537-7547	validation	_	
34-63	7548-7551	and	_	
34-64	7552-7561	parameter	_	
34-65	7562-7570	recovery	_	
34-66	7570-7571	.	_	

#Text=Behavioral Analyses
#Text=Model-agnostic behavioral analyses.
35-1	7572-7582	Behavioral	_	
35-2	7583-7591	Analyses	_	
35-3	7592-7606	Model-agnostic	_	
35-4	7607-7617	behavioral	_	
35-5	7618-7626	analyses	_	
35-6	7626-7627	.	_	

#Text=To verify that participants learned during the task, the behavioral choices of each individual in each drug-use state were examined over time and quantified as the percentage of trials that the objectively better choice was selected.
36-1	7628-7630	To	_	
36-2	7631-7637	verify	_	
36-3	7638-7642	that	_	
36-4	7643-7655	participants	_	
36-5	7656-7663	learned	_	
36-6	7664-7670	during	_	
36-7	7671-7674	the	_	
36-8	7675-7679	task	_	
36-9	7679-7680	,	_	
36-10	7681-7684	the	_	
36-11	7685-7695	behavioral	_	
36-12	7696-7703	choices	_	
36-13	7704-7706	of	_	
36-14	7707-7711	each	_	
36-15	7712-7722	individual	_	
36-16	7723-7725	in	_	
36-17	7726-7730	each	_	
36-18	7731-7739	drug-use	_	
36-19	7740-7745	state	_	
36-20	7746-7750	were	_	
36-21	7751-7759	examined	_	
36-22	7760-7764	over	_	
36-23	7765-7769	time	_	
36-24	7770-7773	and	_	
36-25	7774-7784	quantified	_	
36-26	7785-7787	as	_	
36-27	7788-7791	the	_	
36-28	7792-7802	percentage	_	
36-29	7803-7805	of	_	
36-30	7806-7812	trials	_	
36-31	7813-7817	that	_	
36-32	7818-7821	the	_	
36-33	7822-7833	objectively	_	
36-34	7834-7840	better	_	
36-35	7841-7847	choice	_	
36-36	7848-7851	was	_	
36-37	7852-7860	selected	_	
36-38	7860-7861	.	_	

#Text=Within- sample and paired t-tests on performance were implemented in MATLAB.
37-1	7862-7868	Within	_	
37-2	7868-7869	-	_	
37-3	7870-7876	sample	_	
37-4	7877-7880	and	_	
37-5	7881-7887	paired	_	
37-6	7888-7895	t-tests	_	
37-7	7896-7898	on	_	
37-8	7899-7910	performance	_	
37-9	7911-7915	were	_	
37-10	7916-7927	implemented	_	
37-11	7928-7930	in	_	
37-12	7931-7937	MATLAB	_	
37-13	7937-7938	.	_	

#Text=Computational model-based behavioral analyses.
38-1	7939-7952	Computational	_	
38-2	7953-7964	model-based	_	
38-3	7965-7975	behavioral	_	
38-4	7976-7984	analyses	_	
38-5	7984-7985	.	_	

#Text=To assess model-derived behavioral learning effects for each participant in each drug-use state, participants’ behavioral choices were fit to a basic reinforcement Q-learning model which included two learning rates (α) that provided separate update rules for positive (δ+) and negative (δ-) prediction errors (better or worse than expectations, mapping on to successful and unsuccessful loss avoidance; d+ and S-, adapted from previous studies, in the form of positive (α+) and negative (α-) learning rates (Figure 1B).
39-1	7986-7988	To	_	
39-2	7989-7995	assess	_	
39-3	7996-8009	model-derived	_	
39-4	8010-8020	behavioral	_	
39-5	8021-8029	learning	_	
39-6	8030-8037	effects	_	
39-7	8038-8041	for	_	
39-8	8042-8046	each	_	
39-9	8047-8058	participant	_	
39-10	8059-8061	in	_	
39-11	8062-8066	each	_	
39-12	8067-8075	drug-use	_	
39-13	8076-8081	state	_	
39-14	8081-8082	,	_	
39-15	8083-8095	participants	_	
39-16	8095-8096	’	_	
39-17	8097-8107	behavioral	_	
39-18	8108-8115	choices	_	
39-19	8116-8120	were	_	
39-20	8121-8124	fit	_	
39-21	8125-8127	to	_	
39-22	8128-8129	a	_	
39-23	8130-8135	basic	_	
39-24	8136-8149	reinforcement	_	
39-25	8150-8160	Q-learning	_	
39-26	8161-8166	model	_	
39-27	8167-8172	which	_	
39-28	8173-8181	included	_	
39-29	8182-8185	two	_	
39-30	8186-8194	learning	_	
39-31	8195-8200	rates	_	
39-32	8201-8202	(	_	
39-33	8202-8203	α	_	
39-34	8203-8204	)	_	
39-35	8205-8209	that	_	
39-36	8210-8218	provided	_	
39-37	8219-8227	separate	_	
39-38	8228-8234	update	_	
39-39	8235-8240	rules	_	
39-40	8241-8244	for	_	
39-41	8245-8253	positive	_	
39-42	8254-8255	(	_	
39-43	8255-8256	δ	_	
39-44	8256-8257	+	_	
39-45	8257-8258	)	_	
39-46	8259-8262	and	_	
39-47	8263-8271	negative	_	
39-48	8272-8273	(	_	
39-49	8273-8274	δ	_	
39-50	8274-8275	-	_	
39-51	8275-8276	)	_	
39-52	8277-8287	prediction	_	
39-53	8288-8294	errors	_	
39-54	8295-8296	(	_	
39-55	8296-8302	better	_	
39-56	8303-8305	or	_	
39-57	8306-8311	worse	_	
39-58	8312-8316	than	_	
39-59	8317-8329	expectations	_	
39-60	8329-8330	,	_	
39-61	8331-8338	mapping	_	
39-62	8339-8341	on	_	
39-63	8342-8344	to	_	
39-64	8345-8355	successful	_	
39-65	8356-8359	and	_	
39-66	8360-8372	unsuccessful	_	
39-67	8373-8377	loss	_	
39-68	8378-8387	avoidance	_	
39-69	8387-8388	;	_	
39-70	8389-8390	d	_	
39-71	8390-8391	+	_	
39-72	8392-8395	and	_	
39-73	8396-8397	S	_	
39-74	8397-8398	-	_	
39-75	8398-8399	,	_	
39-76	8400-8407	adapted	_	
39-77	8408-8412	from	_	
39-78	8413-8421	previous	_	
39-79	8422-8429	studies	_	
39-80	8429-8430	,	_	
39-81	8431-8433	in	_	
39-82	8434-8437	the	_	
39-83	8438-8442	form	_	
39-84	8443-8445	of	_	
39-85	8446-8454	positive	_	
39-86	8455-8456	(	_	
39-87	8456-8457	α	_	
39-88	8457-8458	+	_	
39-89	8458-8459	)	_	
39-90	8460-8463	and	_	
39-91	8464-8472	negative	_	
39-92	8473-8474	(	_	
39-93	8474-8475	α	_	
39-94	8475-8476	-	_	
39-95	8476-8477	)	_	
39-96	8478-8486	learning	_	
39-97	8487-8492	rates	_	
39-98	8493-8494	(	_	
39-99	8494-8500	Figure	_	
39-100	8501-8503	1B	_	
39-101	8503-8504	)	_	
39-102	8504-8505	.	_	

#Text=The separate learning rates allowed us to evaluate asymmetries in learning from δ+ and δ- (e.g.,) and assess the possibility that cocaine’s effects on DA systems differentially impact these components.
40-1	8506-8509	The	_	
40-2	8510-8518	separate	_	
40-3	8519-8527	learning	_	
40-4	8528-8533	rates	_	
40-5	8534-8541	allowed	_	
40-6	8542-8544	us	_	
40-7	8545-8547	to	_	
40-8	8548-8556	evaluate	_	
40-9	8557-8568	asymmetries	_	
40-10	8569-8571	in	_	
40-11	8572-8580	learning	_	
40-12	8581-8585	from	_	
40-13	8586-8587	δ	_	
40-14	8587-8588	+	_	
40-15	8589-8592	and	_	
40-16	8593-8594	δ	_	
40-17	8594-8595	-	_	
40-18	8596-8597	(	_	
40-19	8597-8600	e.g	_	
40-20	8600-8601	.	_	
40-21	8601-8602	,	_	
40-22	8602-8603	)	_	
40-23	8604-8607	and	_	
40-24	8608-8614	assess	_	
40-25	8615-8618	the	_	
40-26	8619-8630	possibility	_	
40-27	8631-8635	that	_	
40-28	8636-8643	cocaine	_	
40-29	8643-8644	’	_	
40-30	8644-8645	s	_	
40-31	8646-8653	effects	_	
40-32	8654-8656	on	_	
40-33	8657-8659	DA	_	
40-34	8660-8667	systems	_	
40-35	8668-8682	differentially	_	
40-36	8683-8689	impact	_	
40-37	8690-8695	these	_	
40-38	8696-8706	components	_	
40-39	8706-8707	.	_	

#Text=The model was a good fit of participants’ choices during the loss- learning task (Figure 1C), was a better fit then a single learning rate model, and model and parameter recovery using simulated data further verified the fit of the model to the observed behavior (see Behavioral Results).
41-1	8708-8711	The	_	
41-2	8712-8717	model	_	
41-3	8718-8721	was	_	
41-4	8722-8723	a	_	
41-5	8724-8728	good	_	
41-6	8729-8732	fit	_	
41-7	8733-8735	of	_	
41-8	8736-8748	participants	_	
41-9	8748-8749	’	_	
41-10	8750-8757	choices	_	
41-11	8758-8764	during	_	
41-12	8765-8768	the	_	
41-13	8769-8773	loss	_	
41-14	8773-8774	-	_	
41-15	8775-8783	learning	_	
41-16	8784-8788	task	_	
41-17	8789-8790	(	_	
41-18	8790-8796	Figure	_	
41-19	8797-8799	1C	_	
41-20	8799-8800	)	_	
41-21	8800-8801	,	_	
41-22	8802-8805	was	_	
41-23	8806-8807	a	_	
41-24	8808-8814	better	_	
41-25	8815-8818	fit	_	
41-26	8819-8823	then	_	
41-27	8824-8825	a	_	
41-28	8826-8832	single	_	
41-29	8833-8841	learning	_	
41-30	8842-8846	rate	_	
41-31	8847-8852	model	_	
41-32	8852-8853	,	_	
41-33	8854-8857	and	_	
41-34	8858-8863	model	_	
41-35	8864-8867	and	_	
41-36	8868-8877	parameter	_	
41-37	8878-8886	recovery	_	
41-38	8887-8892	using	_	
41-39	8893-8902	simulated	_	
41-40	8903-8907	data	_	
41-41	8908-8915	further	_	
41-42	8916-8924	verified	_	
41-43	8925-8928	the	_	
41-44	8929-8932	fit	_	
41-45	8933-8935	of	_	
41-46	8936-8939	the	_	
41-47	8940-8945	model	_	
41-48	8946-8948	to	_	
41-49	8949-8952	the	_	
41-50	8953-8961	observed	_	
41-51	8962-8970	behavior	_	
41-52	8971-8972	(	_	
41-53	8972-8975	see	_	
41-54	8976-8986	Behavioral	_	
41-55	8987-8994	Results	_	
41-56	8994-8995	)	_	
41-57	8995-8996	.	_	

#Text=A third estimated parameter, inverse temperature (β), provided a measure of exploration and indicated the sensitivity of choice probabilities to differences in values.
42-1	8997-8998	A	_	
42-2	8999-9004	third	_	
42-3	9005-9014	estimated	_	
42-4	9015-9024	parameter	_	
42-5	9024-9025	,	_	
42-6	9026-9033	inverse	_	
42-7	9034-9045	temperature	_	
42-8	9046-9047	(	_	
42-9	9047-9048	β	_	
42-10	9048-9049	)	_	
42-11	9049-9050	,	_	
42-12	9051-9059	provided	_	
42-13	9060-9061	a	_	
42-14	9062-9069	measure	_	
42-15	9070-9072	of	_	
42-16	9073-9084	exploration	_	
42-17	9085-9088	and	_	
42-18	9089-9098	indicated	_	
42-19	9099-9102	the	_	
42-20	9103-9114	sensitivity	_	
42-21	9115-9117	of	_	
42-22	9118-9124	choice	_	
42-23	9125-9138	probabilities	_	
42-24	9139-9141	to	_	
42-25	9142-9153	differences	_	
42-26	9154-9156	in	_	
42-27	9157-9163	values	_	
42-28	9163-9164	.	_	

#Text=See Supplemental Methods for additional descriptions of model selection, model validation, and parameter recovery procedures (Supplemental Methods, Model Fitting and Selection).
43-1	9165-9168	See	_	
43-2	9169-9181	Supplemental	_	
43-3	9182-9189	Methods	_	
43-4	9190-9193	for	_	
43-5	9194-9204	additional	_	
43-6	9205-9217	descriptions	_	
43-7	9218-9220	of	_	
43-8	9221-9226	model	_	
43-9	9227-9236	selection	_	
43-10	9236-9237	,	_	
43-11	9238-9243	model	_	
43-12	9244-9254	validation	_	
43-13	9254-9255	,	_	
43-14	9256-9259	and	_	
43-15	9260-9269	parameter	_	
43-16	9270-9278	recovery	_	
43-17	9279-9289	procedures	_	
43-18	9290-9291	(	_	
43-19	9291-9303	Supplemental	_	
43-20	9304-9311	Methods	_	
43-21	9311-9312	,	_	
43-22	9313-9318	Model	_	
43-23	9319-9326	Fitting	_	
43-24	9327-9330	and	_	
43-25	9331-9340	Selection	_	
43-26	9340-9341	)	_	
43-27	9341-9342	.	_	

#Text=For the two learning rate model, the initial expected values Q(0) for the possible choices a and b were set to 0 as participants were not instructed a priori about the range of possible outcomes.
44-1	9343-9346	For	_	
44-2	9347-9350	the	_	
44-3	9351-9354	two	_	
44-4	9355-9363	learning	_	
44-5	9364-9368	rate	_	
44-6	9369-9374	model	_	
44-7	9374-9375	,	_	
44-8	9376-9379	the	_	
44-9	9380-9387	initial	_	
44-10	9388-9396	expected	_	
44-11	9397-9403	values	_	
44-12	9404-9405	Q	_	
44-13	9405-9406	(	_	
44-14	9406-9407	0	_	
44-15	9407-9408	)	_	
44-16	9409-9412	for	_	
44-17	9413-9416	the	_	
44-18	9417-9425	possible	_	
44-19	9426-9433	choices	_	
44-20	9434-9435	a	_	
44-21	9436-9439	and	_	
44-22	9440-9441	b	_	
44-23	9442-9446	were	_	
44-24	9447-9450	set	_	
44-25	9451-9453	to	_	
44-26	9454-9455	0	_	
44-27	9456-9458	as	_	
44-28	9459-9471	participants	_	
44-29	9472-9476	were	_	
44-30	9477-9480	not	_	
44-31	9481-9491	instructed	_	
44-32	9492-9493	a	_	
44-33	9494-9500	priori	_	
44-34	9501-9506	about	_	
44-35	9507-9510	the	_	
44-36	9511-9516	range	_	
44-37	9517-9519	of	_	
44-38	9520-9528	possible	_	
44-39	9529-9537	outcomes	_	
44-40	9537-9538	.	_	

#Text=For trial number t, the outcome for the chosen option a was represented by Ra(t) with the expected value represented by Qa(t).
45-1	9539-9542	For	_	
45-2	9543-9548	trial	_	
45-3	9549-9555	number	_	
45-4	9556-9557	t	_	
45-5	9557-9558	,	_	
45-6	9559-9562	the	_	
45-7	9563-9570	outcome	_	
45-8	9571-9574	for	_	
45-9	9575-9578	the	_	
45-10	9579-9585	chosen	_	
45-11	9586-9592	option	_	
45-12	9593-9594	a	_	
45-13	9595-9598	was	_	
45-14	9599-9610	represented	_	
45-15	9611-9613	by	_	
45-16	9614-9616	Ra	_	
45-17	9616-9617	(	_	
45-18	9617-9618	t	_	
45-19	9618-9619	)	_	
45-20	9620-9624	with	_	
45-21	9625-9628	the	_	
45-22	9629-9637	expected	_	
45-23	9638-9643	value	_	
45-24	9644-9655	represented	_	
45-25	9656-9658	by	_	
45-26	9659-9661	Qa	_	
45-27	9661-9662	(	_	
45-28	9662-9663	t	_	
45-29	9663-9664	)	_	
45-30	9664-9665	.	_	

#Text=The prediction error δ(t), which measures the difference in outcome Ra(t) and expectation Qa(t), for a trial was defined as follows:  The parameter estimation procedures included separate update rules for positive and negative prediction errors δ(t) in the form of positive (α+) and negative (α-) learning rates, respectively (Figure 1B).
46-1	9666-9669	The	_	
46-2	9670-9680	prediction	_	
46-3	9681-9686	error	_	
46-4	9687-9688	δ	_	
46-5	9688-9689	(	_	
46-6	9689-9690	t	_	
46-7	9690-9691	)	_	
46-8	9691-9692	,	_	
46-9	9693-9698	which	_	
46-10	9699-9707	measures	_	
46-11	9708-9711	the	_	
46-12	9712-9722	difference	_	
46-13	9723-9725	in	_	
46-14	9726-9733	outcome	_	
46-15	9734-9736	Ra	_	
46-16	9736-9737	(	_	
46-17	9737-9738	t	_	
46-18	9738-9739	)	_	
46-19	9740-9743	and	_	
46-20	9744-9755	expectation	_	
46-21	9756-9758	Qa	_	
46-22	9758-9759	(	_	
46-23	9759-9760	t	_	
46-24	9760-9761	)	_	
46-25	9761-9762	,	_	
46-26	9763-9766	for	_	
46-27	9767-9768	a	_	
46-28	9769-9774	trial	_	
46-29	9775-9778	was	_	
46-30	9779-9786	defined	_	
46-31	9787-9789	as	_	
46-32	9790-9797	follows	_	
46-33	9797-9798	:	_	
46-34	9800-9803	The	_	
46-35	9804-9813	parameter	_	
46-36	9814-9824	estimation	_	
46-37	9825-9835	procedures	_	
46-38	9836-9844	included	_	
46-39	9845-9853	separate	_	
46-40	9854-9860	update	_	
46-41	9861-9866	rules	_	
46-42	9867-9870	for	_	
46-43	9871-9879	positive	_	
46-44	9880-9883	and	_	
46-45	9884-9892	negative	_	
46-46	9893-9903	prediction	_	
46-47	9904-9910	errors	_	
46-48	9911-9912	δ	_	
46-49	9912-9913	(	_	
46-50	9913-9914	t	_	
46-51	9914-9915	)	_	
46-52	9916-9918	in	_	
46-53	9919-9922	the	_	
46-54	9923-9927	form	_	
46-55	9928-9930	of	_	
46-56	9931-9939	positive	_	
46-57	9940-9941	(	_	
46-58	9941-9942	α	_	
46-59	9942-9943	+	_	
46-60	9943-9944	)	_	
46-61	9945-9948	and	_	
46-62	9949-9957	negative	_	
46-63	9958-9959	(	_	
46-64	9959-9960	α	_	
46-65	9960-9961	-	_	
46-66	9961-9962	)	_	
46-67	9963-9971	learning	_	
46-68	9972-9977	rates	_	
46-69	9977-9978	,	_	
46-70	9979-9991	respectively	_	
46-71	9992-9993	(	_	
46-72	9993-9999	Figure	_	
46-73	10000-10002	1B	_	
46-74	10002-10003	)	_	
46-75	10003-10004	.	_	

#Text=The learning rate parameters quantify how much weight the prediction error δ(t) from current trials is given in updating the following trials’ expected value Qa(t+1):  A standard softmax action selection function was used to calculate the probability of selecting choice a at time t and was implemented as follows:  Positive and negative learning rates (α+ and α-) and inverse temperature β were free parameters, iteratively estimated in MATLAB using the function fminsearch, that were evaluated to have the maximum log likelihood.
47-1	10005-10008	The	_	
47-2	10009-10017	learning	_	
47-3	10018-10022	rate	_	
47-4	10023-10033	parameters	_	
47-5	10034-10042	quantify	_	
47-6	10043-10046	how	_	
47-7	10047-10051	much	_	
47-8	10052-10058	weight	_	
47-9	10059-10062	the	_	
47-10	10063-10073	prediction	_	
47-11	10074-10079	error	_	
47-12	10080-10081	δ	_	
47-13	10081-10082	(	_	
47-14	10082-10083	t	_	
47-15	10083-10084	)	_	
47-16	10085-10089	from	_	
47-17	10090-10097	current	_	
47-18	10098-10104	trials	_	
47-19	10105-10107	is	_	
47-20	10108-10113	given	_	
47-21	10114-10116	in	_	
47-22	10117-10125	updating	_	
47-23	10126-10129	the	_	
47-24	10130-10139	following	_	
47-25	10140-10146	trials	_	
47-26	10146-10147	’	_	
47-27	10148-10156	expected	_	
47-28	10157-10162	value	_	
47-29	10163-10165	Qa	_	
47-30	10165-10166	(	_	
47-31	10166-10167	t	_	
47-32	10167-10168	+	_	
47-33	10168-10169	1	_	
47-34	10169-10170	)	_	
47-35	10170-10171	:	_	
47-36	10173-10174	A	_	
47-37	10175-10183	standard	_	
47-38	10184-10191	softmax	_	
47-39	10192-10198	action	_	
47-40	10199-10208	selection	_	
47-41	10209-10217	function	_	
47-42	10218-10221	was	_	
47-43	10222-10226	used	_	
47-44	10227-10229	to	_	
47-45	10230-10239	calculate	_	
47-46	10240-10243	the	_	
47-47	10244-10255	probability	_	
47-48	10256-10258	of	_	
47-49	10259-10268	selecting	_	
47-50	10269-10275	choice	_	
47-51	10276-10277	a	_	
47-52	10278-10280	at	_	
47-53	10281-10285	time	_	
47-54	10286-10287	t	_	
47-55	10288-10291	and	_	
47-56	10292-10295	was	_	
47-57	10296-10307	implemented	_	
47-58	10308-10310	as	_	
47-59	10311-10318	follows	_	
47-60	10318-10319	:	_	
47-61	10321-10329	Positive	_	
47-62	10330-10333	and	_	
47-63	10334-10342	negative	_	
47-64	10343-10351	learning	_	
47-65	10352-10357	rates	_	
47-66	10358-10359	(	_	
47-67	10359-10360	α	_	
47-68	10360-10361	+	_	
47-69	10362-10365	and	_	
47-70	10366-10367	α	_	
47-71	10367-10368	-	_	
47-72	10368-10369	)	_	
47-73	10370-10373	and	_	
47-74	10374-10381	inverse	_	
47-75	10382-10393	temperature	_	
47-76	10394-10395	β	_	
47-77	10396-10400	were	_	
47-78	10401-10405	free	_	
47-79	10406-10416	parameters	_	
47-80	10416-10417	,	_	
47-81	10418-10429	iteratively	_	
47-82	10430-10439	estimated	_	
47-83	10440-10442	in	_	
47-84	10443-10449	MATLAB	_	
47-85	10450-10455	using	_	
47-86	10456-10459	the	_	
47-87	10460-10468	function	_	
47-88	10469-10479	fminsearch	_	
47-89	10479-10480	,	_	
47-90	10481-10485	that	_	
47-91	10486-10490	were	_	
47-92	10491-10500	evaluated	_	
47-93	10501-10503	to	_	
47-94	10504-10508	have	_	
47-95	10509-10512	the	_	
47-96	10513-10520	maximum	_	
47-97	10521-10524	log	_	
47-98	10525-10535	likelihood	_	
47-99	10535-10536	.	_	

#Text=Learning rates were bounded between 0:1 and inverse temperature was bounded between 0:∞.
48-1	10537-10545	Learning	_	
48-2	10546-10551	rates	_	
48-3	10552-10556	were	_	
48-4	10557-10564	bounded	_	
48-5	10565-10572	between	_	
48-6	10573-10574	0	_	
48-7	10574-10575	:	_	
48-8	10575-10576	1	_	
48-9	10577-10580	and	_	
48-10	10581-10588	inverse	_	
48-11	10589-10600	temperature	_	
48-12	10601-10604	was	_	
48-13	10605-10612	bounded	_	
48-14	10613-10620	between	_	
48-15	10621-10622	0	_	
48-16	10622-10623	:	_	
48-17	10623-10624	∞	_	
48-18	10624-10625	.	_	

#Text=For the unchosen option b, the expected value of the subsequent trial  was set to the current trial’s expected value Qb(t) multiplied by an additional decay parameter (ϕ, bounded between 0:∞) similar to previous studies.
49-1	10626-10629	For	_	
49-2	10630-10633	the	_	
49-3	10634-10642	unchosen	_	
49-4	10643-10649	option	_	
49-5	10650-10651	b	_	
49-6	10651-10652	,	_	
49-7	10653-10656	the	_	
49-8	10657-10665	expected	_	
49-9	10666-10671	value	_	
49-10	10672-10674	of	_	
49-11	10675-10678	the	_	
49-12	10679-10689	subsequent	_	
49-13	10690-10695	trial	_	
49-14	10697-10700	was	_	
49-15	10701-10704	set	_	
49-16	10705-10707	to	_	
49-17	10708-10711	the	_	
49-18	10712-10719	current	_	
49-19	10720-10725	trial	_	
49-20	10725-10726	’	_	
49-21	10726-10727	s	_	
49-22	10728-10736	expected	_	
49-23	10737-10742	value	_	
49-24	10743-10745	Qb	_	
49-25	10745-10746	(	_	
49-26	10746-10747	t	_	
49-27	10747-10748	)	_	
49-28	10749-10759	multiplied	_	
49-29	10760-10762	by	_	
49-30	10763-10765	an	_	
49-31	10766-10776	additional	_	
49-32	10777-10782	decay	_	
49-33	10783-10792	parameter	_	
49-34	10793-10794	(	_	
49-35	10794-10795	ϕ	_	
49-36	10795-10796	,	_	
49-37	10797-10804	bounded	_	
49-38	10805-10812	between	_	
49-39	10813-10814	0	_	
49-40	10814-10815	:	_	
49-41	10815-10816	∞	_	
49-42	10816-10817	)	_	
49-43	10818-10825	similar	_	
49-44	10826-10828	to	_	
49-45	10829-10837	previous	_	
49-46	10838-10845	studies	_	
49-47	10845-10846	.	_	

#Text=Individual variances in learning rates (α- and α+) as an effect of drug-state (C- or C+) were estimated for second level fMRI analysis (see Imaging Analysis below).
50-1	10847-10857	Individual	_	
50-2	10858-10867	variances	_	
50-3	10868-10870	in	_	
50-4	10871-10879	learning	_	
50-5	10880-10885	rates	_	
50-6	10886-10887	(	_	
50-7	10887-10888	α	_	
50-8	10888-10889	-	_	
50-9	10890-10893	and	_	
50-10	10894-10895	α	_	
50-11	10895-10896	+	_	
50-12	10896-10897	)	_	
50-13	10898-10900	as	_	
50-14	10901-10903	an	_	
50-15	10904-10910	effect	_	
50-16	10911-10913	of	_	
50-17	10914-10924	drug-state	_	
50-18	10925-10926	(	_	
50-19	10926-10927	C	_	
50-20	10927-10928	-	_	
50-21	10929-10931	or	_	
50-22	10932-10933	C	_	
50-23	10933-10934	+	_	
50-24	10934-10935	)	_	
50-25	10936-10940	were	_	
50-26	10941-10950	estimated	_	
50-27	10951-10954	for	_	
50-28	10955-10961	second	_	
50-29	10962-10967	level	_	
50-30	10968-10972	fMRI	_	
50-31	10973-10981	analysis	_	
50-32	10982-10983	(	_	
50-33	10983-10986	see	_	
50-34	10987-10994	Imaging	_	
50-35	10995-11003	Analysis	_	
50-36	11004-11009	below	_	
50-37	11009-11010	)	_	
50-38	11010-11011	.	_	

#Text=First, the prior mean and distribution of learning rates for participants in each drug state (C- and C+) were estimated using bootstrapped maximum likelihood created via sampling, approximating integration, around a bootstrapped maximum likelihood estimation across subjects.
51-1	11012-11017	First	_	
51-2	11017-11018	,	_	
51-3	11019-11022	the	_	
51-4	11023-11028	prior	_	
51-5	11029-11033	mean	_	
51-6	11034-11037	and	_	
51-7	11038-11050	distribution	_	
51-8	11051-11053	of	_	
51-9	11054-11062	learning	_	
51-10	11063-11068	rates	_	
51-11	11069-11072	for	_	
51-12	11073-11085	participants	_	
51-13	11086-11088	in	_	
51-14	11089-11093	each	_	
51-15	11094-11098	drug	_	
51-16	11099-11104	state	_	
51-17	11105-11106	(	_	
51-18	11106-11107	C	_	
51-19	11107-11108	-	_	
51-20	11109-11112	and	_	
51-21	11113-11114	C	_	
51-22	11114-11115	+	_	
51-23	11115-11116	)	_	
51-24	11117-11121	were	_	
51-25	11122-11131	estimated	_	
51-26	11132-11137	using	_	
51-27	11138-11150	bootstrapped	_	
51-28	11151-11158	maximum	_	
51-29	11159-11169	likelihood	_	
51-30	11170-11177	created	_	
51-31	11178-11181	via	_	
51-32	11182-11190	sampling	_	
51-33	11190-11191	,	_	
51-34	11192-11205	approximating	_	
51-35	11206-11217	integration	_	
51-36	11217-11218	,	_	
51-37	11219-11225	around	_	
51-38	11226-11227	a	_	
51-39	11228-11240	bootstrapped	_	
51-40	11241-11248	maximum	_	
51-41	11249-11259	likelihood	_	
51-42	11260-11270	estimation	_	
51-43	11271-11277	across	_	
51-44	11278-11286	subjects	_	
51-45	11286-11287	.	_	

#Text=Individual learning rates were subsequently estimated by conditioning individuals’ behavioral data on the respective drug state (C- or C+) group’s prior distribution to account for drug-use status differences.
52-1	11288-11298	Individual	_	
52-2	11299-11307	learning	_	
52-3	11308-11313	rates	_	
52-4	11314-11318	were	_	
52-5	11319-11331	subsequently	_	
52-6	11332-11341	estimated	_	
52-7	11342-11344	by	_	
52-8	11345-11357	conditioning	_	
52-9	11358-11369	individuals	_	
52-10	11369-11370	’	_	
52-11	11371-11381	behavioral	_	
52-12	11382-11386	data	_	
52-13	11387-11389	on	_	
52-14	11390-11393	the	_	
52-15	11394-11404	respective	_	
52-16	11405-11409	drug	_	
52-17	11410-11415	state	_	
52-18	11416-11417	(	_	
52-19	11417-11418	C	_	
52-20	11418-11419	-	_	
52-21	11420-11422	or	_	
52-22	11423-11424	C	_	
52-23	11424-11425	+	_	
52-24	11425-11426	)	_	
52-25	11427-11432	group	_	
52-26	11432-11433	’	_	
52-27	11433-11434	s	_	
52-28	11435-11440	prior	_	
52-29	11441-11453	distribution	_	
52-30	11454-11456	to	_	
52-31	11457-11464	account	_	
52-32	11465-11468	for	_	
52-33	11469-11477	drug-use	_	
52-34	11478-11484	status	_	
52-35	11485-11496	differences	_	
52-36	11496-11497	.	_	

#Text=For each participant, individual C+ learning rates were then subtracted from the individual C- learning rates to compute a cocaine ‘deprivation enhanced’ learning rate for each participant.
53-1	11498-11501	For	_	
53-2	11502-11506	each	_	
53-3	11507-11518	participant	_	
53-4	11518-11519	,	_	
53-5	11520-11530	individual	_	
53-6	11531-11532	C	_	
53-7	11532-11533	+	_	
53-8	11534-11542	learning	_	
53-9	11543-11548	rates	_	
53-10	11549-11553	were	_	
53-11	11554-11558	then	_	
53-12	11559-11569	subtracted	_	
53-13	11570-11574	from	_	
53-14	11575-11578	the	_	
53-15	11579-11589	individual	_	
53-16	11590-11591	C	_	
53-17	11591-11592	-	_	
53-18	11593-11601	learning	_	
53-19	11602-11607	rates	_	
53-20	11608-11610	to	_	
53-21	11611-11618	compute	_	
53-22	11619-11620	a	_	
53-23	11621-11628	cocaine	_	
53-24	11629-11630	‘	_	
53-25	11630-11641	deprivation	_	
53-26	11642-11650	enhanced	_	
53-27	11650-11651	’	_	
53-28	11652-11660	learning	_	
53-29	11661-11665	rate	_	
53-30	11666-11669	for	_	
53-31	11670-11674	each	_	
53-32	11675-11686	participant	_	
53-33	11686-11687	.	_	

#Text=Group specific bootstrapped estimates were used for the inverse temperature and decay parameters during individual estimation of learning rates.
54-1	11688-11693	Group	_	
54-2	11694-11702	specific	_	
54-3	11703-11715	bootstrapped	_	
54-4	11716-11725	estimates	_	
54-5	11726-11730	were	_	
54-6	11731-11735	used	_	
54-7	11736-11739	for	_	
54-8	11740-11743	the	_	
54-9	11744-11751	inverse	_	
54-10	11752-11763	temperature	_	
54-11	11764-11767	and	_	
54-12	11768-11773	decay	_	
54-13	11774-11784	parameters	_	
54-14	11785-11791	during	_	
54-15	11792-11802	individual	_	
54-16	11803-11813	estimation	_	
54-17	11814-11816	of	_	
54-18	11817-11825	learning	_	
54-19	11826-11831	rates	_	
54-20	11831-11832	.	_	

#Text=Imaging Analyses
#Text=To examine neural substrates of loss learning associated with cocaine use-state in dependent individuals, model-derived learning variables fit across all participants (as described above) were first correlated with functional MRI data collected during the loss-learning task.
55-1	11833-11840	Imaging	_	
55-2	11841-11849	Analyses	_	
55-3	11850-11852	To	_	
55-4	11853-11860	examine	_	
55-5	11861-11867	neural	_	
55-6	11868-11878	substrates	_	
55-7	11879-11881	of	_	
55-8	11882-11886	loss	_	
55-9	11887-11895	learning	_	
55-10	11896-11906	associated	_	
55-11	11907-11911	with	_	
55-12	11912-11919	cocaine	_	
55-13	11920-11929	use-state	_	
55-14	11930-11932	in	_	
55-15	11933-11942	dependent	_	
55-16	11943-11954	individuals	_	
55-17	11954-11955	,	_	
55-18	11956-11969	model-derived	_	
55-19	11970-11978	learning	_	
55-20	11979-11988	variables	_	
55-21	11989-11992	fit	_	
55-22	11993-11999	across	_	
55-23	12000-12003	all	_	
55-24	12004-12016	participants	_	
55-25	12017-12018	(	_	
55-26	12018-12020	as	_	
55-27	12021-12030	described	_	
55-28	12031-12036	above	_	
55-29	12036-12037	)	_	
55-30	12038-12042	were	_	
55-31	12043-12048	first	_	
55-32	12049-12059	correlated	_	
55-33	12060-12064	with	_	
55-34	12065-12075	functional	_	
55-35	12076-12079	MRI	_	
55-36	12080-12084	data	_	
55-37	12085-12094	collected	_	
55-38	12095-12101	during	_	
55-39	12102-12105	the	_	
55-40	12106-12119	loss-learning	_	
55-41	12120-12124	task	_	
55-42	12124-12125	.	_	

#Text=Next, the model-based neural prediction error signals were related to participants’ self-reported cocaine use measures.
56-1	12126-12130	Next	_	
56-2	12130-12131	,	_	
56-3	12132-12135	the	_	
56-4	12136-12147	model-based	_	
56-5	12148-12154	neural	_	
56-6	12155-12165	prediction	_	
56-7	12166-12171	error	_	
56-8	12172-12179	signals	_	
56-9	12180-12184	were	_	
56-10	12185-12192	related	_	
56-11	12193-12195	to	_	
56-12	12196-12208	participants	_	
56-13	12208-12209	’	_	
56-14	12210-12223	self-reported	_	
56-15	12224-12231	cocaine	_	
56-16	12232-12235	use	_	
56-17	12236-12244	measures	_	
56-18	12244-12245	.	_	

#Text=First-level fMRI processing.
57-1	12246-12257	First-level	_	
57-2	12258-12262	fMRI	_	
57-3	12263-12273	processing	_	
57-4	12273-12274	.	_	

#Text=The general linear model (GLM) implemented in SPM8 was used to perform neuroimaging analyses at the individual and group levels.
58-1	12275-12278	The	_	
58-2	12279-12286	general	_	
58-3	12287-12293	linear	_	
58-4	12294-12299	model	_	
58-5	12300-12301	(	_	
58-6	12301-12304	GLM	_	
58-7	12304-12305	)	_	
58-8	12306-12317	implemented	_	
58-9	12318-12320	in	_	
58-10	12321-12325	SPM8	_	
58-11	12326-12329	was	_	
58-12	12330-12334	used	_	
58-13	12335-12337	to	_	
58-14	12338-12345	perform	_	
58-15	12346-12358	neuroimaging	_	
58-16	12359-12367	analyses	_	
58-17	12368-12370	at	_	
58-18	12371-12374	the	_	
58-19	12375-12385	individual	_	
58-20	12386-12389	and	_	
58-21	12390-12395	group	_	
58-22	12396-12402	levels	_	
58-23	12402-12403	.	_	

#Text=For the first level analyses, onset times for stimuli, outcome events for δ+ outcomes, and outcome events for δ- outcomes for each trial were modeled as separate punctate events.
59-1	12404-12407	For	_	
59-2	12408-12411	the	_	
59-3	12412-12417	first	_	
59-4	12418-12423	level	_	
59-5	12424-12432	analyses	_	
59-6	12432-12433	,	_	
59-7	12434-12439	onset	_	
59-8	12440-12445	times	_	
59-9	12446-12449	for	_	
59-10	12450-12457	stimuli	_	
59-11	12457-12458	,	_	
59-12	12459-12466	outcome	_	
59-13	12467-12473	events	_	
59-14	12474-12477	for	_	
59-15	12478-12479	δ	_	
59-16	12479-12480	+	_	
59-17	12481-12489	outcomes	_	
59-18	12489-12490	,	_	
59-19	12491-12494	and	_	
59-20	12495-12502	outcome	_	
59-21	12503-12509	events	_	
59-22	12510-12513	for	_	
59-23	12514-12515	δ	_	
59-24	12515-12516	-	_	
59-25	12517-12525	outcomes	_	
59-26	12526-12529	for	_	
59-27	12530-12534	each	_	
59-28	12535-12540	trial	_	
59-29	12541-12545	were	_	
59-30	12546-12553	modeled	_	
59-31	12554-12556	as	_	
59-32	12557-12565	separate	_	
59-33	12566-12574	punctate	_	
59-34	12575-12581	events	_	
59-35	12581-12582	.	_	

#Text=The outcomes were categorized based on the sign of the prediction error (δ > 0 or δ < 0, indicating δ+ and δ-), using the fitted estimates of the 2 Learning Rate model, in which trial-by-trial δs were generated (see procedure in Supplemental Methods).
60-1	12583-12586	The	_	
60-2	12587-12595	outcomes	_	
60-3	12596-12600	were	_	
60-4	12601-12612	categorized	_	
60-5	12613-12618	based	_	
60-6	12619-12621	on	_	
60-7	12622-12625	the	_	
60-8	12626-12630	sign	_	
60-9	12631-12633	of	_	
60-10	12634-12637	the	_	
60-11	12638-12648	prediction	_	
60-12	12649-12654	error	_	
60-13	12655-12656	(	_	
60-14	12656-12657	δ	_	
60-15	12658-12659	>	_	
60-16	12660-12661	0	_	
60-17	12662-12664	or	_	
60-18	12665-12666	δ	_	
60-19	12667-12668	<	_	
60-20	12669-12670	0	_	
60-21	12670-12671	,	_	
60-22	12672-12682	indicating	_	
60-23	12683-12684	δ	_	
60-24	12684-12685	+	_	
60-25	12686-12689	and	_	
60-26	12690-12691	δ	_	
60-27	12691-12692	-	_	
60-28	12692-12693	)	_	
60-29	12693-12694	,	_	
60-30	12695-12700	using	_	
60-31	12701-12704	the	_	
60-32	12705-12711	fitted	_	
60-33	12712-12721	estimates	_	
60-34	12722-12724	of	_	
60-35	12725-12728	the	_	
60-36	12729-12730	2	_	
60-37	12731-12739	Learning	_	
60-38	12740-12744	Rate	_	
60-39	12745-12750	model	_	
60-40	12750-12751	,	_	
60-41	12752-12754	in	_	
60-42	12755-12760	which	_	
60-43	12761-12775	trial-by-trial	_	
60-44	12776-12778	δs	_	
60-45	12779-12783	were	_	
60-46	12784-12793	generated	_	
60-47	12794-12795	(	_	
60-48	12795-12798	see	_	
60-49	12799-12808	procedure	_	
60-50	12809-12811	in	_	
60-51	12812-12824	Supplemental	_	
60-52	12825-12832	Methods	_	
60-53	12832-12833	)	_	
60-54	12833-12834	.	_	

#Text=To examine the first level effects of drug-use status on neural representation of learning and valuation, cocaine positive (C+, urine positive for cocaine metabolites) and cocaine negative (C-, urine negative for cocaine metabolites) drug use states for each individual were modeled as separate first level GLMs.
61-1	12835-12837	To	_	
61-2	12838-12845	examine	_	
61-3	12846-12849	the	_	
61-4	12850-12855	first	_	
61-5	12856-12861	level	_	
61-6	12862-12869	effects	_	
61-7	12870-12872	of	_	
61-8	12873-12881	drug-use	_	
61-9	12882-12888	status	_	
61-10	12889-12891	on	_	
61-11	12892-12898	neural	_	
61-12	12899-12913	representation	_	
61-13	12914-12916	of	_	
61-14	12917-12925	learning	_	
61-15	12926-12929	and	_	
61-16	12930-12939	valuation	_	
61-17	12939-12940	,	_	
61-18	12941-12948	cocaine	_	
61-19	12949-12957	positive	_	
61-20	12958-12959	(	_	
61-21	12959-12960	C	_	
61-22	12960-12961	+	_	
61-23	12961-12962	,	_	
61-24	12963-12968	urine	_	
61-25	12969-12977	positive	_	
61-26	12978-12981	for	_	
61-27	12982-12989	cocaine	_	
61-28	12990-13001	metabolites	_	
61-29	13001-13002	)	_	
61-30	13003-13006	and	_	
61-31	13007-13014	cocaine	_	
61-32	13015-13023	negative	_	
61-33	13024-13025	(	_	
61-34	13025-13026	C	_	
61-35	13026-13027	-	_	
61-36	13027-13028	,	_	
61-37	13029-13034	urine	_	
61-38	13035-13043	negative	_	
61-39	13044-13047	for	_	
61-40	13048-13055	cocaine	_	
61-41	13056-13067	metabolites	_	
61-42	13067-13068	)	_	
61-43	13069-13073	drug	_	
61-44	13074-13077	use	_	
61-45	13078-13084	states	_	
61-46	13085-13088	for	_	
61-47	13089-13093	each	_	
61-48	13094-13104	individual	_	
61-49	13105-13109	were	_	
61-50	13110-13117	modeled	_	
61-51	13118-13120	as	_	
61-52	13121-13129	separate	_	
61-53	13130-13135	first	_	
61-54	13136-13141	level	_	
61-55	13142-13146	GLMs	_	
61-56	13146-13147	.	_	

#Text=Trial-by-trial expected values (Q) were modeled as parametric regressors onto the response events.
62-1	13148-13162	Trial-by-trial	_	
62-2	13163-13171	expected	_	
62-3	13172-13178	values	_	
62-4	13179-13180	(	_	
62-5	13180-13181	Q	_	
62-6	13181-13182	)	_	
62-7	13183-13187	were	_	
62-8	13188-13195	modeled	_	
62-9	13196-13198	as	_	
62-10	13199-13209	parametric	_	
62-11	13210-13220	regressors	_	
62-12	13221-13225	onto	_	
62-13	13226-13229	the	_	
62-14	13230-13238	response	_	
62-15	13239-13245	events	_	
62-16	13245-13246	.	_	

#Text=Trial-by-trial δ+ and δ-, and the actual outcomes were modeled as parametric regressors onto separate δ+ and δ- outcome events, respectively.
63-1	13247-13261	Trial-by-trial	_	
63-2	13262-13263	δ	_	
63-3	13263-13264	+	_	
63-4	13265-13268	and	_	
63-5	13269-13270	δ	_	
63-6	13270-13271	-	_	
63-7	13271-13272	,	_	
63-8	13273-13276	and	_	
63-9	13277-13280	the	_	
63-10	13281-13287	actual	_	
63-11	13288-13296	outcomes	_	
63-12	13297-13301	were	_	
63-13	13302-13309	modeled	_	
63-14	13310-13312	as	_	
63-15	13313-13323	parametric	_	
63-16	13324-13334	regressors	_	
63-17	13335-13339	onto	_	
63-18	13340-13348	separate	_	
63-19	13349-13350	δ	_	
63-20	13350-13351	+	_	
63-21	13352-13355	and	_	
63-22	13356-13357	δ	_	
63-23	13357-13358	-	_	
63-24	13359-13366	outcome	_	
63-25	13367-13373	events	_	
63-26	13373-13374	,	_	
63-27	13375-13387	respectively	_	
63-28	13387-13388	.	_	

#Text=Effects due to run number, time in scanner, and head movement parameters were modeled out as nuisance covariates for each time point.
64-1	13389-13396	Effects	_	
64-2	13397-13400	due	_	
64-3	13401-13403	to	_	
64-4	13404-13407	run	_	
64-5	13408-13414	number	_	
64-6	13414-13415	,	_	
64-7	13416-13420	time	_	
64-8	13421-13423	in	_	
64-9	13424-13431	scanner	_	
64-10	13431-13432	,	_	
64-11	13433-13436	and	_	
64-12	13437-13441	head	_	
64-13	13442-13450	movement	_	
64-14	13451-13461	parameters	_	
64-15	13462-13466	were	_	
64-16	13467-13474	modeled	_	
64-17	13475-13478	out	_	
64-18	13479-13481	as	_	
64-19	13482-13490	nuisance	_	
64-20	13491-13501	covariates	_	
64-21	13502-13505	for	_	
64-22	13506-13510	each	_	
64-23	13511-13515	time	_	
64-24	13516-13521	point	_	
64-25	13521-13522	.	_	

#Text=Within and paired drug-state analyses.
65-1	13523-13529	Within	_	
65-2	13530-13533	and	_	
65-3	13534-13540	paired	_	
65-4	13541-13551	drug-state	_	
65-5	13552-13560	analyses	_	
65-6	13560-13561	.	_	

#Text=The within-drug state (C- and C+, respectively) and paired-subjects (C- > C+) effects of cocaine use were compared using one-sample and paired subjects’ second level contrasts in SPM8.
66-1	13562-13565	The	_	
66-2	13566-13577	within-drug	_	
66-3	13578-13583	state	_	
66-4	13584-13585	(	_	
66-5	13585-13586	C	_	
66-6	13586-13587	-	_	
66-7	13588-13591	and	_	
66-8	13592-13593	C	_	
66-9	13593-13594	+	_	
66-10	13594-13595	,	_	
66-11	13596-13608	respectively	_	
66-12	13608-13609	)	_	
66-13	13610-13613	and	_	
66-14	13614-13629	paired-subjects	_	
66-15	13630-13631	(	_	
66-16	13631-13632	C	_	
66-17	13632-13633	-	_	
66-18	13634-13635	>	_	
66-19	13636-13637	C	_	
66-20	13637-13638	+	_	
66-21	13638-13639	)	_	
66-22	13640-13647	effects	_	
66-23	13648-13650	of	_	
66-24	13651-13658	cocaine	_	
66-25	13659-13662	use	_	
66-26	13663-13667	were	_	
66-27	13668-13676	compared	_	
66-28	13677-13682	using	_	
66-29	13683-13693	one-sample	_	
66-30	13694-13697	and	_	
66-31	13698-13704	paired	_	
66-32	13705-13713	subjects	_	
66-33	13713-13714	’	_	
66-34	13715-13721	second	_	
66-35	13722-13727	level	_	
66-36	13728-13737	contrasts	_	
66-37	13738-13740	in	_	
66-38	13741-13745	SPM8	_	
66-39	13745-13746	.	_	

#Text=The effects of interest were neural responses to δ+ and δ−.
67-1	13747-13750	The	_	
67-2	13751-13758	effects	_	
67-3	13759-13761	of	_	
67-4	13762-13770	interest	_	
67-5	13771-13775	were	_	
67-6	13776-13782	neural	_	
67-7	13783-13792	responses	_	
67-8	13793-13795	to	_	
67-9	13796-13797	δ	_	
67-10	13797-13798	+	_	
67-11	13799-13802	and	_	
67-12	13803-13804	δ	_	
67-13	13804-13805	−	_	
67-14	13805-13806	.	_	

#Text=In line with previous data demonstrating the role of striatum and DA in learning, the imaging analyses were masked for the striatum.
68-1	13807-13809	In	_	
68-2	13810-13814	line	_	
68-3	13815-13819	with	_	
68-4	13820-13828	previous	_	
68-5	13829-13833	data	_	
68-6	13834-13847	demonstrating	_	
68-7	13848-13851	the	_	
68-8	13852-13856	role	_	
68-9	13857-13859	of	_	
68-10	13860-13868	striatum	_	
68-11	13869-13872	and	_	
68-12	13873-13875	DA	_	
68-13	13876-13878	in	_	
68-14	13879-13887	learning	_	
68-15	13887-13888	,	_	
68-16	13889-13892	the	_	
68-17	13893-13900	imaging	_	
68-18	13901-13909	analyses	_	
68-19	13910-13914	were	_	
68-20	13915-13921	masked	_	
68-21	13922-13925	for	_	
68-22	13926-13929	the	_	
68-23	13930-13938	striatum	_	
68-24	13938-13939	.	_	

#Text=Anatomical masks were constructed using WFU-pickatlas including the structures of the caudate, putamen, and globus pallidus.
69-1	13940-13950	Anatomical	_	
69-2	13951-13956	masks	_	
69-3	13957-13961	were	_	
69-4	13962-13973	constructed	_	
69-5	13974-13979	using	_	
69-6	13980-13993	WFU-pickatlas	_	
69-7	13994-14003	including	_	
69-8	14004-14007	the	_	
69-9	14008-14018	structures	_	
69-10	14019-14021	of	_	
69-11	14022-14025	the	_	
69-12	14026-14033	caudate	_	
69-13	14033-14034	,	_	
69-14	14035-14042	putamen	_	
69-15	14042-14043	,	_	
69-16	14044-14047	and	_	
69-17	14048-14054	globus	_	
69-18	14055-14063	pallidus	_	
69-19	14063-14064	.	_	

#Text=Also included in the striatum mask was the nucleus accumbens (per Garrison et al.,).
70-1	14065-14069	Also	_	
70-2	14070-14078	included	_	
70-3	14079-14081	in	_	
70-4	14082-14085	the	_	
70-5	14086-14094	striatum	_	
70-6	14095-14099	mask	_	
70-7	14100-14103	was	_	
70-8	14104-14107	the	_	
70-9	14108-14115	nucleus	_	
70-10	14116-14125	accumbens	_	
70-11	14126-14127	(	_	
70-12	14127-14130	per	_	
70-13	14131-14139	Garrison	_	
70-14	14140-14142	et	_	
70-15	14143-14145	al	_	
70-16	14145-14146	.	_	
70-17	14146-14147	,	_	
70-18	14147-14148	)	_	
70-19	14148-14149	.	_	

#Text=Results were thresholded with a voxel level uncorrected p < 0.001, unless noted, and significant clusters were defined using family-wise-error correction.
71-1	14150-14157	Results	_	
71-2	14158-14162	were	_	
71-3	14163-14174	thresholded	_	
71-4	14175-14179	with	_	
71-5	14180-14181	a	_	
71-6	14182-14187	voxel	_	
71-7	14188-14193	level	_	
71-8	14194-14205	uncorrected	_	
71-9	14206-14207	p	_	
71-10	14208-14209	<	_	
71-11	14210-14215	0.001	_	
71-12	14215-14216	,	_	
71-13	14217-14223	unless	_	
71-14	14224-14229	noted	_	
71-15	14229-14230	,	_	
71-16	14231-14234	and	_	
71-17	14235-14246	significant	_	
71-18	14247-14255	clusters	_	
71-19	14256-14260	were	_	
71-20	14261-14268	defined	_	
71-21	14269-14274	using	_	
71-22	14275-14292	family-wise-error	_	
71-23	14293-14303	correction	_	
71-24	14303-14304	.	_	

#Text=Correlation analyses between cocaine-state modulated learning rate and neural prediction error signals.
72-1	14305-14316	Correlation	_	
72-2	14317-14325	analyses	_	
72-3	14326-14333	between	_	
72-4	14334-14347	cocaine-state	_	
72-5	14348-14357	modulated	_	
72-6	14358-14366	learning	_	
72-7	14367-14371	rate	_	
72-8	14372-14375	and	_	
72-9	14376-14382	neural	_	
72-10	14383-14393	prediction	_	
72-11	14394-14399	error	_	
72-12	14400-14407	signals	_	
72-13	14407-14408	.	_	

#Text=To relate drug-state effects on behavioral learning rates (α+ and α-) with the corresponding neural δ signals, separate first level and second level GLMs were created to correlate within-subject drug-modulated α+ and α- differences (C- > C+ for α+ and C- > C+ for δ-, respectively) with the corresponding neural differences for positive and negative δ, respectively (C- > C+ for δ+ and C- > C+ for δ-, respectively).
73-1	14409-14411	To	_	
73-2	14412-14418	relate	_	
73-3	14419-14429	drug-state	_	
73-4	14430-14437	effects	_	
73-5	14438-14440	on	_	
73-6	14441-14451	behavioral	_	
73-7	14452-14460	learning	_	
73-8	14461-14466	rates	_	
73-9	14467-14468	(	_	
73-10	14468-14469	α	_	
73-11	14469-14470	+	_	
73-12	14471-14474	and	_	
73-13	14475-14476	α	_	
73-14	14476-14477	-	_	
73-15	14477-14478	)	_	
73-16	14479-14483	with	_	
73-17	14484-14487	the	_	
73-18	14488-14501	corresponding	_	
73-19	14502-14508	neural	_	
73-20	14509-14510	δ	_	
73-21	14511-14518	signals	_	
73-22	14518-14519	,	_	
73-23	14520-14528	separate	_	
73-24	14529-14534	first	_	
73-25	14535-14540	level	_	
73-26	14541-14544	and	_	
73-27	14545-14551	second	_	
73-28	14552-14557	level	_	
73-29	14558-14562	GLMs	_	
73-30	14563-14567	were	_	
73-31	14568-14575	created	_	
73-32	14576-14578	to	_	
73-33	14579-14588	correlate	_	
73-34	14589-14603	within-subject	_	
73-35	14604-14618	drug-modulated	_	
73-36	14619-14620	α	_	
73-37	14620-14621	+	_	
73-38	14622-14625	and	_	
73-39	14626-14627	α	_	
73-40	14627-14628	-	_	
73-41	14629-14640	differences	_	
73-42	14641-14642	(	_	
73-43	14642-14643	C	_	
73-44	14643-14644	-	_	
73-45	14645-14646	>	_	
73-46	14647-14648	C	_	
73-47	14648-14649	+	_	
73-48	14650-14653	for	_	
73-49	14654-14655	α	_	
73-50	14655-14656	+	_	
73-51	14657-14660	and	_	
73-52	14661-14662	C	_	
73-53	14662-14663	-	_	
73-54	14664-14665	>	_	
73-55	14666-14667	C	_	
73-56	14667-14668	+	_	
73-57	14669-14672	for	_	
73-58	14673-14674	δ	_	
73-59	14674-14675	-	_	
73-60	14675-14676	,	_	
73-61	14677-14689	respectively	_	
73-62	14689-14690	)	_	
73-63	14691-14695	with	_	
73-64	14696-14699	the	_	
73-65	14700-14713	corresponding	_	
73-66	14714-14720	neural	_	
73-67	14721-14732	differences	_	
73-68	14733-14736	for	_	
73-69	14737-14745	positive	_	
73-70	14746-14749	and	_	
73-71	14750-14758	negative	_	
73-72	14759-14760	δ	_	
73-73	14760-14761	,	_	
73-74	14762-14774	respectively	_	
73-75	14775-14776	(	_	
73-76	14776-14777	C	_	
73-77	14777-14778	-	_	
73-78	14779-14780	>	_	
73-79	14781-14782	C	_	
73-80	14782-14783	+	_	
73-81	14784-14787	for	_	
73-82	14788-14789	δ	_	
73-83	14789-14790	+	_	
73-84	14791-14794	and	_	
73-85	14795-14796	C	_	
73-86	14796-14797	-	_	
73-87	14798-14799	>	_	
73-88	14800-14801	C	_	
73-89	14801-14802	+	_	
73-90	14803-14806	for	_	
73-91	14807-14808	δ	_	
73-92	14808-14809	-	_	
73-93	14809-14810	,	_	
73-94	14811-14823	respectively	_	
73-95	14823-14824	)	_	
73-96	14824-14825	.	_	

#Text=Results were again thresholded with a voxel level uncorrected p < 0.001, and significant clusters were defined using family- wise-error correction.
74-1	14826-14833	Results	_	
74-2	14834-14838	were	_	
74-3	14839-14844	again	_	
74-4	14845-14856	thresholded	_	
74-5	14857-14861	with	_	
74-6	14862-14863	a	_	
74-7	14864-14869	voxel	_	
74-8	14870-14875	level	_	
74-9	14876-14887	uncorrected	_	
74-10	14888-14889	p	_	
74-11	14890-14891	<	_	
74-12	14892-14897	0.001	_	
74-13	14897-14898	,	_	
74-14	14899-14902	and	_	
74-15	14903-14914	significant	_	
74-16	14915-14923	clusters	_	
74-17	14924-14928	were	_	
74-18	14929-14936	defined	_	
74-19	14937-14942	using	_	
74-20	14943-14949	family	_	
74-21	14949-14950	-	_	
74-22	14951-14961	wise-error	_	
74-23	14962-14972	correction	_	
74-24	14972-14973	.	_	

#Text=In addition, leave-one-out cross-validation analyses were performed in regions of interest (see Supplemental Methods) to reduce bias due to non-independence.
75-1	14974-14976	In	_	
75-2	14977-14985	addition	_	
75-3	14985-14986	,	_	
75-4	14987-15000	leave-one-out	_	
75-5	15001-15017	cross-validation	_	
75-6	15018-15026	analyses	_	
75-7	15027-15031	were	_	
75-8	15032-15041	performed	_	
75-9	15042-15044	in	_	
75-10	15045-15052	regions	_	
75-11	15053-15055	of	_	
75-12	15056-15064	interest	_	
75-13	15065-15066	(	_	
75-14	15066-15069	see	_	
75-15	15070-15082	Supplemental	_	
75-16	15083-15090	Methods	_	
75-17	15090-15091	)	_	
75-18	15092-15094	to	_	
75-19	15095-15101	reduce	_	
75-20	15102-15106	bias	_	
75-21	15107-15110	due	_	
75-22	15111-15113	to	_	
75-23	15114-15130	non-independence	_	
75-24	15130-15131	.	_	

#Text=Relationships between neural prediction error responses and behavioral cocaine use measures.
76-1	15132-15145	Relationships	_	
76-2	15146-15153	between	_	
76-3	15154-15160	neural	_	
76-4	15161-15171	prediction	_	
76-5	15172-15177	error	_	
76-6	15178-15187	responses	_	
76-7	15188-15191	and	_	
76-8	15192-15202	behavioral	_	
76-9	15203-15210	cocaine	_	
76-10	15211-15214	use	_	
76-11	15215-15223	measures	_	
76-12	15223-15224	.	_	

#Text=To test relationships between the observed neural learning signals and cocaine use measures, questionnaire data characterizing individual drug use history and current cocaine craving were tested against subjects’ C- neural prediction error responses (given the primary results of interest involving enhanced δ+ from drug deprivation).
77-1	15225-15227	To	_	
77-2	15228-15232	test	_	
77-3	15233-15246	relationships	_	
77-4	15247-15254	between	_	
77-5	15255-15258	the	_	
77-6	15259-15267	observed	_	
77-7	15268-15274	neural	_	
77-8	15275-15283	learning	_	
77-9	15284-15291	signals	_	
77-10	15292-15295	and	_	
77-11	15296-15303	cocaine	_	
77-12	15304-15307	use	_	
77-13	15308-15316	measures	_	
77-14	15316-15317	,	_	
77-15	15318-15331	questionnaire	_	
77-16	15332-15336	data	_	
77-17	15337-15351	characterizing	_	
77-18	15352-15362	individual	_	
77-19	15363-15367	drug	_	
77-20	15368-15371	use	_	
77-21	15372-15379	history	_	
77-22	15380-15383	and	_	
77-23	15384-15391	current	_	
77-24	15392-15399	cocaine	_	
77-25	15400-15407	craving	_	
77-26	15408-15412	were	_	
77-27	15413-15419	tested	_	
77-28	15420-15427	against	_	
77-29	15428-15436	subjects	_	
77-30	15436-15437	’	_	
77-31	15438-15439	C	_	
77-32	15439-15440	-	_	
77-33	15441-15447	neural	_	
77-34	15448-15458	prediction	_	
77-35	15459-15464	error	_	
77-36	15465-15474	responses	_	
77-37	15475-15476	(	_	
77-38	15476-15481	given	_	
77-39	15482-15485	the	_	
77-40	15486-15493	primary	_	
77-41	15494-15501	results	_	
77-42	15502-15504	of	_	
77-43	15505-15513	interest	_	
77-44	15514-15523	involving	_	
77-45	15524-15532	enhanced	_	
77-46	15533-15534	δ	_	
77-47	15534-15535	+	_	
77-48	15536-15540	from	_	
77-49	15541-15545	drug	_	
77-50	15546-15557	deprivation	_	
77-51	15557-15558	)	_	
77-52	15558-15559	.	_	

#Text=Again, using leave-one-out cross-validation analysis, neural signals from trials with δ+ were correlated with years of drug use and subscales of the Cocaine Craving Questionnaire.
78-1	15560-15565	Again	_	
78-2	15565-15566	,	_	
78-3	15567-15572	using	_	
78-4	15573-15586	leave-one-out	_	
78-5	15587-15603	cross-validation	_	
78-6	15604-15612	analysis	_	
78-7	15612-15613	,	_	
78-8	15614-15620	neural	_	
78-9	15621-15628	signals	_	
78-10	15629-15633	from	_	
78-11	15634-15640	trials	_	
78-12	15641-15645	with	_	
78-13	15646-15647	δ	_	
78-14	15647-15648	+	_	
78-15	15649-15653	were	_	
78-16	15654-15664	correlated	_	
78-17	15665-15669	with	_	
78-18	15670-15675	years	_	
78-19	15676-15678	of	_	
78-20	15679-15683	drug	_	
78-21	15684-15687	use	_	
78-22	15688-15691	and	_	
78-23	15692-15701	subscales	_	
78-24	15702-15704	of	_	
78-25	15705-15708	the	_	
78-26	15709-15716	Cocaine	_	
78-27	15717-15724	Craving	_	
78-28	15725-15738	Questionnaire	_	
78-29	15738-15739	.	_	

#Text=The analyses identified relationships among years of drug use, δ+ neural signal, and the desire to use cocaine.
79-1	15740-15743	The	_	
79-2	15744-15752	analyses	_	
79-3	15753-15763	identified	_	
79-4	15764-15777	relationships	_	
79-5	15778-15783	among	_	
79-6	15784-15789	years	_	
79-7	15790-15792	of	_	
79-8	15793-15797	drug	_	
79-9	15798-15801	use	_	
79-10	15801-15802	,	_	
79-11	15803-15804	δ	_	
79-12	15804-15805	+	_	
79-13	15806-15812	neural	_	
79-14	15813-15819	signal	_	
79-15	15819-15820	,	_	
79-16	15821-15824	and	_	
79-17	15825-15828	the	_	
79-18	15829-15835	desire	_	
79-19	15836-15838	to	_	
79-20	15839-15842	use	_	
79-21	15843-15850	cocaine	_	
79-22	15850-15851	.	_	

#Text=Based on the results of the correlation analysis, a mediation analysis was performed testing whether neural learning signals mediated the relationship between duration of drug use and individuals’ desire to use cocaine or expected positive outcome from cocaine use (C- measures).
80-1	15852-15857	Based	_	
80-2	15858-15860	on	_	
80-3	15861-15864	the	_	
80-4	15865-15872	results	_	
80-5	15873-15875	of	_	
80-6	15876-15879	the	_	
80-7	15880-15891	correlation	_	
80-8	15892-15900	analysis	_	
80-9	15900-15901	,	_	
80-10	15902-15903	a	_	
80-11	15904-15913	mediation	_	
80-12	15914-15922	analysis	_	
80-13	15923-15926	was	_	
80-14	15927-15936	performed	_	
80-15	15937-15944	testing	_	
80-16	15945-15952	whether	_	
80-17	15953-15959	neural	_	
80-18	15960-15968	learning	_	
80-19	15969-15976	signals	_	
80-20	15977-15985	mediated	_	
80-21	15986-15989	the	_	
80-22	15990-16002	relationship	_	
80-23	16003-16010	between	_	
80-24	16011-16019	duration	_	
80-25	16020-16022	of	_	
80-26	16023-16027	drug	_	
80-27	16028-16031	use	_	
80-28	16032-16035	and	_	
80-29	16036-16047	individuals	_	
80-30	16047-16048	’	_	
80-31	16049-16055	desire	_	
80-32	16056-16058	to	_	
80-33	16059-16062	use	_	
80-34	16063-16070	cocaine	_	
80-35	16071-16073	or	_	
80-36	16074-16082	expected	_	
80-37	16083-16091	positive	_	
80-38	16092-16099	outcome	_	
80-39	16100-16104	from	_	
80-40	16105-16112	cocaine	_	
80-41	16113-16116	use	_	
80-42	16117-16118	(	_	
80-43	16118-16119	C	_	
80-44	16119-16120	-	_	
80-45	16121-16129	measures	_	
80-46	16129-16130	)	_	
80-47	16130-16131	.	_	

#Text=A bootstrap approach to mediation was implemented in R to calculate a 95% confidence interval with 10,000 bootstrapped resamples.
81-1	16132-16133	A	_	
81-2	16134-16143	bootstrap	_	
81-3	16144-16152	approach	_	
81-4	16153-16155	to	_	
81-5	16156-16165	mediation	_	
81-6	16166-16169	was	_	
81-7	16170-16181	implemented	_	
81-8	16182-16184	in	_	
81-9	16185-16186	R	_	
81-10	16187-16189	to	_	
81-11	16190-16199	calculate	_	
81-12	16200-16201	a	_	
81-13	16202-16205	95%	_	
81-14	16206-16216	confidence	_	
81-15	16217-16225	interval	_	
81-16	16226-16230	with	_	
81-17	16231-16237	10,000	_	
81-18	16238-16250	bootstrapped	_	
81-19	16251-16260	resamples	_	
81-20	16260-16261	.	_	

#Text=Results
#Text=Behavioral Results
#Text=Model-agnostic behavioral results.
82-1	16262-16269	Results	_	
82-2	16270-16280	Behavioral	_	
82-3	16281-16288	Results	_	
82-4	16289-16303	Model-agnostic	_	
82-5	16304-16314	behavioral	_	
82-6	16315-16322	results	_	
82-7	16322-16323	.	_	

#Text=In both drug-use states, participants demonstrated learning and performed significantly above chance (percentage of trials on which the ‘better’ option was chosen; C-: 62.76%, s.e. 3.22%, t(17) = 3.91, d = 0.96, p < 0.01; C+: 73.61%, s.e. 2.69%, t(17) = 8.70, d = 2.12, p < 0.01; chance: 50%; Figure 1D).
83-1	16324-16326	In	_	
83-2	16327-16331	both	_	
83-3	16332-16340	drug-use	_	
83-4	16341-16347	states	_	
83-5	16347-16348	,	_	
83-6	16349-16361	participants	_	
83-7	16362-16374	demonstrated	_	
83-8	16375-16383	learning	_	
83-9	16384-16387	and	_	
83-10	16388-16397	performed	_	
83-11	16398-16411	significantly	_	
83-12	16412-16417	above	_	
83-13	16418-16424	chance	_	
83-14	16425-16426	(	_	
83-15	16426-16436	percentage	_	
83-16	16437-16439	of	_	
83-17	16440-16446	trials	_	
83-18	16447-16449	on	_	
83-19	16450-16455	which	_	
83-20	16456-16459	the	_	
83-21	16460-16461	‘	_	
83-22	16461-16467	better	_	
83-23	16467-16468	’	_	
83-24	16469-16475	option	_	
83-25	16476-16479	was	_	
83-26	16480-16486	chosen	_	
83-27	16486-16487	;	_	
83-28	16488-16489	C	_	
83-29	16489-16490	-	_	
83-30	16490-16491	:	_	
83-31	16492-16498	62.76%	_	
83-32	16498-16499	,	_	
83-33	16500-16503	s.e	_	
83-34	16503-16504	.	_	
83-35	16505-16510	3.22%	_	
83-36	16510-16511	,	_	
83-37	16512-16513	t	_	
83-38	16513-16514	(	_	
83-39	16514-16516	17	_	
83-40	16516-16517	)	_	
83-41	16518-16519	=	_	
83-42	16520-16524	3.91	_	
83-43	16524-16525	,	_	
83-44	16526-16527	d	_	
83-45	16528-16529	=	_	
83-46	16530-16534	0.96	_	
83-47	16534-16535	,	_	
83-48	16536-16537	p	_	
83-49	16538-16539	<	_	
83-50	16540-16544	0.01	_	
83-51	16544-16545	;	_	
83-52	16546-16547	C	_	
83-53	16547-16548	+	_	
83-54	16548-16549	:	_	
83-55	16550-16556	73.61%	_	
83-56	16556-16557	,	_	
83-57	16558-16561	s.e	_	
83-58	16561-16562	.	_	
83-59	16563-16568	2.69%	_	
83-60	16568-16569	,	_	
83-61	16570-16571	t	_	
83-62	16571-16572	(	_	
83-63	16572-16574	17	_	
83-64	16574-16575	)	_	
83-65	16576-16577	=	_	
83-66	16578-16582	8.70	_	
83-67	16582-16583	,	_	
83-68	16584-16585	d	_	
83-69	16586-16587	=	_	
83-70	16588-16592	2.12	_	
83-71	16592-16593	,	_	
83-72	16594-16595	p	_	
83-73	16596-16597	<	_	
83-74	16598-16602	0.01	_	
83-75	16602-16603	;	_	
83-76	16604-16610	chance	_	
83-77	16610-16611	:	_	
83-78	16612-16615	50%	_	
83-79	16615-16616	;	_	
83-80	16617-16623	Figure	_	
83-81	16624-16626	1D	_	
83-82	16626-16627	)	_	
83-83	16627-16628	.	_	

#Text=In addition, participants in the C- state showed diminished accuracy, relative to C+ participants (t(17) = 2.62, d = 0.30, p = 0.01).
84-1	16629-16631	In	_	
84-2	16632-16640	addition	_	
84-3	16640-16641	,	_	
84-4	16642-16654	participants	_	
84-5	16655-16657	in	_	
84-6	16658-16661	the	_	
84-7	16662-16663	C	_	
84-8	16663-16664	-	_	
84-9	16665-16670	state	_	
84-10	16671-16677	showed	_	
84-11	16678-16688	diminished	_	
84-12	16689-16697	accuracy	_	
84-13	16697-16698	,	_	
84-14	16699-16707	relative	_	
84-15	16708-16710	to	_	
84-16	16711-16712	C	_	
84-17	16712-16713	+	_	
84-18	16714-16726	participants	_	
84-19	16727-16728	(	_	
84-20	16728-16729	t	_	
84-21	16729-16730	(	_	
84-22	16730-16732	17	_	
84-23	16732-16733	)	_	
84-24	16734-16735	=	_	
84-25	16736-16740	2.62	_	
84-26	16740-16741	,	_	
84-27	16742-16743	d	_	
84-28	16744-16745	=	_	
84-29	16746-16750	0.30	_	
84-30	16750-16751	,	_	
84-31	16752-16753	p	_	
84-32	16754-16755	=	_	
84-33	16756-16760	0.01	_	
84-34	16760-16761	)	_	
84-35	16761-16762	.	_	

#Text=Computational model-derived behavioral results.
85-1	16763-16776	Computational	_	
85-2	16777-16790	model-derived	_	
85-3	16791-16801	behavioral	_	
85-4	16802-16809	results	_	
85-5	16809-16810	.	_	

#Text=Computational model-based analyses, using bootstrapped group parameters (per; 200 iterations draws of subjects within drug-use state) for positive and negative learning rate (α+ and α-, respectively) and inverse temperature (β), suggested increased positive learning rates (α+) and decreased inverse temperature (β) in C- relative to C+ participants; negative learning rates (α-) did not differ between participants in the C- and C+ states (Figure 1E).
86-1	16811-16824	Computational	_	
86-2	16825-16836	model-based	_	
86-3	16837-16845	analyses	_	
86-4	16845-16846	,	_	
86-5	16847-16852	using	_	
86-6	16853-16865	bootstrapped	_	
86-7	16866-16871	group	_	
86-8	16872-16882	parameters	_	
86-9	16883-16884	(	_	
86-10	16884-16887	per	_	
86-11	16887-16888	;	_	
86-12	16889-16892	200	_	
86-13	16893-16903	iterations	_	
86-14	16904-16909	draws	_	
86-15	16910-16912	of	_	
86-16	16913-16921	subjects	_	
86-17	16922-16928	within	_	
86-18	16929-16937	drug-use	_	
86-19	16938-16943	state	_	
86-20	16943-16944	)	_	
86-21	16945-16948	for	_	
86-22	16949-16957	positive	_	
86-23	16958-16961	and	_	
86-24	16962-16970	negative	_	
86-25	16971-16979	learning	_	
86-26	16980-16984	rate	_	
86-27	16985-16986	(	_	
86-28	16986-16987	α	_	
86-29	16987-16988	+	_	
86-30	16989-16992	and	_	
86-31	16993-16994	α	_	
86-32	16994-16995	-	_	
86-33	16995-16996	,	_	
86-34	16997-17009	respectively	_	
86-35	17009-17010	)	_	
86-36	17011-17014	and	_	
86-37	17015-17022	inverse	_	
86-38	17023-17034	temperature	_	
86-39	17035-17036	(	_	
86-40	17036-17037	β	_	
86-41	17037-17038	)	_	
86-42	17038-17039	,	_	
86-43	17040-17049	suggested	_	
86-44	17050-17059	increased	_	
86-45	17060-17068	positive	_	
86-46	17069-17077	learning	_	
86-47	17078-17083	rates	_	
86-48	17084-17085	(	_	
86-49	17085-17086	α	_	
86-50	17086-17087	+	_	
86-51	17087-17088	)	_	
86-52	17089-17092	and	_	
86-53	17093-17102	decreased	_	
86-54	17103-17110	inverse	_	
86-55	17111-17122	temperature	_	
86-56	17123-17124	(	_	
86-57	17124-17125	β	_	
86-58	17125-17126	)	_	
86-59	17127-17129	in	_	
86-60	17130-17131	C	_	
86-61	17131-17132	-	_	
86-62	17133-17141	relative	_	
86-63	17142-17144	to	_	
86-64	17145-17146	C	_	
86-65	17146-17147	+	_	
86-66	17148-17160	participants	_	
86-67	17160-17161	;	_	
86-68	17162-17170	negative	_	
86-69	17171-17179	learning	_	
86-70	17180-17185	rates	_	
86-71	17186-17187	(	_	
86-72	17187-17188	α	_	
86-73	17188-17189	-	_	
86-74	17189-17190	)	_	
86-75	17191-17194	did	_	
86-76	17195-17198	not	_	
86-77	17199-17205	differ	_	
86-78	17206-17213	between	_	
86-79	17214-17226	participants	_	
86-80	17227-17229	in	_	
86-81	17230-17233	the	_	
86-82	17234-17235	C	_	
86-83	17235-17236	-	_	
86-84	17237-17240	and	_	
86-85	17241-17242	C	_	
86-86	17242-17243	+	_	
86-87	17244-17250	states	_	
86-88	17251-17252	(	_	
86-89	17252-17258	Figure	_	
86-90	17259-17261	1E	_	
86-91	17261-17262	)	_	
86-92	17262-17263	.	_	

#Text=To clarify whether cocaine-state modulation of positive learning rate (α+) or inverse temperature (β) was associated with the diminished behavioral accuracy in C- participants, we simulated behavioral choices holding α+ constant (iterating through the ranges of the observed parameter values) while allowing β to vary, and similarly holding β constant and allowing α+ to vary.
87-1	17264-17266	To	_	
87-2	17267-17274	clarify	_	
87-3	17275-17282	whether	_	
87-4	17283-17296	cocaine-state	_	
87-5	17297-17307	modulation	_	
87-6	17308-17310	of	_	
87-7	17311-17319	positive	_	
87-8	17320-17328	learning	_	
87-9	17329-17333	rate	_	
87-10	17334-17335	(	_	
87-11	17335-17336	α	_	
87-12	17336-17337	+	_	
87-13	17337-17338	)	_	
87-14	17339-17341	or	_	
87-15	17342-17349	inverse	_	
87-16	17350-17361	temperature	_	
87-17	17362-17363	(	_	
87-18	17363-17364	β	_	
87-19	17364-17365	)	_	
87-20	17366-17369	was	_	
87-21	17370-17380	associated	_	
87-22	17381-17385	with	_	
87-23	17386-17389	the	_	
87-24	17390-17400	diminished	_	
87-25	17401-17411	behavioral	_	
87-26	17412-17420	accuracy	_	
87-27	17421-17423	in	_	
87-28	17424-17425	C	_	
87-29	17425-17426	-	_	
87-30	17427-17439	participants	_	
87-31	17439-17440	,	_	
87-32	17441-17443	we	_	
87-33	17444-17453	simulated	_	
87-34	17454-17464	behavioral	_	
87-35	17465-17472	choices	_	
87-36	17473-17480	holding	_	
87-37	17481-17482	α	_	
87-38	17482-17483	+	_	
87-39	17484-17492	constant	_	
87-40	17493-17494	(	_	
87-41	17494-17503	iterating	_	
87-42	17504-17511	through	_	
87-43	17512-17515	the	_	
87-44	17516-17522	ranges	_	
87-45	17523-17525	of	_	
87-46	17526-17529	the	_	
87-47	17530-17538	observed	_	
87-48	17539-17548	parameter	_	
87-49	17549-17555	values	_	
87-50	17555-17556	)	_	
87-51	17557-17562	while	_	
87-52	17563-17571	allowing	_	
87-53	17572-17573	β	_	
87-54	17574-17576	to	_	
87-55	17577-17581	vary	_	
87-56	17581-17582	,	_	
87-57	17583-17586	and	_	
87-58	17587-17596	similarly	_	
87-59	17597-17604	holding	_	
87-60	17605-17606	β	_	
87-61	17607-17615	constant	_	
87-62	17616-17619	and	_	
87-63	17620-17628	allowing	_	
87-64	17629-17630	α	_	
87-65	17630-17631	+	_	
87-66	17632-17634	to	_	
87-67	17635-17639	vary	_	
87-68	17639-17640	.	_	

#Text=As shown in Figure 1F, these simulations revealed increased α+ to be associated with decreased performance and no relationship between β and performance (see simulation details in Supplemental Methods).
88-1	17641-17643	As	_	
88-2	17644-17649	shown	_	
88-3	17650-17652	in	_	
88-4	17653-17659	Figure	_	
88-5	17660-17662	1F	_	
88-6	17662-17663	,	_	
88-7	17664-17669	these	_	
88-8	17670-17681	simulations	_	
88-9	17682-17690	revealed	_	
88-10	17691-17700	increased	_	
88-11	17701-17702	α	_	
88-12	17702-17703	+	_	
88-13	17704-17706	to	_	
88-14	17707-17709	be	_	
88-15	17710-17720	associated	_	
88-16	17721-17725	with	_	
88-17	17726-17735	decreased	_	
88-18	17736-17747	performance	_	
88-19	17748-17751	and	_	
88-20	17752-17754	no	_	
88-21	17755-17767	relationship	_	
88-22	17768-17775	between	_	
88-23	17776-17777	β	_	
88-24	17778-17781	and	_	
88-25	17782-17793	performance	_	
88-26	17794-17795	(	_	
88-27	17795-17798	see	_	
88-28	17799-17809	simulation	_	
88-29	17810-17817	details	_	
88-30	17818-17820	in	_	
88-31	17821-17833	Supplemental	_	
88-32	17834-17841	Methods	_	
88-33	17841-17842	)	_	
88-34	17842-17843	.	_	

#Text=Together, these data provided initial evidence of drug-state modulation of learning, wherein cocaine deprivation-related increases in positive learning rates are associated with diminished behavioral performance.
89-1	17844-17852	Together	_	
89-2	17852-17853	,	_	
89-3	17854-17859	these	_	
89-4	17860-17864	data	_	
89-5	17865-17873	provided	_	
89-6	17874-17881	initial	_	
89-7	17882-17890	evidence	_	
89-8	17891-17893	of	_	
89-9	17894-17904	drug-state	_	
89-10	17905-17915	modulation	_	
89-11	17916-17918	of	_	
89-12	17919-17927	learning	_	
89-13	17927-17928	,	_	
89-14	17929-17936	wherein	_	
89-15	17937-17944	cocaine	_	
89-16	17945-17964	deprivation-related	_	
89-17	17965-17974	increases	_	
89-18	17975-17977	in	_	
89-19	17978-17986	positive	_	
89-20	17987-17995	learning	_	
89-21	17996-18001	rates	_	
89-22	18002-18005	are	_	
89-23	18006-18016	associated	_	
89-24	18017-18021	with	_	
89-25	18022-18032	diminished	_	
89-26	18033-18043	behavioral	_	
89-27	18044-18055	performance	_	
89-28	18055-18056	.	_	

#Text=Imaging Results
#Text=Effects of cocaine-use state on neural prediction error signals.
90-1	18057-18064	Imaging	_	
90-2	18065-18072	Results	_	
90-3	18073-18080	Effects	_	
90-4	18081-18083	of	_	
90-5	18084-18095	cocaine-use	_	
90-6	18096-18101	state	_	
90-7	18102-18104	on	_	
90-8	18105-18111	neural	_	
90-9	18112-18122	prediction	_	
90-10	18123-18128	error	_	
90-11	18129-18136	signals	_	
90-12	18136-18137	.	_	

#Text=Significant neural correlates of positive prediction error were observed in striatum for C- participants (δ+ for C-; Figure 2A; Table S2A), but not for C+ participants.
91-1	18138-18149	Significant	_	
91-2	18150-18156	neural	_	
91-3	18157-18167	correlates	_	
91-4	18168-18170	of	_	
91-5	18171-18179	positive	_	
91-6	18180-18190	prediction	_	
91-7	18191-18196	error	_	
91-8	18197-18201	were	_	
91-9	18202-18210	observed	_	
91-10	18211-18213	in	_	
91-11	18214-18222	striatum	_	
91-12	18223-18226	for	_	
91-13	18227-18228	C	_	
91-14	18228-18229	-	_	
91-15	18230-18242	participants	_	
91-16	18243-18244	(	_	
91-17	18244-18245	δ	_	
91-18	18245-18246	+	_	
91-19	18247-18250	for	_	
91-20	18251-18252	C	_	
91-21	18252-18253	-	_	
91-22	18253-18254	;	_	
91-23	18255-18261	Figure	_	
91-24	18262-18264	2A	_	
91-25	18264-18265	;	_	
91-26	18266-18271	Table	_	
91-27	18272-18275	S2A	_	
91-28	18275-18276	)	_	
91-29	18276-18277	,	_	
91-30	18278-18281	but	_	
91-31	18282-18285	not	_	
91-32	18286-18289	for	_	
91-33	18290-18291	C	_	
91-34	18291-18292	+	_	
91-35	18293-18305	participants	_	
91-36	18305-18306	.	_	

#Text=In addition, no significant neural correlates of negative prediction error (δ-) were found during either drug-use state.
92-1	18307-18309	In	_	
92-2	18310-18318	addition	_	
92-3	18318-18319	,	_	
92-4	18320-18322	no	_	
92-5	18323-18334	significant	_	
92-6	18335-18341	neural	_	
92-7	18342-18352	correlates	_	
92-8	18353-18355	of	_	
92-9	18356-18364	negative	_	
92-10	18365-18375	prediction	_	
92-11	18376-18381	error	_	
92-12	18382-18383	(	_	
92-13	18383-18384	δ	_	
92-14	18384-18385	-	_	
92-15	18385-18386	)	_	
92-16	18387-18391	were	_	
92-17	18392-18397	found	_	
92-18	18398-18404	during	_	
92-19	18405-18411	either	_	
92-20	18412-18420	drug-use	_	
92-21	18421-18426	state	_	
92-22	18426-18427	.	_	

#Text=Positive prediction error (δ+) responses were verified in the non-psychiatric participants (Figure S1, Table S2B), and post hoc analyses using an independent striatum ROI indicated that δ+ in C- participants was comparable to this control cohort whereas C+ participants showed significantly diminished δ+ responses (C-vs non-psychiatric control, t(70) = 0.15, d = 0.004, p = 0.87; C+ vs non-psychiatric control, t(70) = 3.22, d = 0.09, p = 0.001; Figure S1; see analytic details in Supplemental Methods).
93-1	18428-18436	Positive	_	
93-2	18437-18447	prediction	_	
93-3	18448-18453	error	_	
93-4	18454-18455	(	_	
93-5	18455-18456	δ	_	
93-6	18456-18457	+	_	
93-7	18457-18458	)	_	
93-8	18459-18468	responses	_	
93-9	18469-18473	were	_	
93-10	18474-18482	verified	_	
93-11	18483-18485	in	_	
93-12	18486-18489	the	_	
93-13	18490-18505	non-psychiatric	_	
93-14	18506-18518	participants	_	
93-15	18519-18520	(	_	
93-16	18520-18526	Figure	_	
93-17	18527-18529	S1	_	
93-18	18529-18530	,	_	
93-19	18531-18536	Table	_	
93-20	18537-18540	S2B	_	
93-21	18540-18541	)	_	
93-22	18541-18542	,	_	
93-23	18543-18546	and	_	
93-24	18547-18551	post	_	
93-25	18552-18555	hoc	_	
93-26	18556-18564	analyses	_	
93-27	18565-18570	using	_	
93-28	18571-18573	an	_	
93-29	18574-18585	independent	_	
93-30	18586-18594	striatum	_	
93-31	18595-18598	ROI	_	
93-32	18599-18608	indicated	_	
93-33	18609-18613	that	_	
93-34	18614-18615	δ	_	
93-35	18615-18616	+	_	
93-36	18617-18619	in	_	
93-37	18620-18621	C	_	
93-38	18621-18622	-	_	
93-39	18623-18635	participants	_	
93-40	18636-18639	was	_	
93-41	18640-18650	comparable	_	
93-42	18651-18653	to	_	
93-43	18654-18658	this	_	
93-44	18659-18666	control	_	
93-45	18667-18673	cohort	_	
93-46	18674-18681	whereas	_	
93-47	18682-18683	C	_	
93-48	18683-18684	+	_	
93-49	18685-18697	participants	_	
93-50	18698-18704	showed	_	
93-51	18705-18718	significantly	_	
93-52	18719-18729	diminished	_	
93-53	18730-18731	δ	_	
93-54	18731-18732	+	_	
93-55	18733-18742	responses	_	
93-56	18743-18744	(	_	
93-57	18744-18748	C-vs	_	
93-58	18749-18764	non-psychiatric	_	
93-59	18765-18772	control	_	
93-60	18772-18773	,	_	
93-61	18774-18775	t	_	
93-62	18775-18776	(	_	
93-63	18776-18778	70	_	
93-64	18778-18779	)	_	
93-65	18780-18781	=	_	
93-66	18782-18786	0.15	_	
93-67	18786-18787	,	_	
93-68	18788-18789	d	_	
93-69	18790-18791	=	_	
93-70	18792-18797	0.004	_	
93-71	18797-18798	,	_	
93-72	18799-18800	p	_	
93-73	18801-18802	=	_	
93-74	18803-18807	0.87	_	
93-75	18807-18808	;	_	
93-76	18809-18810	C	_	
93-77	18810-18811	+	_	
93-78	18812-18814	vs	_	
93-79	18815-18830	non-psychiatric	_	
93-80	18831-18838	control	_	
93-81	18838-18839	,	_	
93-82	18840-18841	t	_	
93-83	18841-18842	(	_	
93-84	18842-18844	70	_	
93-85	18844-18845	)	_	
93-86	18846-18847	=	_	
93-87	18848-18852	3.22	_	
93-88	18852-18853	,	_	
93-89	18854-18855	d	_	
93-90	18856-18857	=	_	
93-91	18858-18862	0.09	_	
93-92	18862-18863	,	_	
93-93	18864-18865	p	_	
93-94	18866-18867	=	_	
93-95	18868-18873	0.001	_	
93-96	18873-18874	;	_	
93-97	18875-18881	Figure	_	
93-98	18882-18884	S1	_	
93-99	18884-18885	;	_	
93-100	18886-18889	see	_	
93-101	18890-18898	analytic	_	
93-102	18899-18906	details	_	
93-103	18907-18909	in	_	
93-104	18910-18922	Supplemental	_	
93-105	18923-18930	Methods	_	
93-106	18930-18931	)	_	
93-107	18931-18932	.	_	

#Text=The specificity of the neural encoding of positive prediction errors in the C- participants (Figure 2A) was striking in its parallel with the increased positive learning rate in these participants.
94-1	18933-18936	The	_	
94-2	18937-18948	specificity	_	
94-3	18949-18951	of	_	
94-4	18952-18955	the	_	
94-5	18956-18962	neural	_	
94-6	18963-18971	encoding	_	
94-7	18972-18974	of	_	
94-8	18975-18983	positive	_	
94-9	18984-18994	prediction	_	
94-10	18995-19001	errors	_	
94-11	19002-19004	in	_	
94-12	19005-19008	the	_	
94-13	19009-19010	C	_	
94-14	19010-19011	-	_	
94-15	19012-19024	participants	_	
94-16	19025-19026	(	_	
94-17	19026-19032	Figure	_	
94-18	19033-19035	2A	_	
94-19	19035-19036	)	_	
94-20	19037-19040	was	_	
94-21	19041-19049	striking	_	
94-22	19050-19052	in	_	
94-23	19053-19056	its	_	
94-24	19057-19065	parallel	_	
94-25	19066-19070	with	_	
94-26	19071-19074	the	_	
94-27	19075-19084	increased	_	
94-28	19085-19093	positive	_	
94-29	19094-19102	learning	_	
94-30	19103-19107	rate	_	
94-31	19108-19110	in	_	
94-32	19111-19116	these	_	
94-33	19117-19129	participants	_	
94-34	19129-19130	.	_	

#Text=Thus, to test for a neural instantiation of the deprivation-increased positive learning rate, we first computed individual behavioral learning rate estimates for each participant in the C- and C+ states, respectively (see Methods), and generated for each participant ‘deprivation-enhanced’ positive and negative learning rate metrics (i.e., C- > C+ for α- and α+, respectively, for each individual).
95-1	19131-19135	Thus	_	
95-2	19135-19136	,	_	
95-3	19137-19139	to	_	
95-4	19140-19144	test	_	
95-5	19145-19148	for	_	
95-6	19149-19150	a	_	
95-7	19151-19157	neural	_	
95-8	19158-19171	instantiation	_	
95-9	19172-19174	of	_	
95-10	19175-19178	the	_	
95-11	19179-19200	deprivation-increased	_	
95-12	19201-19209	positive	_	
95-13	19210-19218	learning	_	
95-14	19219-19223	rate	_	
95-15	19223-19224	,	_	
95-16	19225-19227	we	_	
95-17	19228-19233	first	_	
95-18	19234-19242	computed	_	
95-19	19243-19253	individual	_	
95-20	19254-19264	behavioral	_	
95-21	19265-19273	learning	_	
95-22	19274-19278	rate	_	
95-23	19279-19288	estimates	_	
95-24	19289-19292	for	_	
95-25	19293-19297	each	_	
95-26	19298-19309	participant	_	
95-27	19310-19312	in	_	
95-28	19313-19316	the	_	
95-29	19317-19318	C	_	
95-30	19318-19319	-	_	
95-31	19320-19323	and	_	
95-32	19324-19325	C	_	
95-33	19325-19326	+	_	
95-34	19327-19333	states	_	
95-35	19333-19334	,	_	
95-36	19335-19347	respectively	_	
95-37	19348-19349	(	_	
95-38	19349-19352	see	_	
95-39	19353-19360	Methods	_	
95-40	19360-19361	)	_	
95-41	19361-19362	,	_	
95-42	19363-19366	and	_	
95-43	19367-19376	generated	_	
95-44	19377-19380	for	_	
95-45	19381-19385	each	_	
95-46	19386-19397	participant	_	
95-47	19398-19399	‘	_	
95-48	19399-19419	deprivation-enhanced	_	
95-49	19419-19420	’	_	
95-50	19421-19429	positive	_	
95-51	19430-19433	and	_	
95-52	19434-19442	negative	_	
95-53	19443-19451	learning	_	
95-54	19452-19456	rate	_	
95-55	19457-19464	metrics	_	
95-56	19465-19466	(	_	
95-57	19466-19469	i.e	_	
95-58	19469-19470	.	_	
95-59	19470-19471	,	_	
95-60	19472-19473	C	_	
95-61	19473-19474	-	_	
95-62	19475-19476	>	_	
95-63	19477-19478	C	_	
95-64	19478-19479	+	_	
95-65	19480-19483	for	_	
95-66	19484-19485	α	_	
95-67	19485-19486	-	_	
95-68	19487-19490	and	_	
95-69	19491-19492	α	_	
95-70	19492-19493	+	_	
95-71	19493-19494	,	_	
95-72	19495-19507	respectively	_	
95-73	19507-19508	,	_	
95-74	19509-19512	for	_	
95-75	19513-19517	each	_	
95-76	19518-19528	individual	_	
95-77	19528-19529	)	_	
95-78	19529-19530	.	_	

#Text=For positive learning rate, the degree of participants’ deprivation-enhancement was significantly associated with the degree of deprivation-enhancement of positive prediction error responses in the striatum (C- > C+ for α+ and neural C- > C+ for δ+; Figure 2B; Table S2C; r = 0.79, p < 0.01; using leave-one-out cross validation to avoid potential bias due to non-independence; 35).
96-1	19531-19534	For	_	
96-2	19535-19543	positive	_	
96-3	19544-19552	learning	_	
96-4	19553-19557	rate	_	
96-5	19557-19558	,	_	
96-6	19559-19562	the	_	
96-7	19563-19569	degree	_	
96-8	19570-19572	of	_	
96-9	19573-19585	participants	_	
96-10	19585-19586	’	_	
96-11	19587-19610	deprivation-enhancement	_	
96-12	19611-19614	was	_	
96-13	19615-19628	significantly	_	
96-14	19629-19639	associated	_	
96-15	19640-19644	with	_	
96-16	19645-19648	the	_	
96-17	19649-19655	degree	_	
96-18	19656-19658	of	_	
96-19	19659-19682	deprivation-enhancement	_	
96-20	19683-19685	of	_	
96-21	19686-19694	positive	_	
96-22	19695-19705	prediction	_	
96-23	19706-19711	error	_	
96-24	19712-19721	responses	_	
96-25	19722-19724	in	_	
96-26	19725-19728	the	_	
96-27	19729-19737	striatum	_	
96-28	19738-19739	(	_	
96-29	19739-19740	C	_	
96-30	19740-19741	-	_	
96-31	19742-19743	>	_	
96-32	19744-19745	C	_	
96-33	19745-19746	+	_	
96-34	19747-19750	for	_	
96-35	19751-19752	α	_	
96-36	19752-19753	+	_	
96-37	19754-19757	and	_	
96-38	19758-19764	neural	_	
96-39	19765-19766	C	_	
96-40	19766-19767	-	_	
96-41	19768-19769	>	_	
96-42	19770-19771	C	_	
96-43	19771-19772	+	_	
96-44	19773-19776	for	_	
96-45	19777-19778	δ	_	
96-46	19778-19779	+	_	
96-47	19779-19780	;	_	
96-48	19781-19787	Figure	_	
96-49	19788-19790	2B	_	
96-50	19790-19791	;	_	
96-51	19792-19797	Table	_	
96-52	19798-19801	S2C	_	
96-53	19801-19802	;	_	
96-54	19803-19804	r	_	
96-55	19805-19806	=	_	
96-56	19807-19811	0.79	_	
96-57	19811-19812	,	_	
96-58	19813-19814	p	_	
96-59	19815-19816	<	_	
96-60	19817-19821	0.01	_	
96-61	19821-19822	;	_	
96-62	19823-19828	using	_	
96-63	19829-19842	leave-one-out	_	
96-64	19843-19848	cross	_	
96-65	19849-19859	validation	_	
96-66	19860-19862	to	_	
96-67	19863-19868	avoid	_	
96-68	19869-19878	potential	_	
96-69	19879-19883	bias	_	
96-70	19884-19887	due	_	
96-71	19888-19890	to	_	
96-72	19891-19907	non-independence	_	
96-73	19907-19908	;	_	
96-74	19909-19911	35	_	
96-75	19911-19912	)	_	
96-76	19912-19913	.	_	

#Text=No relationship between drug-state modulation of negative learning rates and their associated neural prediction error signals was observed (C- > C+ for α- and neural C- > C+ for δ-; r = −0.08, p = 0.72; Figure 2C).
97-1	19914-19916	No	_	
97-2	19917-19929	relationship	_	
97-3	19930-19937	between	_	
97-4	19938-19948	drug-state	_	
97-5	19949-19959	modulation	_	
97-6	19960-19962	of	_	
97-7	19963-19971	negative	_	
97-8	19972-19980	learning	_	
97-9	19981-19986	rates	_	
97-10	19987-19990	and	_	
97-11	19991-19996	their	_	
97-12	19997-20007	associated	_	
97-13	20008-20014	neural	_	
97-14	20015-20025	prediction	_	
97-15	20026-20031	error	_	
97-16	20032-20039	signals	_	
97-17	20040-20043	was	_	
97-18	20044-20052	observed	_	
97-19	20053-20054	(	_	
97-20	20054-20055	C	_	
97-21	20055-20056	-	_	
97-22	20057-20058	>	_	
97-23	20059-20060	C	_	
97-24	20060-20061	+	_	
97-25	20062-20065	for	_	
97-26	20066-20067	α	_	
97-27	20067-20068	-	_	
97-28	20069-20072	and	_	
97-29	20073-20079	neural	_	
97-30	20080-20081	C	_	
97-31	20081-20082	-	_	
97-32	20083-20084	>	_	
97-33	20085-20086	C	_	
97-34	20086-20087	+	_	
97-35	20088-20091	for	_	
97-36	20092-20093	δ	_	
97-37	20093-20094	-	_	
97-38	20094-20095	;	_	
97-39	20096-20097	r	_	
97-40	20098-20099	=	_	
97-41	20100-20101	−	_	
97-42	20101-20105	0.08	_	
97-43	20105-20106	,	_	
97-44	20107-20108	p	_	
97-45	20109-20110	=	_	
97-46	20111-20115	0.72	_	
97-47	20115-20116	;	_	
97-48	20117-20123	Figure	_	
97-49	20124-20126	2C	_	
97-50	20126-20127	)	_	
97-51	20127-20128	.	_	

#Text=For C- > C+ contrasts that further show ‘deprivation- enhancement’ see Figure S2A and Table S2D.
98-1	20129-20132	For	_	
98-2	20133-20134	C	_	
98-3	20134-20135	-	_	
98-4	20136-20137	>	_	
98-5	20138-20139	C	_	
98-6	20139-20140	+	_	
98-7	20141-20150	contrasts	_	
98-8	20151-20155	that	_	
98-9	20156-20163	further	_	
98-10	20164-20168	show	_	
98-11	20169-20170	‘	_	
98-12	20170-20181	deprivation	_	
98-13	20181-20182	-	_	
98-14	20183-20194	enhancement	_	
98-15	20194-20195	’	_	
98-16	20196-20199	see	_	
98-17	20200-20206	Figure	_	
98-18	20207-20210	S2A	_	
98-19	20211-20214	and	_	
98-20	20215-20220	Table	_	
98-21	20221-20224	S2D	_	
98-22	20224-20225	.	_	

#Text=Figure S3 shows similar imaging results when using group estimates from within-status behavioral estimates.
99-1	20226-20232	Figure	_	
99-2	20233-20235	S3	_	
99-3	20236-20241	shows	_	
99-4	20242-20249	similar	_	
99-5	20250-20257	imaging	_	
99-6	20258-20265	results	_	
99-7	20266-20270	when	_	
99-8	20271-20276	using	_	
99-9	20277-20282	group	_	
99-10	20283-20292	estimates	_	
99-11	20293-20297	from	_	
99-12	20298-20311	within-status	_	
99-13	20312-20322	behavioral	_	
99-14	20323-20332	estimates	_	
99-15	20332-20333	.	_	

#Text=In addition, no effects of cocaine deprivation on neural expected value signals were detected (Figure S2B), indicating generally intact outcome valuation unaffected by drug use status.
100-1	20334-20336	In	_	
100-2	20337-20345	addition	_	
100-3	20345-20346	,	_	
100-4	20347-20349	no	_	
100-5	20350-20357	effects	_	
100-6	20358-20360	of	_	
100-7	20361-20368	cocaine	_	
100-8	20369-20380	deprivation	_	
100-9	20381-20383	on	_	
100-10	20384-20390	neural	_	
100-11	20391-20399	expected	_	
100-12	20400-20405	value	_	
100-13	20406-20413	signals	_	
100-14	20414-20418	were	_	
100-15	20419-20427	detected	_	
100-16	20428-20429	(	_	
100-17	20429-20435	Figure	_	
100-18	20436-20439	S2B	_	
100-19	20439-20440	)	_	
100-20	20440-20441	,	_	
100-21	20442-20452	indicating	_	
100-22	20453-20462	generally	_	
100-23	20463-20469	intact	_	
100-24	20470-20477	outcome	_	
100-25	20478-20487	valuation	_	
100-26	20488-20498	unaffected	_	
100-27	20499-20501	by	_	
100-28	20502-20506	drug	_	
100-29	20507-20510	use	_	
100-30	20511-20517	status	_	
100-31	20517-20518	.	_	

#Text=Results relating neural prediction error signals and behavioral cocaine use measures.
101-1	20519-20526	Results	_	
101-2	20527-20535	relating	_	
101-3	20536-20542	neural	_	
101-4	20543-20553	prediction	_	
101-5	20554-20559	error	_	
101-6	20560-20567	signals	_	
101-7	20568-20571	and	_	
101-8	20572-20582	behavioral	_	
101-9	20583-20590	cocaine	_	
101-10	20591-20594	use	_	
101-11	20595-20603	measures	_	
101-12	20603-20604	.	_	

#Text=As described above, the specificity of drug-state modulation and deprivation-enhancement to positive (i.e., successful loss avoidance) prediction errors (δ+) was consistent with the hypothesis that reinforcement from successfully avoiding negative states contributes to continued drug seeking in addiction.
102-1	20605-20607	As	_	
102-2	20608-20617	described	_	
102-3	20618-20623	above	_	
102-4	20623-20624	,	_	
102-5	20625-20628	the	_	
102-6	20629-20640	specificity	_	
102-7	20641-20643	of	_	
102-8	20644-20654	drug-state	_	
102-9	20655-20665	modulation	_	
102-10	20666-20669	and	_	
102-11	20670-20693	deprivation-enhancement	_	
102-12	20694-20696	to	_	
102-13	20697-20705	positive	_	
102-14	20706-20707	(	_	
102-15	20707-20710	i.e	_	
102-16	20710-20711	.	_	
102-17	20711-20712	,	_	
102-18	20713-20723	successful	_	
102-19	20724-20728	loss	_	
102-20	20729-20738	avoidance	_	
102-21	20738-20739	)	_	
102-22	20740-20750	prediction	_	
102-23	20751-20757	errors	_	
102-24	20758-20759	(	_	
102-25	20759-20760	δ	_	
102-26	20760-20761	+	_	
102-27	20761-20762	)	_	
102-28	20763-20766	was	_	
102-29	20767-20777	consistent	_	
102-30	20778-20782	with	_	
102-31	20783-20786	the	_	
102-32	20787-20797	hypothesis	_	
102-33	20798-20802	that	_	
102-34	20803-20816	reinforcement	_	
102-35	20817-20821	from	_	
102-36	20822-20834	successfully	_	
102-37	20835-20843	avoiding	_	
102-38	20844-20852	negative	_	
102-39	20853-20859	states	_	
102-40	20860-20871	contributes	_	
102-41	20872-20874	to	_	
102-42	20875-20884	continued	_	
102-43	20885-20889	drug	_	
102-44	20890-20897	seeking	_	
102-45	20898-20900	in	_	
102-46	20901-20910	addiction	_	
102-47	20910-20911	.	_	

#Text=In this case, successful loss avoidance in cocaine-deprived participants should be further related to aspects of real-world cocaine use.
103-1	20912-20914	In	_	
103-2	20915-20919	this	_	
103-3	20920-20924	case	_	
103-4	20924-20925	,	_	
103-5	20926-20936	successful	_	
103-6	20937-20941	loss	_	
103-7	20942-20951	avoidance	_	
103-8	20952-20954	in	_	
103-9	20955-20971	cocaine-deprived	_	
103-10	20972-20984	participants	_	
103-11	20985-20991	should	_	
103-12	20992-20994	be	_	
103-13	20995-21002	further	_	
103-14	21003-21010	related	_	
103-15	21011-21013	to	_	
103-16	21014-21021	aspects	_	
103-17	21022-21024	of	_	
103-18	21025-21035	real-world	_	
103-19	21036-21043	cocaine	_	
103-20	21044-21047	use	_	
103-21	21047-21048	.	_	

#Text=To test this possibility, we regressed C- individuals’ neural δ+ responses (beta values from outcomes with δ+) against self-reported drug craving (subscales of Cocaine Craving Questionnaire, CCQ; Figure S4A; Table S3) and observed that neural δ+ responses were related specifically to the desire to use cocaine (Figure 3A; Table S3; r = 0.70, p < 0.01; correlations again performed using neural signals obtained from leave-one-out cross-validation analyses and Bonferroni corrected for multiple comparisons as described in Methods; 35).
104-1	21049-21051	To	_	
104-2	21052-21056	test	_	
104-3	21057-21061	this	_	
104-4	21062-21073	possibility	_	
104-5	21073-21074	,	_	
104-6	21075-21077	we	_	
104-7	21078-21087	regressed	_	
104-8	21088-21089	C	_	
104-9	21089-21090	-	_	
104-10	21091-21102	individuals	_	
104-11	21102-21103	’	_	
104-12	21104-21110	neural	_	
104-13	21111-21112	δ	_	
104-14	21112-21113	+	_	
104-15	21114-21123	responses	_	
104-16	21124-21125	(	_	
104-17	21125-21129	beta	_	
104-18	21130-21136	values	_	
104-19	21137-21141	from	_	
104-20	21142-21150	outcomes	_	
104-21	21151-21155	with	_	
104-22	21156-21157	δ	_	
104-23	21157-21158	+	_	
104-24	21158-21159	)	_	
104-25	21160-21167	against	_	
104-26	21168-21181	self-reported	_	
104-27	21182-21186	drug	_	
104-28	21187-21194	craving	_	
104-29	21195-21196	(	_	
104-30	21196-21205	subscales	_	
104-31	21206-21208	of	_	
104-32	21209-21216	Cocaine	_	
104-33	21217-21224	Craving	_	
104-34	21225-21238	Questionnaire	_	
104-35	21238-21239	,	_	
104-36	21240-21243	CCQ	_	
104-37	21243-21244	;	_	
104-38	21245-21251	Figure	_	
104-39	21252-21255	S4A	_	
104-40	21255-21256	;	_	
104-41	21257-21262	Table	_	
104-42	21263-21265	S3	_	
104-43	21265-21266	)	_	
104-44	21267-21270	and	_	
104-45	21271-21279	observed	_	
104-46	21280-21284	that	_	
104-47	21285-21291	neural	_	
104-48	21292-21293	δ	_	
104-49	21293-21294	+	_	
104-50	21295-21304	responses	_	
104-51	21305-21309	were	_	
104-52	21310-21317	related	_	
104-53	21318-21330	specifically	_	
104-54	21331-21333	to	_	
104-55	21334-21337	the	_	
104-56	21338-21344	desire	_	
104-57	21345-21347	to	_	
104-58	21348-21351	use	_	
104-59	21352-21359	cocaine	_	
104-60	21360-21361	(	_	
104-61	21361-21367	Figure	_	
104-62	21368-21370	3A	_	
104-63	21370-21371	;	_	
104-64	21372-21377	Table	_	
104-65	21378-21380	S3	_	
104-66	21380-21381	;	_	
104-67	21382-21383	r	_	
104-68	21384-21385	=	_	
104-69	21386-21390	0.70	_	
104-70	21390-21391	,	_	
104-71	21392-21393	p	_	
104-72	21394-21395	<	_	
104-73	21396-21400	0.01	_	
104-74	21400-21401	;	_	
104-75	21402-21414	correlations	_	
104-76	21415-21420	again	_	
104-77	21421-21430	performed	_	
104-78	21431-21436	using	_	
104-79	21437-21443	neural	_	
104-80	21444-21451	signals	_	
104-81	21452-21460	obtained	_	
104-82	21461-21465	from	_	
104-83	21466-21479	leave-one-out	_	
104-84	21480-21496	cross-validation	_	
104-85	21497-21505	analyses	_	
104-86	21506-21509	and	_	
104-87	21510-21520	Bonferroni	_	
104-88	21521-21530	corrected	_	
104-89	21531-21534	for	_	
104-90	21535-21543	multiple	_	
104-91	21544-21555	comparisons	_	
104-92	21556-21558	as	_	
104-93	21559-21568	described	_	
104-94	21569-21571	in	_	
104-95	21572-21579	Methods	_	
104-96	21579-21580	;	_	
104-97	21581-21583	35	_	
104-98	21583-21584	)	_	
104-99	21584-21585	.	_	

#Text=These relationships were also present using the deprivation-enhanced neural δ+ signal (i.e., C- > C+, extracted from outcomes with δ+; r = 0.67, p < 0.01) and not observed in the C+ state (i.e., signal from outcomes with ô+ while C+; Figure S4B; r = −0.20, p = 0.42).
105-1	21586-21591	These	_	
105-2	21592-21605	relationships	_	
105-3	21606-21610	were	_	
105-4	21611-21615	also	_	
105-5	21616-21623	present	_	
105-6	21624-21629	using	_	
105-7	21630-21633	the	_	
105-8	21634-21654	deprivation-enhanced	_	
105-9	21655-21661	neural	_	
105-10	21662-21663	δ	_	
105-11	21663-21664	+	_	
105-12	21665-21671	signal	_	
105-13	21672-21673	(	_	
105-14	21673-21676	i.e	_	
105-15	21676-21677	.	_	
105-16	21677-21678	,	_	
105-17	21679-21680	C	_	
105-18	21680-21681	-	_	
105-19	21682-21683	>	_	
105-20	21684-21685	C	_	
105-21	21685-21686	+	_	
105-22	21686-21687	,	_	
105-23	21688-21697	extracted	_	
105-24	21698-21702	from	_	
105-25	21703-21711	outcomes	_	
105-26	21712-21716	with	_	
105-27	21717-21718	δ	_	
105-28	21718-21719	+	_	
105-29	21719-21720	;	_	
105-30	21721-21722	r	_	
105-31	21723-21724	=	_	
105-32	21725-21729	0.67	_	
105-33	21729-21730	,	_	
105-34	21731-21732	p	_	
105-35	21733-21734	<	_	
105-36	21735-21739	0.01	_	
105-37	21739-21740	)	_	
105-38	21741-21744	and	_	
105-39	21745-21748	not	_	
105-40	21749-21757	observed	_	
105-41	21758-21760	in	_	
105-42	21761-21764	the	_	
105-43	21765-21766	C	_	
105-44	21766-21767	+	_	
105-45	21768-21773	state	_	
105-46	21774-21775	(	_	
105-47	21775-21778	i.e	_	
105-48	21778-21779	.	_	
105-49	21779-21780	,	_	
105-50	21781-21787	signal	_	
105-51	21788-21792	from	_	
105-52	21793-21801	outcomes	_	
105-53	21802-21806	with	_	
105-54	21807-21808	ô	_	
105-55	21808-21809	+	_	
105-56	21810-21815	while	_	
105-57	21816-21817	C	_	
105-58	21817-21818	+	_	
105-59	21818-21819	;	_	
105-60	21820-21826	Figure	_	
105-61	21827-21830	S4B	_	
105-62	21830-21831	;	_	
105-63	21832-21833	r	_	
105-64	21834-21835	=	_	
105-65	21836-21837	−	_	
105-66	21837-21841	0.20	_	
105-67	21841-21842	,	_	
105-68	21843-21844	p	_	
105-69	21845-21846	=	_	
105-70	21847-21851	0.42	_	
105-71	21851-21852	)	_	
105-72	21852-21853	.	_	

#Text=Greater neural δ+ responses during cocaine deprivation were also associated with greater years of cocaine use (C-; Figure 3A; r = 0.64, p < 0.01; no relationship between neural δ+ and chronicity of use was observed for participants in the C+ state, Figure S4C, r = −0.09, p = 0.71).
106-1	21854-21861	Greater	_	
106-2	21862-21868	neural	_	
106-3	21869-21870	δ	_	
106-4	21870-21871	+	_	
106-5	21872-21881	responses	_	
106-6	21882-21888	during	_	
106-7	21889-21896	cocaine	_	
106-8	21897-21908	deprivation	_	
106-9	21909-21913	were	_	
106-10	21914-21918	also	_	
106-11	21919-21929	associated	_	
106-12	21930-21934	with	_	
106-13	21935-21942	greater	_	
106-14	21943-21948	years	_	
106-15	21949-21951	of	_	
106-16	21952-21959	cocaine	_	
106-17	21960-21963	use	_	
106-18	21964-21965	(	_	
106-19	21965-21966	C	_	
106-20	21966-21967	-	_	
106-21	21967-21968	;	_	
106-22	21969-21975	Figure	_	
106-23	21976-21978	3A	_	
106-24	21978-21979	;	_	
106-25	21980-21981	r	_	
106-26	21982-21983	=	_	
106-27	21984-21988	0.64	_	
106-28	21988-21989	,	_	
106-29	21990-21991	p	_	
106-30	21992-21993	<	_	
106-31	21994-21998	0.01	_	
106-32	21998-21999	;	_	
106-33	22000-22002	no	_	
106-34	22003-22015	relationship	_	
106-35	22016-22023	between	_	
106-36	22024-22030	neural	_	
106-37	22031-22032	δ	_	
106-38	22032-22033	+	_	
106-39	22034-22037	and	_	
106-40	22038-22048	chronicity	_	
106-41	22049-22051	of	_	
106-42	22052-22055	use	_	
106-43	22056-22059	was	_	
106-44	22060-22068	observed	_	
106-45	22069-22072	for	_	
106-46	22073-22085	participants	_	
106-47	22086-22088	in	_	
106-48	22089-22092	the	_	
106-49	22093-22094	C	_	
106-50	22094-22095	+	_	
106-51	22096-22101	state	_	
106-52	22101-22102	,	_	
106-53	22103-22109	Figure	_	
106-54	22110-22113	S4C	_	
106-55	22113-22114	,	_	
106-56	22115-22116	r	_	
106-57	22117-22118	=	_	
106-58	22119-22120	−	_	
106-59	22120-22124	0.09	_	
106-60	22124-22125	,	_	
106-61	22126-22127	p	_	
106-62	22128-22129	=	_	
106-63	22130-22134	0.71	_	
106-64	22134-22135	)	_	
106-65	22135-22136	.	_	

#Text=No other subscales of the CCQ were correlated with striatal δ+ signals (Table S3).
107-1	22137-22139	No	_	
107-2	22140-22145	other	_	
107-3	22146-22155	subscales	_	
107-4	22156-22158	of	_	
107-5	22159-22162	the	_	
107-6	22163-22166	CCQ	_	
107-7	22167-22171	were	_	
107-8	22172-22182	correlated	_	
107-9	22183-22187	with	_	
107-10	22188-22196	striatal	_	
107-11	22197-22198	δ	_	
107-12	22198-22199	+	_	
107-13	22200-22207	signals	_	
107-14	22208-22209	(	_	
107-15	22209-22214	Table	_	
107-16	22215-22217	S3	_	
107-17	22217-22218	)	_	
107-18	22218-22219	.	_	

#Text=Lastly, desire to use cocaine (Figure 3A; r = 0.61, p < 0.01) was also positively correlated with participants’ years of cocaine use.
108-1	22220-22226	Lastly	_	
108-2	22226-22227	,	_	
108-3	22228-22234	desire	_	
108-4	22235-22237	to	_	
108-5	22238-22241	use	_	
108-6	22242-22249	cocaine	_	
108-7	22250-22251	(	_	
108-8	22251-22257	Figure	_	
108-9	22258-22260	3A	_	
108-10	22260-22261	;	_	
108-11	22262-22263	r	_	
108-12	22264-22265	=	_	
108-13	22266-22270	0.61	_	
108-14	22270-22271	,	_	
108-15	22272-22273	p	_	
108-16	22274-22275	<	_	
108-17	22276-22280	0.01	_	
108-18	22280-22281	)	_	
108-19	22282-22285	was	_	
108-20	22286-22290	also	_	
108-21	22291-22301	positively	_	
108-22	22302-22312	correlated	_	
108-23	22313-22317	with	_	
108-24	22318-22330	participants	_	
108-25	22330-22331	’	_	
108-26	22332-22337	years	_	
108-27	22338-22340	of	_	
108-28	22341-22348	cocaine	_	
108-29	22349-22352	use	_	
108-30	22352-22353	.	_	

#Text=Following these observed relationships, a mediation analysis (; see Methods) revealed that the deprivation-enhanced neural δ+ signal fully mediated the relationship between years of cocaine use and desire to use cocaine use while deprived (Figure 3B; path c: β = 0.09, p < 0.01; path a: β = 0.06, p = 0.04; path b: β = 0.66, p = 0.01; path c’: β = 0.05, p = 0.07; mediation effect a*b: 95% CI 0.0008–0.0953).
109-1	22354-22363	Following	_	
109-2	22364-22369	these	_	
109-3	22370-22378	observed	_	
109-4	22379-22392	relationships	_	
109-5	22392-22393	,	_	
109-6	22394-22395	a	_	
109-7	22396-22405	mediation	_	
109-8	22406-22414	analysis	_	
109-9	22415-22416	(	_	
109-10	22416-22417	;	_	
109-11	22418-22421	see	_	
109-12	22422-22429	Methods	_	
109-13	22429-22430	)	_	
109-14	22431-22439	revealed	_	
109-15	22440-22444	that	_	
109-16	22445-22448	the	_	
109-17	22449-22469	deprivation-enhanced	_	
109-18	22470-22476	neural	_	
109-19	22477-22478	δ	_	
109-20	22478-22479	+	_	
109-21	22480-22486	signal	_	
109-22	22487-22492	fully	_	
109-23	22493-22501	mediated	_	
109-24	22502-22505	the	_	
109-25	22506-22518	relationship	_	
109-26	22519-22526	between	_	
109-27	22527-22532	years	_	
109-28	22533-22535	of	_	
109-29	22536-22543	cocaine	_	
109-30	22544-22547	use	_	
109-31	22548-22551	and	_	
109-32	22552-22558	desire	_	
109-33	22559-22561	to	_	
109-34	22562-22565	use	_	
109-35	22566-22573	cocaine	_	
109-36	22574-22577	use	_	
109-37	22578-22583	while	_	
109-38	22584-22592	deprived	_	
109-39	22593-22594	(	_	
109-40	22594-22600	Figure	_	
109-41	22601-22603	3B	_	
109-42	22603-22604	;	_	
109-43	22605-22609	path	_	
109-44	22610-22611	c	_	
109-45	22611-22612	:	_	
109-46	22613-22614	β	_	
109-47	22615-22616	=	_	
109-48	22617-22621	0.09	_	
109-49	22621-22622	,	_	
109-50	22623-22624	p	_	
109-51	22625-22626	<	_	
109-52	22627-22631	0.01	_	
109-53	22631-22632	;	_	
109-54	22633-22637	path	_	
109-55	22638-22639	a	_	
109-56	22639-22640	:	_	
109-57	22641-22642	β	_	
109-58	22643-22644	=	_	
109-59	22645-22649	0.06	_	
109-60	22649-22650	,	_	
109-61	22651-22652	p	_	
109-62	22653-22654	=	_	
109-63	22655-22659	0.04	_	
109-64	22659-22660	;	_	
109-65	22661-22665	path	_	
109-66	22666-22667	b	_	
109-67	22667-22668	:	_	
109-68	22669-22670	β	_	
109-69	22671-22672	=	_	
109-70	22673-22677	0.66	_	
109-71	22677-22678	,	_	
109-72	22679-22680	p	_	
109-73	22681-22682	=	_	
109-74	22683-22687	0.01	_	
109-75	22687-22688	;	_	
109-76	22689-22693	path	_	
109-77	22694-22695	c	_	
109-78	22695-22696	’	_	
109-79	22696-22697	:	_	
109-80	22698-22699	β	_	
109-81	22700-22701	=	_	
109-82	22702-22706	0.05	_	
109-83	22706-22707	,	_	
109-84	22708-22709	p	_	
109-85	22710-22711	=	_	
109-86	22712-22716	0.07	_	
109-87	22716-22717	;	_	
109-88	22718-22727	mediation	_	
109-89	22728-22734	effect	_	
109-90	22735-22736	a	_	
109-91	22736-22737	*	_	
109-92	22737-22738	b	_	
109-93	22738-22739	:	_	
109-94	22740-22743	95%	_	
109-95	22744-22746	CI	_	
109-96	22747-22753	0.0008	_	
109-97	22753-22754	–	_	
109-98	22754-22760	0.0953	_	
109-99	22760-22761	)	_	
109-100	22761-22762	.	_	

#Text=Discussion
#Text=Using a computational psychiatry approach, we show drug-state modulation of learning signals in cocaine dependent participants, such that successful loss avoidance signals are greater during deprivation, and the neural responses are associated with both longer history of drug use and greater desire for cocaine.
110-1	22763-22773	Discussion	_	
110-2	22774-22779	Using	_	
110-3	22780-22781	a	_	
110-4	22782-22795	computational	_	
110-5	22796-22806	psychiatry	_	
110-6	22807-22815	approach	_	
110-7	22815-22816	,	_	
110-8	22817-22819	we	_	
110-9	22820-22824	show	_	
110-10	22825-22835	drug-state	_	
110-11	22836-22846	modulation	_	
110-12	22847-22849	of	_	
110-13	22850-22858	learning	_	
110-14	22859-22866	signals	_	
110-15	22867-22869	in	_	
110-16	22870-22877	cocaine	_	
110-17	22878-22887	dependent	_	
110-18	22888-22900	participants	_	
110-19	22900-22901	,	_	
110-20	22902-22906	such	_	
110-21	22907-22911	that	_	
110-22	22912-22922	successful	_	
110-23	22923-22927	loss	_	
110-24	22928-22937	avoidance	_	
110-25	22938-22945	signals	_	
110-26	22946-22949	are	_	
110-27	22950-22957	greater	_	
110-28	22958-22964	during	_	
110-29	22965-22976	deprivation	_	
110-30	22976-22977	,	_	
110-31	22978-22981	and	_	
110-32	22982-22985	the	_	
110-33	22986-22992	neural	_	
110-34	22993-23002	responses	_	
110-35	23003-23006	are	_	
110-36	23007-23017	associated	_	
110-37	23018-23022	with	_	
110-38	23023-23027	both	_	
110-39	23028-23034	longer	_	
110-40	23035-23042	history	_	
110-41	23043-23045	of	_	
110-42	23046-23050	drug	_	
110-43	23051-23054	use	_	
110-44	23055-23058	and	_	
110-45	23059-23066	greater	_	
110-46	23067-23073	desire	_	
110-47	23074-23077	for	_	
110-48	23078-23085	cocaine	_	
110-49	23085-23086	.	_	

#Text=The specificity of the deprivation-enhancement to positive neural prediction error signals during loss-avoidance appears to parallel clinical descriptions of addiction as a cycle maintained by negative reinforcement wherein drug-deprived dependent individuals seek drugs and thus successfully avoid negative states (e.g., withdrawal, isolation etc.); such successful loss-avoidance has been posited to reinforce continued drug seeking (for relevant discussions see).
111-1	23087-23090	The	_	
111-2	23091-23102	specificity	_	
111-3	23103-23105	of	_	
111-4	23106-23109	the	_	
111-5	23110-23133	deprivation-enhancement	_	
111-6	23134-23136	to	_	
111-7	23137-23145	positive	_	
111-8	23146-23152	neural	_	
111-9	23153-23163	prediction	_	
111-10	23164-23169	error	_	
111-11	23170-23177	signals	_	
111-12	23178-23184	during	_	
111-13	23185-23199	loss-avoidance	_	
111-14	23200-23207	appears	_	
111-15	23208-23210	to	_	
111-16	23211-23219	parallel	_	
111-17	23220-23228	clinical	_	
111-18	23229-23241	descriptions	_	
111-19	23242-23244	of	_	
111-20	23245-23254	addiction	_	
111-21	23255-23257	as	_	
111-22	23258-23259	a	_	
111-23	23260-23265	cycle	_	
111-24	23266-23276	maintained	_	
111-25	23277-23279	by	_	
111-26	23280-23288	negative	_	
111-27	23289-23302	reinforcement	_	
111-28	23303-23310	wherein	_	
111-29	23311-23324	drug-deprived	_	
111-30	23325-23334	dependent	_	
111-31	23335-23346	individuals	_	
111-32	23347-23351	seek	_	
111-33	23352-23357	drugs	_	
111-34	23358-23361	and	_	
111-35	23362-23366	thus	_	
111-36	23367-23379	successfully	_	
111-37	23380-23385	avoid	_	
111-38	23386-23394	negative	_	
111-39	23395-23401	states	_	
111-40	23402-23403	(	_	
111-41	23403-23406	e.g	_	
111-42	23406-23407	.	_	
111-43	23407-23408	,	_	
111-44	23409-23419	withdrawal	_	
111-45	23419-23420	,	_	
111-46	23421-23430	isolation	_	
111-47	23431-23434	etc	_	
111-48	23434-23435	.	_	
111-49	23435-23436	)	_	
111-50	23436-23437	;	_	
111-51	23438-23442	such	_	
111-52	23443-23453	successful	_	
111-53	23454-23468	loss-avoidance	_	
111-54	23469-23472	has	_	
111-55	23473-23477	been	_	
111-56	23478-23485	posited	_	
111-57	23486-23488	to	_	
111-58	23489-23498	reinforce	_	
111-59	23499-23508	continued	_	
111-60	23509-23513	drug	_	
111-61	23514-23521	seeking	_	
111-62	23522-23523	(	_	
111-63	23523-23526	for	_	
111-64	23527-23535	relevant	_	
111-65	23536-23547	discussions	_	
111-66	23548-23551	see	_	
111-67	23551-23552	)	_	
111-68	23552-23553	.	_	

#Text=These data are consonant with prior studies showing that with greater chronicity of cocaine use, physiological adaptations occur in DA systems.
112-1	23554-23559	These	_	
112-2	23560-23564	data	_	
112-3	23565-23568	are	_	
112-4	23569-23578	consonant	_	
112-5	23579-23583	with	_	
112-6	23584-23589	prior	_	
112-7	23590-23597	studies	_	
112-8	23598-23605	showing	_	
112-9	23606-23610	that	_	
112-10	23611-23615	with	_	
112-11	23616-23623	greater	_	
112-12	23624-23634	chronicity	_	
112-13	23635-23637	of	_	
112-14	23638-23645	cocaine	_	
112-15	23646-23649	use	_	
112-16	23649-23650	,	_	
112-17	23651-23664	physiological	_	
112-18	23665-23676	adaptations	_	
112-19	23677-23682	occur	_	
112-20	23683-23685	in	_	
112-21	23686-23688	DA	_	
112-22	23689-23696	systems	_	
112-23	23696-23697	.	_	

#Text=In particular, the enhanced neural positive prediction error (δ+) encoding in C- relative to C+ cocaine dependent participants is consistent with studies showing that long term cocaine dependent humans have decreased density of striatal DA receptors and lower tonic DA levels and that acute cocaine intake in chronically cocaine-treated mice reduces DA signaling.
113-1	23698-23700	In	_	
113-2	23701-23711	particular	_	
113-3	23711-23712	,	_	
113-4	23713-23716	the	_	
113-5	23717-23725	enhanced	_	
113-6	23726-23732	neural	_	
113-7	23733-23741	positive	_	
113-8	23742-23752	prediction	_	
113-9	23753-23758	error	_	
113-10	23759-23760	(	_	
113-11	23760-23761	δ	_	
113-12	23761-23762	+	_	
113-13	23762-23763	)	_	
113-14	23764-23772	encoding	_	
113-15	23773-23775	in	_	
113-16	23776-23777	C	_	
113-17	23777-23778	-	_	
113-18	23779-23787	relative	_	
113-19	23788-23790	to	_	
113-20	23791-23792	C	_	
113-21	23792-23793	+	_	
113-22	23794-23801	cocaine	_	
113-23	23802-23811	dependent	_	
113-24	23812-23824	participants	_	
113-25	23825-23827	is	_	
113-26	23828-23838	consistent	_	
113-27	23839-23843	with	_	
113-28	23844-23851	studies	_	
113-29	23852-23859	showing	_	
113-30	23860-23864	that	_	
113-31	23865-23869	long	_	
113-32	23870-23874	term	_	
113-33	23875-23882	cocaine	_	
113-34	23883-23892	dependent	_	
113-35	23893-23899	humans	_	
113-36	23900-23904	have	_	
113-37	23905-23914	decreased	_	
113-38	23915-23922	density	_	
113-39	23923-23925	of	_	
113-40	23926-23934	striatal	_	
113-41	23935-23937	DA	_	
113-42	23938-23947	receptors	_	
113-43	23948-23951	and	_	
113-44	23952-23957	lower	_	
113-45	23958-23963	tonic	_	
113-46	23964-23966	DA	_	
113-47	23967-23973	levels	_	
113-48	23974-23977	and	_	
113-49	23978-23982	that	_	
113-50	23983-23988	acute	_	
113-51	23989-23996	cocaine	_	
113-52	23997-24003	intake	_	
113-53	24004-24006	in	_	
113-54	24007-24018	chronically	_	
113-55	24019-24034	cocaine-treated	_	
113-56	24035-24039	mice	_	
113-57	24040-24047	reduces	_	
113-58	24048-24050	DA	_	
113-59	24051-24060	signaling	_	
113-60	24060-24061	.	_	

#Text=Following from these studies, δ+ signals ought to be more evident during drug deprivation (as observed here) than during drug use, as DA receptors, though diminished in density, are free in the deprived state to detect δ+ fluctuations.
114-1	24062-24071	Following	_	
114-2	24072-24076	from	_	
114-3	24077-24082	these	_	
114-4	24083-24090	studies	_	
114-5	24090-24091	,	_	
114-6	24092-24093	δ	_	
114-7	24093-24094	+	_	
114-8	24095-24102	signals	_	
114-9	24103-24108	ought	_	
114-10	24109-24111	to	_	
114-11	24112-24114	be	_	
114-12	24115-24119	more	_	
114-13	24120-24127	evident	_	
114-14	24128-24134	during	_	
114-15	24135-24139	drug	_	
114-16	24140-24151	deprivation	_	
114-17	24152-24153	(	_	
114-18	24153-24155	as	_	
114-19	24156-24164	observed	_	
114-20	24165-24169	here	_	
114-21	24169-24170	)	_	
114-22	24171-24175	than	_	
114-23	24176-24182	during	_	
114-24	24183-24187	drug	_	
114-25	24188-24191	use	_	
114-26	24191-24192	,	_	
114-27	24193-24195	as	_	
114-28	24196-24198	DA	_	
114-29	24199-24208	receptors	_	
114-30	24208-24209	,	_	
114-31	24210-24216	though	_	
114-32	24217-24227	diminished	_	
114-33	24228-24230	in	_	
114-34	24231-24238	density	_	
114-35	24238-24239	,	_	
114-36	24240-24243	are	_	
114-37	24244-24248	free	_	
114-38	24249-24251	in	_	
114-39	24252-24255	the	_	
114-40	24256-24264	deprived	_	
114-41	24265-24270	state	_	
114-42	24271-24273	to	_	
114-43	24274-24280	detect	_	
114-44	24281-24282	δ	_	
114-45	24282-24283	+	_	
114-46	24284-24296	fluctuations	_	
114-47	24296-24297	.	_	

#Text=We note that in the present cocaine dependent participants, neural δ+ responses in the drug-deprived state are comparable with the δ+ observed in non-psychiatric control participants, whereas δ+ signaling in the drug-using state was diminished relative to the control participants.
115-1	24298-24300	We	_	
115-2	24301-24305	note	_	
115-3	24306-24310	that	_	
115-4	24311-24313	in	_	
115-5	24314-24317	the	_	
115-6	24318-24325	present	_	
115-7	24326-24333	cocaine	_	
115-8	24334-24343	dependent	_	
115-9	24344-24356	participants	_	
115-10	24356-24357	,	_	
115-11	24358-24364	neural	_	
115-12	24365-24366	δ	_	
115-13	24366-24367	+	_	
115-14	24368-24377	responses	_	
115-15	24378-24380	in	_	
115-16	24381-24384	the	_	
115-17	24385-24398	drug-deprived	_	
115-18	24399-24404	state	_	
115-19	24405-24408	are	_	
115-20	24409-24419	comparable	_	
115-21	24420-24424	with	_	
115-22	24425-24428	the	_	
115-23	24429-24430	δ	_	
115-24	24430-24431	+	_	
115-25	24432-24440	observed	_	
115-26	24441-24443	in	_	
115-27	24444-24459	non-psychiatric	_	
115-28	24460-24467	control	_	
115-29	24468-24480	participants	_	
115-30	24480-24481	,	_	
115-31	24482-24489	whereas	_	
115-32	24490-24491	δ	_	
115-33	24491-24492	+	_	
115-34	24493-24502	signaling	_	
115-35	24503-24505	in	_	
115-36	24506-24509	the	_	
115-37	24510-24520	drug-using	_	
115-38	24521-24526	state	_	
115-39	24527-24530	was	_	
115-40	24531-24541	diminished	_	
115-41	24542-24550	relative	_	
115-42	24551-24553	to	_	
115-43	24554-24557	the	_	
115-44	24558-24565	control	_	
115-45	24566-24578	participants	_	
115-46	24578-24579	.	_	

#Text=Together these data suggest that although learning signal impairments appear restored by cocaine deprivation in dependent participants, such intact learning can have increasingly detrimental consequences in the context of unhealthy reinforcers, negative environmental states, and adverse outcomes (e.g., when dependent individuals are faced with withdrawal avoidance, drug-available environments, and drug-use).
116-1	24580-24588	Together	_	
116-2	24589-24594	these	_	
116-3	24595-24599	data	_	
116-4	24600-24607	suggest	_	
116-5	24608-24612	that	_	
116-6	24613-24621	although	_	
116-7	24622-24630	learning	_	
116-8	24631-24637	signal	_	
116-9	24638-24649	impairments	_	
116-10	24650-24656	appear	_	
116-11	24657-24665	restored	_	
116-12	24666-24668	by	_	
116-13	24669-24676	cocaine	_	
116-14	24677-24688	deprivation	_	
116-15	24689-24691	in	_	
116-16	24692-24701	dependent	_	
116-17	24702-24714	participants	_	
116-18	24714-24715	,	_	
116-19	24716-24720	such	_	
116-20	24721-24727	intact	_	
116-21	24728-24736	learning	_	
116-22	24737-24740	can	_	
116-23	24741-24745	have	_	
116-24	24746-24758	increasingly	_	
116-25	24759-24770	detrimental	_	
116-26	24771-24783	consequences	_	
116-27	24784-24786	in	_	
116-28	24787-24790	the	_	
116-29	24791-24798	context	_	
116-30	24799-24801	of	_	
116-31	24802-24811	unhealthy	_	
116-32	24812-24823	reinforcers	_	
116-33	24823-24824	,	_	
116-34	24825-24833	negative	_	
116-35	24834-24847	environmental	_	
116-36	24848-24854	states	_	
116-37	24854-24855	,	_	
116-38	24856-24859	and	_	
116-39	24860-24867	adverse	_	
116-40	24868-24876	outcomes	_	
116-41	24877-24878	(	_	
116-42	24878-24881	e.g	_	
116-43	24881-24882	.	_	
116-44	24882-24883	,	_	
116-45	24884-24888	when	_	
116-46	24889-24898	dependent	_	
116-47	24899-24910	individuals	_	
116-48	24911-24914	are	_	
116-49	24915-24920	faced	_	
116-50	24921-24925	with	_	
116-51	24926-24936	withdrawal	_	
116-52	24937-24946	avoidance	_	
116-53	24946-24947	,	_	
116-54	24948-24962	drug-available	_	
116-55	24963-24975	environments	_	
116-56	24975-24976	,	_	
116-57	24977-24980	and	_	
116-58	24981-24989	drug-use	_	
116-59	24989-24990	)	_	
116-60	24990-24991	.	_	

#Text=The present data are also relevant for closely related reports of significant increase in prediction error correlates following DA agonist administration and computational model based theories that drug use exacerbates prediction errors or triggers ‘false’ phasic activation of DA neurons.
117-1	24992-24995	The	_	
117-2	24996-25003	present	_	
117-3	25004-25008	data	_	
117-4	25009-25012	are	_	
117-5	25013-25017	also	_	
117-6	25018-25026	relevant	_	
117-7	25027-25030	for	_	
117-8	25031-25038	closely	_	
117-9	25039-25046	related	_	
117-10	25047-25054	reports	_	
117-11	25055-25057	of	_	
117-12	25058-25069	significant	_	
117-13	25070-25078	increase	_	
117-14	25079-25081	in	_	
117-15	25082-25092	prediction	_	
117-16	25093-25098	error	_	
117-17	25099-25109	correlates	_	
117-18	25110-25119	following	_	
117-19	25120-25122	DA	_	
117-20	25123-25130	agonist	_	
117-21	25131-25145	administration	_	
117-22	25146-25149	and	_	
117-23	25150-25163	computational	_	
117-24	25164-25169	model	_	
117-25	25170-25175	based	_	
117-26	25176-25184	theories	_	
117-27	25185-25189	that	_	
117-28	25190-25194	drug	_	
117-29	25195-25198	use	_	
117-30	25199-25210	exacerbates	_	
117-31	25211-25221	prediction	_	
117-32	25222-25228	errors	_	
117-33	25229-25231	or	_	
117-34	25232-25240	triggers	_	
117-35	25241-25242	‘	_	
117-36	25242-25247	false	_	
117-37	25247-25248	’	_	
117-38	25249-25255	phasic	_	
117-39	25256-25266	activation	_	
117-40	25267-25269	of	_	
117-41	25270-25272	DA	_	
117-42	25273-25280	neurons	_	
117-43	25280-25281	.	_	

#Text=A key difference between these previous reports and the present findings is the incorporation of the consequences of long-term drug dependence (i.e., diminished DA functioning) into an understanding of learning in addiction.
118-1	25282-25283	A	_	
118-2	25284-25287	key	_	
118-3	25288-25298	difference	_	
118-4	25299-25306	between	_	
118-5	25307-25312	these	_	
118-6	25313-25321	previous	_	
118-7	25322-25329	reports	_	
118-8	25330-25333	and	_	
118-9	25334-25337	the	_	
118-10	25338-25345	present	_	
118-11	25346-25354	findings	_	
118-12	25355-25357	is	_	
118-13	25358-25361	the	_	
118-14	25362-25375	incorporation	_	
118-15	25376-25378	of	_	
118-16	25379-25382	the	_	
118-17	25383-25395	consequences	_	
118-18	25396-25398	of	_	
118-19	25399-25408	long-term	_	
118-20	25409-25413	drug	_	
118-21	25414-25424	dependence	_	
118-22	25425-25426	(	_	
118-23	25426-25429	i.e	_	
118-24	25429-25430	.	_	
118-25	25430-25431	,	_	
118-26	25432-25442	diminished	_	
118-27	25443-25445	DA	_	
118-28	25446-25457	functioning	_	
118-29	25457-25458	)	_	
118-30	25459-25463	into	_	
118-31	25464-25466	an	_	
118-32	25467-25480	understanding	_	
118-33	25481-25483	of	_	
118-34	25484-25492	learning	_	
118-35	25493-25495	in	_	
118-36	25496-25505	addiction	_	
118-37	25505-25506	.	_	

#Text=In addition, the present diminished δ+ signaling in C+ and enhancement in C- individuals is consistent with related work showing DA drug-state modulation of learning signals in participants with Parkinson’s disease (who are known to have impaired DA function); these participants similarly show reduced prediction error-related BOLD responses when on DA enhancing medication (levodopa) and greater prediction error responses while off medication, specifically to positive prediction errors (δ+; ).
119-1	25507-25509	In	_	
119-2	25510-25518	addition	_	
119-3	25518-25519	,	_	
119-4	25520-25523	the	_	
119-5	25524-25531	present	_	
119-6	25532-25542	diminished	_	
119-7	25543-25544	δ	_	
119-8	25544-25545	+	_	
119-9	25546-25555	signaling	_	
119-10	25556-25558	in	_	
119-11	25559-25560	C	_	
119-12	25560-25561	+	_	
119-13	25562-25565	and	_	
119-14	25566-25577	enhancement	_	
119-15	25578-25580	in	_	
119-16	25581-25582	C	_	
119-17	25582-25583	-	_	
119-18	25584-25595	individuals	_	
119-19	25596-25598	is	_	
119-20	25599-25609	consistent	_	
119-21	25610-25614	with	_	
119-22	25615-25622	related	_	
119-23	25623-25627	work	_	
119-24	25628-25635	showing	_	
119-25	25636-25638	DA	_	
119-26	25639-25649	drug-state	_	
119-27	25650-25660	modulation	_	
119-28	25661-25663	of	_	
119-29	25664-25672	learning	_	
119-30	25673-25680	signals	_	
119-31	25681-25683	in	_	
119-32	25684-25696	participants	_	
119-33	25697-25701	with	_	
119-34	25702-25711	Parkinson	_	
119-35	25711-25712	’	_	
119-36	25712-25713	s	_	
119-37	25714-25721	disease	_	
119-38	25722-25723	(	_	
119-39	25723-25726	who	_	
119-40	25727-25730	are	_	
119-41	25731-25736	known	_	
119-42	25737-25739	to	_	
119-43	25740-25744	have	_	
119-44	25745-25753	impaired	_	
119-45	25754-25756	DA	_	
119-46	25757-25765	function	_	
119-47	25765-25766	)	_	
119-48	25766-25767	;	_	
119-49	25768-25773	these	_	
119-50	25774-25786	participants	_	
119-51	25787-25796	similarly	_	
119-52	25797-25801	show	_	
119-53	25802-25809	reduced	_	
119-54	25810-25820	prediction	_	
119-55	25821-25834	error-related	_	
119-56	25835-25839	BOLD	_	
119-57	25840-25849	responses	_	
119-58	25850-25854	when	_	
119-59	25855-25857	on	_	
119-60	25858-25860	DA	_	
119-61	25861-25870	enhancing	_	
119-62	25871-25881	medication	_	
119-63	25882-25883	(	_	
119-64	25883-25891	levodopa	_	
119-65	25891-25892	)	_	
119-66	25893-25896	and	_	
119-67	25897-25904	greater	_	
119-68	25905-25915	prediction	_	
119-69	25916-25921	error	_	
119-70	25922-25931	responses	_	
119-71	25932-25937	while	_	
119-72	25938-25941	off	_	
119-73	25942-25952	medication	_	
119-74	25952-25953	,	_	
119-75	25954-25966	specifically	_	
119-76	25967-25969	to	_	
119-77	25970-25978	positive	_	
119-78	25979-25989	prediction	_	
119-79	25990-25996	errors	_	
119-80	25997-25998	(	_	
119-81	25998-25999	δ	_	
119-82	25999-26000	+	_	
119-83	26000-26001	;	_	
119-84	26002-26003	)	_	
119-85	26003-26004	.	_	

#Text=Finally, we show that greater neural loss-learning δ+ (signaling successful loss-avoidance) during deprivation mediates a relationship between chronicity of drug use and desire for cocaine.
120-1	26005-26012	Finally	_	
120-2	26012-26013	,	_	
120-3	26014-26016	we	_	
120-4	26017-26021	show	_	
120-5	26022-26026	that	_	
120-6	26027-26034	greater	_	
120-7	26035-26041	neural	_	
120-8	26042-26055	loss-learning	_	
120-9	26056-26057	δ	_	
120-10	26057-26058	+	_	
120-11	26059-26060	(	_	
120-12	26060-26069	signaling	_	
120-13	26070-26080	successful	_	
120-14	26081-26095	loss-avoidance	_	
120-15	26095-26096	)	_	
120-16	26097-26103	during	_	
120-17	26104-26115	deprivation	_	
120-18	26116-26124	mediates	_	
120-19	26125-26126	a	_	
120-20	26127-26139	relationship	_	
120-21	26140-26147	between	_	
120-22	26148-26158	chronicity	_	
120-23	26159-26161	of	_	
120-24	26162-26166	drug	_	
120-25	26167-26170	use	_	
120-26	26171-26174	and	_	
120-27	26175-26181	desire	_	
120-28	26182-26185	for	_	
120-29	26186-26193	cocaine	_	
120-30	26193-26194	.	_	

#Text=This relationship supports the hypothesis that drug-state dependent learning signals play a role in maintaining drug use.
121-1	26195-26199	This	_	
121-2	26200-26212	relationship	_	
121-3	26213-26221	supports	_	
121-4	26222-26225	the	_	
121-5	26226-26236	hypothesis	_	
121-6	26237-26241	that	_	
121-7	26242-26252	drug-state	_	
121-8	26253-26262	dependent	_	
121-9	26263-26271	learning	_	
121-10	26272-26279	signals	_	
121-11	26280-26284	play	_	
121-12	26285-26286	a	_	
121-13	26287-26291	role	_	
121-14	26292-26294	in	_	
121-15	26295-26306	maintaining	_	
121-16	26307-26311	drug	_	
121-17	26312-26315	use	_	
121-18	26315-26316	.	_	

#Text=The present data thus emphasize that both drug-use chronicity and the context in which learning is assessed (e.g., loss, gain, etc.) may be critical for identifying neurobehavioral mechanisms that maintain drug use (for related data indicating differences in neural substrates of loss and gain learning, see).
122-1	26317-26320	The	_	
122-2	26321-26328	present	_	
122-3	26329-26333	data	_	
122-4	26334-26338	thus	_	
122-5	26339-26348	emphasize	_	
122-6	26349-26353	that	_	
122-7	26354-26358	both	_	
122-8	26359-26367	drug-use	_	
122-9	26368-26378	chronicity	_	
122-10	26379-26382	and	_	
122-11	26383-26386	the	_	
122-12	26387-26394	context	_	
122-13	26395-26397	in	_	
122-14	26398-26403	which	_	
122-15	26404-26412	learning	_	
122-16	26413-26415	is	_	
122-17	26416-26424	assessed	_	
122-18	26425-26426	(	_	
122-19	26426-26429	e.g	_	
122-20	26429-26430	.	_	
122-21	26430-26431	,	_	
122-22	26432-26436	loss	_	
122-23	26436-26437	,	_	
122-24	26438-26442	gain	_	
122-25	26442-26443	,	_	
122-26	26444-26447	etc	_	
122-27	26447-26448	.	_	
122-28	26448-26449	)	_	
122-29	26450-26453	may	_	
122-30	26454-26456	be	_	
122-31	26457-26465	critical	_	
122-32	26466-26469	for	_	
122-33	26470-26481	identifying	_	
122-34	26482-26497	neurobehavioral	_	
122-35	26498-26508	mechanisms	_	
122-36	26509-26513	that	_	
122-37	26514-26522	maintain	_	
122-38	26523-26527	drug	_	
122-39	26528-26531	use	_	
122-40	26532-26533	(	_	
122-41	26533-26536	for	_	
122-42	26537-26544	related	_	
122-43	26545-26549	data	_	
122-44	26550-26560	indicating	_	
122-45	26561-26572	differences	_	
122-46	26573-26575	in	_	
122-47	26576-26582	neural	_	
122-48	26583-26593	substrates	_	
122-49	26594-26596	of	_	
122-50	26597-26601	loss	_	
122-51	26602-26605	and	_	
122-52	26606-26610	gain	_	
122-53	26611-26619	learning	_	
122-54	26619-26620	,	_	
122-55	26621-26624	see	_	
122-56	26624-26625	)	_	
122-57	26625-26626	.	_	

#Text=The limitations of the current work provide avenues for further study.
123-1	26627-26630	The	_	
123-2	26631-26642	limitations	_	
123-3	26643-26645	of	_	
123-4	26646-26649	the	_	
123-5	26650-26657	current	_	
123-6	26658-26662	work	_	
123-7	26663-26670	provide	_	
123-8	26671-26678	avenues	_	
123-9	26679-26682	for	_	
123-10	26683-26690	further	_	
123-11	26691-26696	study	_	
123-12	26696-26697	.	_	

#Text=First, a relatively small number of male participants were included in this study (N = 22).
124-1	26698-26703	First	_	
124-2	26703-26704	,	_	
124-3	26705-26706	a	_	
124-4	26707-26717	relatively	_	
124-5	26718-26723	small	_	
124-6	26724-26730	number	_	
124-7	26731-26733	of	_	
124-8	26734-26738	male	_	
124-9	26739-26751	participants	_	
124-10	26752-26756	were	_	
124-11	26757-26765	included	_	
124-12	26766-26768	in	_	
124-13	26769-26773	this	_	
124-14	26774-26779	study	_	
124-15	26780-26781	(	_	
124-16	26781-26782	N	_	
124-17	26783-26784	=	_	
124-18	26785-26787	22	_	
124-19	26787-26788	)	_	
124-20	26788-26789	.	_	

#Text=While the within-subjects design and advantages of sample homogeneity partially mitigate the sample size, replication in a larger, more diverse sample would address questions regarding generalizability.
125-1	26790-26795	While	_	
125-2	26796-26799	the	_	
125-3	26800-26815	within-subjects	_	
125-4	26816-26822	design	_	
125-5	26823-26826	and	_	
125-6	26827-26837	advantages	_	
125-7	26838-26840	of	_	
125-8	26841-26847	sample	_	
125-9	26848-26859	homogeneity	_	
125-10	26860-26869	partially	_	
125-11	26870-26878	mitigate	_	
125-12	26879-26882	the	_	
125-13	26883-26889	sample	_	
125-14	26890-26894	size	_	
125-15	26894-26895	,	_	
125-16	26896-26907	replication	_	
125-17	26908-26910	in	_	
125-18	26911-26912	a	_	
125-19	26913-26919	larger	_	
125-20	26919-26920	,	_	
125-21	26921-26925	more	_	
125-22	26926-26933	diverse	_	
125-23	26934-26940	sample	_	
125-24	26941-26946	would	_	
125-25	26947-26954	address	_	
125-26	26955-26964	questions	_	
125-27	26965-26974	regarding	_	
125-28	26975-26991	generalizability	_	
125-29	26991-26992	.	_	

#Text=In addition, the present study identified drug-state modulation of responses to negative outcomes but does not evaluate the degree to which the physical consequences per se (i.e., small or large monetary loss), affect associated with the consequences, or other aspect of the outcomes, contribute to the reinforcement provided by successful loss avoidance.
126-1	26993-26995	In	_	
126-2	26996-27004	addition	_	
126-3	27004-27005	,	_	
126-4	27006-27009	the	_	
126-5	27010-27017	present	_	
126-6	27018-27023	study	_	
126-7	27024-27034	identified	_	
126-8	27035-27045	drug-state	_	
126-9	27046-27056	modulation	_	
126-10	27057-27059	of	_	
126-11	27060-27069	responses	_	
126-12	27070-27072	to	_	
126-13	27073-27081	negative	_	
126-14	27082-27090	outcomes	_	
126-15	27091-27094	but	_	
126-16	27095-27099	does	_	
126-17	27100-27103	not	_	
126-18	27104-27112	evaluate	_	
126-19	27113-27116	the	_	
126-20	27117-27123	degree	_	
126-21	27124-27126	to	_	
126-22	27127-27132	which	_	
126-23	27133-27136	the	_	
126-24	27137-27145	physical	_	
126-25	27146-27158	consequences	_	
126-26	27159-27162	per	_	
126-27	27163-27165	se	_	
126-28	27166-27167	(	_	
126-29	27167-27170	i.e	_	
126-30	27170-27171	.	_	
126-31	27171-27172	,	_	
126-32	27173-27178	small	_	
126-33	27179-27181	or	_	
126-34	27182-27187	large	_	
126-35	27188-27196	monetary	_	
126-36	27197-27201	loss	_	
126-37	27201-27202	)	_	
126-38	27202-27203	,	_	
126-39	27204-27210	affect	_	
126-40	27211-27221	associated	_	
126-41	27222-27226	with	_	
126-42	27227-27230	the	_	
126-43	27231-27243	consequences	_	
126-44	27243-27244	,	_	
126-45	27245-27247	or	_	
126-46	27248-27253	other	_	
126-47	27254-27260	aspect	_	
126-48	27261-27263	of	_	
126-49	27264-27267	the	_	
126-50	27268-27276	outcomes	_	
126-51	27276-27277	,	_	
126-52	27278-27288	contribute	_	
126-53	27289-27291	to	_	
126-54	27292-27295	the	_	
126-55	27296-27309	reinforcement	_	
126-56	27310-27318	provided	_	
126-57	27319-27321	by	_	
126-58	27322-27332	successful	_	
126-59	27333-27337	loss	_	
126-60	27338-27347	avoidance	_	
126-61	27347-27348	.	_	

#Text=Clarifying the role of components of negative outcomes in maintaining substance use in dependence ought to be a focus of future studies.
127-1	27349-27359	Clarifying	_	
127-2	27360-27363	the	_	
127-3	27364-27368	role	_	
127-4	27369-27371	of	_	
127-5	27372-27382	components	_	
127-6	27383-27385	of	_	
127-7	27386-27394	negative	_	
127-8	27395-27403	outcomes	_	
127-9	27404-27406	in	_	
127-10	27407-27418	maintaining	_	
127-11	27419-27428	substance	_	
127-12	27429-27432	use	_	
127-13	27433-27435	in	_	
127-14	27436-27446	dependence	_	
127-15	27447-27452	ought	_	
127-16	27453-27455	to	_	
127-17	27456-27458	be	_	
127-18	27459-27460	a	_	
127-19	27461-27466	focus	_	
127-20	27467-27469	of	_	
127-21	27470-27476	future	_	
127-22	27477-27484	studies	_	
127-23	27484-27485	.	_	

#Text=Finally, we focused our neural analyses primarily on regions of striatum, given previous work linking learning mechanisms and cocaine pharmacodynamics to these regions.
128-1	27486-27493	Finally	_	
128-2	27493-27494	,	_	
128-3	27495-27497	we	_	
128-4	27498-27505	focused	_	
128-5	27506-27509	our	_	
128-6	27510-27516	neural	_	
128-7	27517-27525	analyses	_	
128-8	27526-27535	primarily	_	
128-9	27536-27538	on	_	
128-10	27539-27546	regions	_	
128-11	27547-27549	of	_	
128-12	27550-27558	striatum	_	
128-13	27558-27559	,	_	
128-14	27560-27565	given	_	
128-15	27566-27574	previous	_	
128-16	27575-27579	work	_	
128-17	27580-27587	linking	_	
128-18	27588-27596	learning	_	
128-19	27597-27607	mechanisms	_	
128-20	27608-27611	and	_	
128-21	27612-27619	cocaine	_	
128-22	27620-27636	pharmacodynamics	_	
128-23	27637-27639	to	_	
128-24	27640-27645	these	_	
128-25	27646-27653	regions	_	
128-26	27653-27654	.	_	

#Text=Supplemental analyses found no effects of cocaine-state on encoding of expected value (see Figure S2B), indicating generally intact outcome valuation unaffected by drug use status; nonetheless, other neural regions implicated in learning may be of interest in future investigations.
129-1	27655-27667	Supplemental	_	
129-2	27668-27676	analyses	_	
129-3	27677-27682	found	_	
129-4	27683-27685	no	_	
129-5	27686-27693	effects	_	
129-6	27694-27696	of	_	
129-7	27697-27710	cocaine-state	_	
129-8	27711-27713	on	_	
129-9	27714-27722	encoding	_	
129-10	27723-27725	of	_	
129-11	27726-27734	expected	_	
129-12	27735-27740	value	_	
129-13	27741-27742	(	_	
129-14	27742-27745	see	_	
129-15	27746-27752	Figure	_	
129-16	27753-27756	S2B	_	
129-17	27756-27757	)	_	
129-18	27757-27758	,	_	
129-19	27759-27769	indicating	_	
129-20	27770-27779	generally	_	
129-21	27780-27786	intact	_	
129-22	27787-27794	outcome	_	
129-23	27795-27804	valuation	_	
129-24	27805-27815	unaffected	_	
129-25	27816-27818	by	_	
129-26	27819-27823	drug	_	
129-27	27824-27827	use	_	
129-28	27828-27834	status	_	
129-29	27834-27835	;	_	
129-30	27836-27847	nonetheless	_	
129-31	27847-27848	,	_	
129-32	27849-27854	other	_	
129-33	27855-27861	neural	_	
129-34	27862-27869	regions	_	
129-35	27870-27880	implicated	_	
129-36	27881-27883	in	_	
129-37	27884-27892	learning	_	
129-38	27893-27896	may	_	
129-39	27897-27899	be	_	
129-40	27900-27902	of	_	
129-41	27903-27911	interest	_	
129-42	27912-27914	in	_	
129-43	27915-27921	future	_	
129-44	27922-27936	investigations	_	
129-45	27936-27937	.	_	

#Text=In summary, in cocaine dependent participants, we show that drug deprivation enhances neural signaling of successful loss avoidance, which in turn predicts increased desire to use cocaine.
130-1	27938-27940	In	_	
130-2	27941-27948	summary	_	
130-3	27948-27949	,	_	
130-4	27950-27952	in	_	
130-5	27953-27960	cocaine	_	
130-6	27961-27970	dependent	_	
130-7	27971-27983	participants	_	
130-8	27983-27984	,	_	
130-9	27985-27987	we	_	
130-10	27988-27992	show	_	
130-11	27993-27997	that	_	
130-12	27998-28002	drug	_	
130-13	28003-28014	deprivation	_	
130-14	28015-28023	enhances	_	
130-15	28024-28030	neural	_	
130-16	28031-28040	signaling	_	
130-17	28041-28043	of	_	
130-18	28044-28054	successful	_	
130-19	28055-28059	loss	_	
130-20	28060-28069	avoidance	_	
130-21	28069-28070	,	_	
130-22	28071-28076	which	_	
130-23	28077-28079	in	_	
130-24	28080-28084	turn	_	
130-25	28085-28093	predicts	_	
130-26	28094-28103	increased	_	
130-27	28104-28110	desire	_	
130-28	28111-28113	to	_	
130-29	28114-28117	use	_	
130-30	28118-28125	cocaine	_	
130-31	28125-28126	.	_	

#Text=The deprivation-enhanced neural prediction error is in-line with prior reports of DA adaptations associated with chronic substance use and also points to a potential mechanism via which drug seeking is maintained.
131-1	28127-28130	The	_	
131-2	28131-28151	deprivation-enhanced	_	
131-3	28152-28158	neural	_	
131-4	28159-28169	prediction	_	
131-5	28170-28175	error	_	
131-6	28176-28178	is	_	
131-7	28179-28186	in-line	_	
131-8	28187-28191	with	_	
131-9	28192-28197	prior	_	
131-10	28198-28205	reports	_	
131-11	28206-28208	of	_	
131-12	28209-28211	DA	_	
131-13	28212-28223	adaptations	_	
131-14	28224-28234	associated	_	
131-15	28235-28239	with	_	
131-16	28240-28247	chronic	_	
131-17	28248-28257	substance	_	
131-18	28258-28261	use	_	
131-19	28262-28265	and	_	
131-20	28266-28270	also	_	
131-21	28271-28277	points	_	
131-22	28278-28280	to	_	
131-23	28281-28282	a	_	
131-24	28283-28292	potential	_	
131-25	28293-28302	mechanism	_	
131-26	28303-28306	via	_	
131-27	28307-28312	which	_	
131-28	28313-28317	drug	_	
131-29	28318-28325	seeking	_	
131-30	28326-28328	is	_	
131-31	28329-28339	maintained	_	
131-32	28339-28340	.	_	

#Text=That is, when dependent individuals are at their most vulnerable (i.e., during drug deprivation), reward signals associated with successful avoidance of negative states are at their greatest and may contribute to a pernicious cycle of drug seeking in the face of quit attempts.
132-1	28341-28345	That	_	
132-2	28346-28348	is	_	
132-3	28348-28349	,	_	
132-4	28350-28354	when	_	
132-5	28355-28364	dependent	_	
132-6	28365-28376	individuals	_	
132-7	28377-28380	are	_	
132-8	28381-28383	at	_	
132-9	28384-28389	their	_	
132-10	28390-28394	most	_	
132-11	28395-28405	vulnerable	_	
132-12	28406-28407	(	_	
132-13	28407-28410	i.e	_	
132-14	28410-28411	.	_	
132-15	28411-28412	,	_	
132-16	28413-28419	during	_	
132-17	28420-28424	drug	_	
132-18	28425-28436	deprivation	_	
132-19	28436-28437	)	_	
132-20	28437-28438	,	_	
132-21	28439-28445	reward	_	
132-22	28446-28453	signals	_	
132-23	28454-28464	associated	_	
132-24	28465-28469	with	_	
132-25	28470-28480	successful	_	
132-26	28481-28490	avoidance	_	
132-27	28491-28493	of	_	
132-28	28494-28502	negative	_	
132-29	28503-28509	states	_	
132-30	28510-28513	are	_	
132-31	28514-28516	at	_	
132-32	28517-28522	their	_	
132-33	28523-28531	greatest	_	
132-34	28532-28535	and	_	
132-35	28536-28539	may	_	
132-36	28540-28550	contribute	_	
132-37	28551-28553	to	_	
132-38	28554-28555	a	_	
132-39	28556-28566	pernicious	_	
132-40	28567-28572	cycle	_	
132-41	28573-28575	of	_	
132-42	28576-28580	drug	_	
132-43	28581-28588	seeking	_	
132-44	28589-28591	in	_	
132-45	28592-28595	the	_	
132-46	28596-28600	face	_	
132-47	28601-28603	of	_	
132-48	28604-28608	quit	_	
132-49	28609-28617	attempts	_	
132-50	28617-28618	.	_	

#Text=Of note, DA dysregulation has been associated with poor response to behavioral treatments in addiction and innovative behavioral training protocols have identified learning systems as potential new mechanistic treatment targets for cocaine dependence.
133-1	28619-28621	Of	_	
133-2	28622-28626	note	_	
133-3	28626-28627	,	_	
133-4	28628-28630	DA	_	
133-5	28631-28644	dysregulation	_	
133-6	28645-28648	has	_	
133-7	28649-28653	been	_	
133-8	28654-28664	associated	_	
133-9	28665-28669	with	_	
133-10	28670-28674	poor	_	
133-11	28675-28683	response	_	
133-12	28684-28686	to	_	
133-13	28687-28697	behavioral	_	
133-14	28698-28708	treatments	_	
133-15	28709-28711	in	_	
133-16	28712-28721	addiction	_	
133-17	28722-28725	and	_	
133-18	28726-28736	innovative	_	
133-19	28737-28747	behavioral	_	
133-20	28748-28756	training	_	
133-21	28757-28766	protocols	_	
133-22	28767-28771	have	_	
133-23	28772-28782	identified	_	
133-24	28783-28791	learning	_	
133-25	28792-28799	systems	_	
133-26	28800-28802	as	_	
133-27	28803-28812	potential	_	
133-28	28813-28816	new	_	
133-29	28817-28828	mechanistic	_	
133-30	28829-28838	treatment	_	
133-31	28839-28846	targets	_	
133-32	28847-28850	for	_	
133-33	28851-28858	cocaine	_	
133-34	28859-28869	dependence	_	
133-35	28869-28870	.	_	

#Text=More generally, the current results support targeting learning-based therapies to identify goal driven behaviors that provide relief from the negative outcomes of drug deprivation and indicate that attention to drug state may be critical for understanding neural mechanisms of addiction and refining learning-based therapies.
134-1	28871-28875	More	_	
134-2	28876-28885	generally	_	
134-3	28885-28886	,	_	
134-4	28887-28890	the	_	
134-5	28891-28898	current	_	
134-6	28899-28906	results	_	
134-7	28907-28914	support	_	
134-8	28915-28924	targeting	_	
134-9	28925-28939	learning-based	_	
134-10	28940-28949	therapies	_	
134-11	28950-28952	to	_	
134-12	28953-28961	identify	_	
134-13	28962-28966	goal	_	
134-14	28967-28973	driven	_	
134-15	28974-28983	behaviors	_	
134-16	28984-28988	that	_	
134-17	28989-28996	provide	_	
134-18	28997-29003	relief	_	
134-19	29004-29008	from	_	
134-20	29009-29012	the	_	
134-21	29013-29021	negative	_	
134-22	29022-29030	outcomes	_	
134-23	29031-29033	of	_	
134-24	29034-29038	drug	_	
134-25	29039-29050	deprivation	_	
134-26	29051-29054	and	_	
134-27	29055-29063	indicate	_	
134-28	29064-29068	that	_	
134-29	29069-29078	attention	_	
134-30	29079-29081	to	_	
134-31	29082-29086	drug	_	
134-32	29087-29092	state	_	
134-33	29093-29096	may	_	
134-34	29097-29099	be	_	
134-35	29100-29108	critical	_	
134-36	29109-29112	for	_	
134-37	29113-29126	understanding	_	
134-38	29127-29133	neural	_	
134-39	29134-29144	mechanisms	_	
134-40	29145-29147	of	_	
134-41	29148-29157	addiction	_	
134-42	29158-29161	and	_	
134-43	29162-29170	refining	_	
134-44	29171-29185	learning-based	_	
134-45	29186-29195	therapies	_	
134-46	29195-29196	.	_	

#Text=Supplementary Material
#Text=Financial Disclosures
#Text=The authors report no biomedical financial interests or potential conflicts of interest.
135-1	29197-29210	Supplementary	_	
135-2	29211-29219	Material	_	
135-3	29220-29229	Financial	_	
135-4	29230-29241	Disclosures	_	
135-5	29242-29245	The	_	
135-6	29246-29253	authors	_	
135-7	29254-29260	report	_	
135-8	29261-29263	no	_	
135-9	29264-29274	biomedical	_	
135-10	29275-29284	financial	_	
135-11	29285-29294	interests	_	
135-12	29295-29297	or	_	
135-13	29298-29307	potential	_	
135-14	29308-29317	conflicts	_	
135-15	29318-29320	of	_	
135-16	29321-29329	interest	_	
135-17	29329-29330	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
136-1	29331-29335	This	_	
136-2	29336-29338	is	_	
136-3	29339-29340	a	_	
136-4	29341-29344	PDF	_	
136-5	29345-29349	file	_	
136-6	29350-29352	of	_	
136-7	29353-29355	an	_	
136-8	29356-29364	unedited	_	
136-9	29365-29375	manuscript	_	
136-10	29376-29380	that	_	
136-11	29381-29384	has	_	
136-12	29385-29389	been	_	
136-13	29390-29398	accepted	_	
136-14	29399-29402	for	_	
136-15	29403-29414	publication	_	
136-16	29414-29415	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
137-1	29416-29418	As	_	
137-2	29419-29420	a	_	
137-3	29421-29428	service	_	
137-4	29429-29431	to	_	
137-5	29432-29435	our	_	
137-6	29436-29445	customers	_	
137-7	29446-29448	we	_	
137-8	29449-29452	are	_	
137-9	29453-29462	providing	_	
137-10	29463-29467	this	_	
137-11	29468-29473	early	_	
137-12	29474-29481	version	_	
137-13	29482-29484	of	_	
137-14	29485-29488	the	_	
137-15	29489-29499	manuscript	_	
137-16	29499-29500	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
138-1	29501-29504	The	_	
138-2	29505-29515	manuscript	_	
138-3	29516-29520	will	_	
138-4	29521-29528	undergo	_	
138-5	29529-29540	copyediting	_	
138-6	29540-29541	,	_	
138-7	29542-29553	typesetting	_	
138-8	29553-29554	,	_	
138-9	29555-29558	and	_	
138-10	29559-29565	review	_	
138-11	29566-29568	of	_	
138-12	29569-29572	the	_	
138-13	29573-29582	resulting	_	
138-14	29583-29588	proof	_	
138-15	29589-29595	before	_	
138-16	29596-29598	it	_	
138-17	29599-29601	is	_	
138-18	29602-29611	published	_	
138-19	29612-29614	in	_	
138-20	29615-29618	its	_	
138-21	29619-29624	final	_	
138-22	29625-29632	citable	_	
138-23	29633-29637	form	_	
138-24	29637-29638	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
139-1	29639-29645	Please	_	
139-2	29646-29650	note	_	
139-3	29651-29655	that	_	
139-4	29656-29662	during	_	
139-5	29663-29666	the	_	
139-6	29667-29677	production	_	
139-7	29678-29685	process	_	
139-8	29686-29692	errors	_	
139-9	29693-29696	may	_	
139-10	29697-29699	be	_	
139-11	29700-29710	discovered	_	
139-12	29711-29716	which	_	
139-13	29717-29722	could	_	
139-14	29723-29729	affect	_	
139-15	29730-29733	the	_	
139-16	29734-29741	content	_	
139-17	29741-29742	,	_	
139-18	29743-29746	and	_	
139-19	29747-29750	all	_	
139-20	29751-29756	legal	_	
139-21	29757-29768	disclaimers	_	
139-22	29769-29773	that	_	
139-23	29774-29779	apply	_	
139-24	29780-29782	to	_	
139-25	29783-29786	the	_	
139-26	29787-29794	journal	_	
139-27	29795-29802	pertain	_	
139-28	29802-29803	.	_	

#Text=References
#Text=
#Text=Neuroscience of Behavioral and Pharmacological Treatments for Addictions
#Text=The Impact of Orbitofrontal Dysfunction on Cocaine Addiction
#Text=Neural Mechanisms of Addiction: The Role of Reward-Related Learning and Memory
#Text=Computational Roles for Dopamine in Behavioural Control
#Text=A Neural Substrate of Prediction and Reward
#Text=Dopamine-Dependent Prediction Errors Underpin Reward-Seeking Behaviour in Humans
#Text=Cocaine Inhibition of Nicotinic Acetylcholine Receptors Influences Dopamine Release
#Text=Dopamine in Drug Abuse and Addiction: Results from Imaging Studies and Treatment Implications
#Text=Imaging Dopamine Transmission in Cocaine Dependence: Link Between Neurochemistry and Response to Treatment
#Text=Chronic Cocaine Dampens Dopamine Signaling during Cocaine Intoxication and Unbalances D1 over D2 Receptor Signaling
#Text=Cocaine addiction as a homeostatic reinforcement learning disorder
#Text=Dopamine Signaling in the Nucleus Accumbens of Animals Self-Administering Drugs of Abuse
#Text=Imaging Valuation Models in Human Choice
#Text=Differential Modulation of Reinforcement Learning by D2 Dopamine and NMDA Glutamate Receptor Antagonism
#Text=Impaired Neural Response to Negative Prediction Errors in Cocaine Addiction
#Text=Reduced Neural Tracking of Prediction Error in Substance-Dependent Individuals
#Text=Temporal Difference Error Prediction Signal Dysregulation in Cocaine Dependence
#Text=Cocaine Dependent Individuals with Attenuated Striatal Activation during Reinforcement Learning are More Susceptible to Relapse
#Text=Associability- modulated loss learning is increased in posttraumatic stress disorder
#Text=Neural Prediction Errors Reveal a Risk- Sensitive Reinforcement-Learning Process in the Human Brain
#Text=Neural and Psychological Maturation of Decision-making in Adolescence and Young Adulthood
#Text=How Instructed Knowledge Modulates the Neural Systems of Reward Learning
#Text=Confirmation Bias in Human Reinforcement Learning
#Text=
#Text=Reinforcement Learning in Multidimensional Environments Relies on Attention Mechanisms
#Text=How Green Is the Grass on the Other Side?
140-1	29804-29814	References	_	
140-2	29816-29828	Neuroscience	_	
140-3	29829-29831	of	_	
140-4	29832-29842	Behavioral	_	
140-5	29843-29846	and	_	
140-6	29847-29862	Pharmacological	_	
140-7	29863-29873	Treatments	_	
140-8	29874-29877	for	_	
140-9	29878-29888	Addictions	_	
140-10	29889-29892	The	_	
140-11	29893-29899	Impact	_	
140-12	29900-29902	of	_	
140-13	29903-29916	Orbitofrontal	_	
140-14	29917-29928	Dysfunction	_	
140-15	29929-29931	on	_	
140-16	29932-29939	Cocaine	_	
140-17	29940-29949	Addiction	_	
140-18	29950-29956	Neural	_	
140-19	29957-29967	Mechanisms	_	
140-20	29968-29970	of	_	
140-21	29971-29980	Addiction	_	
140-22	29980-29981	:	_	
140-23	29982-29985	The	_	
140-24	29986-29990	Role	_	
140-25	29991-29993	of	_	
140-26	29994-30008	Reward-Related	_	
140-27	30009-30017	Learning	_	
140-28	30018-30021	and	_	
140-29	30022-30028	Memory	_	
140-30	30029-30042	Computational	_	
140-31	30043-30048	Roles	_	
140-32	30049-30052	for	_	
140-33	30053-30061	Dopamine	_	
140-34	30062-30064	in	_	
140-35	30065-30076	Behavioural	_	
140-36	30077-30084	Control	_	
140-37	30085-30086	A	_	
140-38	30087-30093	Neural	_	
140-39	30094-30103	Substrate	_	
140-40	30104-30106	of	_	
140-41	30107-30117	Prediction	_	
140-42	30118-30121	and	_	
140-43	30122-30128	Reward	_	
140-44	30129-30147	Dopamine-Dependent	_	
140-45	30148-30158	Prediction	_	
140-46	30159-30165	Errors	_	
140-47	30166-30174	Underpin	_	
140-48	30175-30189	Reward-Seeking	_	
140-49	30190-30199	Behaviour	_	
140-50	30200-30202	in	_	
140-51	30203-30209	Humans	_	
140-52	30210-30217	Cocaine	_	
140-53	30218-30228	Inhibition	_	
140-54	30229-30231	of	_	
140-55	30232-30241	Nicotinic	_	
140-56	30242-30255	Acetylcholine	_	
140-57	30256-30265	Receptors	_	
140-58	30266-30276	Influences	_	
140-59	30277-30285	Dopamine	_	
140-60	30286-30293	Release	_	
140-61	30294-30302	Dopamine	_	
140-62	30303-30305	in	_	
140-63	30306-30310	Drug	_	
140-64	30311-30316	Abuse	_	
140-65	30317-30320	and	_	
140-66	30321-30330	Addiction	_	
140-67	30330-30331	:	_	
140-68	30332-30339	Results	_	
140-69	30340-30344	from	_	
140-70	30345-30352	Imaging	_	
140-71	30353-30360	Studies	_	
140-72	30361-30364	and	_	
140-73	30365-30374	Treatment	_	
140-74	30375-30387	Implications	_	
140-75	30388-30395	Imaging	_	
140-76	30396-30404	Dopamine	_	
140-77	30405-30417	Transmission	_	
140-78	30418-30420	in	_	
140-79	30421-30428	Cocaine	_	
140-80	30429-30439	Dependence	_	
140-81	30439-30440	:	_	
140-82	30441-30445	Link	_	
140-83	30446-30453	Between	_	
140-84	30454-30468	Neurochemistry	_	
140-85	30469-30472	and	_	
140-86	30473-30481	Response	_	
140-87	30482-30484	to	_	
140-88	30485-30494	Treatment	_	
140-89	30495-30502	Chronic	_	
140-90	30503-30510	Cocaine	_	
140-91	30511-30518	Dampens	_	
140-92	30519-30527	Dopamine	_	
140-93	30528-30537	Signaling	_	
140-94	30538-30544	during	_	
140-95	30545-30552	Cocaine	_	
140-96	30553-30565	Intoxication	_	
140-97	30566-30569	and	_	
140-98	30570-30580	Unbalances	_	
140-99	30581-30583	D1	_	
140-100	30584-30588	over	_	
140-101	30589-30591	D2	_	
140-102	30592-30600	Receptor	_	
140-103	30601-30610	Signaling	_	
140-104	30611-30618	Cocaine	_	
140-105	30619-30628	addiction	_	
140-106	30629-30631	as	_	
140-107	30632-30633	a	_	
140-108	30634-30645	homeostatic	_	
140-109	30646-30659	reinforcement	_	
140-110	30660-30668	learning	_	
140-111	30669-30677	disorder	_	
140-112	30678-30686	Dopamine	_	
140-113	30687-30696	Signaling	_	
140-114	30697-30699	in	_	
140-115	30700-30703	the	_	
140-116	30704-30711	Nucleus	_	
140-117	30712-30721	Accumbens	_	
140-118	30722-30724	of	_	
140-119	30725-30732	Animals	_	
140-120	30733-30751	Self-Administering	_	
140-121	30752-30757	Drugs	_	
140-122	30758-30760	of	_	
140-123	30761-30766	Abuse	_	
140-124	30767-30774	Imaging	_	
140-125	30775-30784	Valuation	_	
140-126	30785-30791	Models	_	
140-127	30792-30794	in	_	
140-128	30795-30800	Human	_	
140-129	30801-30807	Choice	_	
140-130	30808-30820	Differential	_	
140-131	30821-30831	Modulation	_	
140-132	30832-30834	of	_	
140-133	30835-30848	Reinforcement	_	
140-134	30849-30857	Learning	_	
140-135	30858-30860	by	_	
140-136	30861-30863	D2	_	
140-137	30864-30872	Dopamine	_	
140-138	30873-30876	and	_	
140-139	30877-30881	NMDA	_	
140-140	30882-30891	Glutamate	_	
140-141	30892-30900	Receptor	_	
140-142	30901-30911	Antagonism	_	
140-143	30912-30920	Impaired	_	
140-144	30921-30927	Neural	_	
140-145	30928-30936	Response	_	
140-146	30937-30939	to	_	
140-147	30940-30948	Negative	_	
140-148	30949-30959	Prediction	_	
140-149	30960-30966	Errors	_	
140-150	30967-30969	in	_	
140-151	30970-30977	Cocaine	_	
140-152	30978-30987	Addiction	_	
140-153	30988-30995	Reduced	_	
140-154	30996-31002	Neural	_	
140-155	31003-31011	Tracking	_	
140-156	31012-31014	of	_	
140-157	31015-31025	Prediction	_	
140-158	31026-31031	Error	_	
140-159	31032-31034	in	_	
140-160	31035-31054	Substance-Dependent	_	
140-161	31055-31066	Individuals	_	
140-162	31067-31075	Temporal	_	
140-163	31076-31086	Difference	_	
140-164	31087-31092	Error	_	
140-165	31093-31103	Prediction	_	
140-166	31104-31110	Signal	_	
140-167	31111-31124	Dysregulation	_	
140-168	31125-31127	in	_	
140-169	31128-31135	Cocaine	_	
140-170	31136-31146	Dependence	_	
140-171	31147-31154	Cocaine	_	
140-172	31155-31164	Dependent	_	
140-173	31165-31176	Individuals	_	
140-174	31177-31181	with	_	
140-175	31182-31192	Attenuated	_	
140-176	31193-31201	Striatal	_	
140-177	31202-31212	Activation	_	
140-178	31213-31219	during	_	
140-179	31220-31233	Reinforcement	_	
140-180	31234-31242	Learning	_	
140-181	31243-31246	are	_	
140-182	31247-31251	More	_	
140-183	31252-31263	Susceptible	_	
140-184	31264-31266	to	_	
140-185	31267-31274	Relapse	_	
140-186	31275-31288	Associability	_	
140-187	31288-31289	-	_	
140-188	31290-31299	modulated	_	
140-189	31300-31304	loss	_	
140-190	31305-31313	learning	_	
140-191	31314-31316	is	_	
140-192	31317-31326	increased	_	
140-193	31327-31329	in	_	
140-194	31330-31343	posttraumatic	_	
140-195	31344-31350	stress	_	
140-196	31351-31359	disorder	_	
140-197	31360-31366	Neural	_	
140-198	31367-31377	Prediction	_	
140-199	31378-31384	Errors	_	
140-200	31385-31391	Reveal	_	
140-201	31392-31393	a	_	
140-202	31394-31398	Risk	_	
140-203	31398-31399	-	_	
140-204	31400-31409	Sensitive	_	
140-205	31410-31432	Reinforcement-Learning	_	
140-206	31433-31440	Process	_	
140-207	31441-31443	in	_	
140-208	31444-31447	the	_	
140-209	31448-31453	Human	_	
140-210	31454-31459	Brain	_	
140-211	31460-31466	Neural	_	
140-212	31467-31470	and	_	
140-213	31471-31484	Psychological	_	
140-214	31485-31495	Maturation	_	
140-215	31496-31498	of	_	
140-216	31499-31514	Decision-making	_	
140-217	31515-31517	in	_	
140-218	31518-31529	Adolescence	_	
140-219	31530-31533	and	_	
140-220	31534-31539	Young	_	
140-221	31540-31549	Adulthood	_	
140-222	31550-31553	How	_	
140-223	31554-31564	Instructed	_	
140-224	31565-31574	Knowledge	_	
140-225	31575-31584	Modulates	_	
140-226	31585-31588	the	_	
140-227	31589-31595	Neural	_	
140-228	31596-31603	Systems	_	
140-229	31604-31606	of	_	
140-230	31607-31613	Reward	_	
140-231	31614-31622	Learning	_	
140-232	31623-31635	Confirmation	_	
140-233	31636-31640	Bias	_	
140-234	31641-31643	in	_	
140-235	31644-31649	Human	_	
140-236	31650-31663	Reinforcement	_	
140-237	31664-31672	Learning	_	
140-238	31674-31687	Reinforcement	_	
140-239	31688-31696	Learning	_	
140-240	31697-31699	in	_	
140-241	31700-31716	Multidimensional	_	
140-242	31717-31729	Environments	_	
140-243	31730-31736	Relies	_	
140-244	31737-31739	on	_	
140-245	31740-31749	Attention	_	
140-246	31750-31760	Mechanisms	_	
140-247	31761-31764	How	_	
140-248	31765-31770	Green	_	
140-249	31771-31773	Is	_	
140-250	31774-31777	the	_	
140-251	31778-31783	Grass	_	
140-252	31784-31786	on	_	
140-253	31787-31790	the	_	
140-254	31791-31796	Other	_	
140-255	31797-31801	Side	_	
140-256	31801-31802	?	_	

#Text=Frontopolar Cortex and the Evidence in Favor of Alternative Courses of Action
#Text=Cortical delta activity reflects reward prediction error and related behavioral adjustments, but at different times
#Text=Neural signature of hierarchically structured expectations predicts clustering and transfer of rule sets in reinforcement learning
#Text=
#Text=A Model-Based fMRI Analysis with Hierarchical Bayesian Parameter Estimation
#Text=Statistical Parametric Maps in Functional Imaging: A General Linear Approach
#Text=An Automated Method for Neuroanatomic and Cytoarchitectonic Atlas-Based Interrogation of fMRI Data Sets
#Text=Prediction Error in Reinforcement Learning: A Meta- Analysis of Neuroimaging Studies
#Text=Avoiding Non-Independence in fMRI Data Analysis: Leave One Subject Out
#Text=The Development of a Cocaine Craving Questionnaire
#Text=Bootstrap Methods for Standard Errors, Confidence Intervals, and Other Measures of Statistical Accuracy
#Text=
#Text=From Reinforcement Learning Models to Psychiatric and Neurological Disorders
#Text=Computational Psychiatry: the Brain as a Phantastic organ
#Text=Computational Nosology and Precision Psychiatry
#Text=Addiction as a Computational Process Gone Awry
#Text=Potential Vulnerabilities of Neuronal Reward, Risk, and Decision Mechanisms to Addictive Drugs
#Text=Dopamine Prediction Errors in Reward Learning and Addiction: From Theory to Neural Circuitry
#Text=Mechanisms Underlying Dopamine-Mediated Reward Bias in Compulsive Behaviors
#Text=Mind Matters: Placebo Enhances Reward Learning in Parkinson’s Disease
#Text=Critical Roles for Anterior Insula and Dorsal Striatum in Punishment-Based Avoidance Learning
#Text=Differential encoding of losses and gains in the human striatum
#Text=Striatal D1 and D2 Signaling Differentially Predict Learning from Positive and Negative Outcomes
#Text=The Good, the Bad and the Brain: Neural Correlates of Appetitive and Aversive Values Underlying Decision Making
#Text=Carrots and sticks fail to change behavior in cocaine addiction
#Text=Experimental design and cocaine-modulation of learning.
141-1	31803-31814	Frontopolar	_	
141-2	31815-31821	Cortex	_	
141-3	31822-31825	and	_	
141-4	31826-31829	the	_	
141-5	31830-31838	Evidence	_	
141-6	31839-31841	in	_	
141-7	31842-31847	Favor	_	
141-8	31848-31850	of	_	
141-9	31851-31862	Alternative	_	
141-10	31863-31870	Courses	_	
141-11	31871-31873	of	_	
141-12	31874-31880	Action	_	
141-13	31881-31889	Cortical	_	
141-14	31890-31895	delta	_	
141-15	31896-31904	activity	_	
141-16	31905-31913	reflects	_	
141-17	31914-31920	reward	_	
141-18	31921-31931	prediction	_	
141-19	31932-31937	error	_	
141-20	31938-31941	and	_	
141-21	31942-31949	related	_	
141-22	31950-31960	behavioral	_	
141-23	31961-31972	adjustments	_	
141-24	31972-31973	,	_	
141-25	31974-31977	but	_	
141-26	31978-31980	at	_	
141-27	31981-31990	different	_	
141-28	31991-31996	times	_	
141-29	31997-32003	Neural	_	
141-30	32004-32013	signature	_	
141-31	32014-32016	of	_	
141-32	32017-32031	hierarchically	_	
141-33	32032-32042	structured	_	
141-34	32043-32055	expectations	_	
141-35	32056-32064	predicts	_	
141-36	32065-32075	clustering	_	
141-37	32076-32079	and	_	
141-38	32080-32088	transfer	_	
141-39	32089-32091	of	_	
141-40	32092-32096	rule	_	
141-41	32097-32101	sets	_	
141-42	32102-32104	in	_	
141-43	32105-32118	reinforcement	_	
141-44	32119-32127	learning	_	
141-45	32129-32130	A	_	
141-46	32131-32142	Model-Based	_	
141-47	32143-32147	fMRI	_	
141-48	32148-32156	Analysis	_	
141-49	32157-32161	with	_	
141-50	32162-32174	Hierarchical	_	
141-51	32175-32183	Bayesian	_	
141-52	32184-32193	Parameter	_	
141-53	32194-32204	Estimation	_	
141-54	32205-32216	Statistical	_	
141-55	32217-32227	Parametric	_	
141-56	32228-32232	Maps	_	
141-57	32233-32235	in	_	
141-58	32236-32246	Functional	_	
141-59	32247-32254	Imaging	_	
141-60	32254-32255	:	_	
141-61	32256-32257	A	_	
141-62	32258-32265	General	_	
141-63	32266-32272	Linear	_	
141-64	32273-32281	Approach	_	
141-65	32282-32284	An	_	
141-66	32285-32294	Automated	_	
141-67	32295-32301	Method	_	
141-68	32302-32305	for	_	
141-69	32306-32319	Neuroanatomic	_	
141-70	32320-32323	and	_	
141-71	32324-32341	Cytoarchitectonic	_	
141-72	32342-32353	Atlas-Based	_	
141-73	32354-32367	Interrogation	_	
141-74	32368-32370	of	_	
141-75	32371-32375	fMRI	_	
141-76	32376-32380	Data	_	
141-77	32381-32385	Sets	_	
141-78	32386-32396	Prediction	_	
141-79	32397-32402	Error	_	
141-80	32403-32405	in	_	
141-81	32406-32419	Reinforcement	_	
141-82	32420-32428	Learning	_	
141-83	32428-32429	:	_	
141-84	32430-32431	A	_	
141-85	32432-32436	Meta	_	
141-86	32436-32437	-	_	
141-87	32438-32446	Analysis	_	
141-88	32447-32449	of	_	
141-89	32450-32462	Neuroimaging	_	
141-90	32463-32470	Studies	_	
141-91	32471-32479	Avoiding	_	
141-92	32480-32496	Non-Independence	_	
141-93	32497-32499	in	_	
141-94	32500-32504	fMRI	_	
141-95	32505-32509	Data	_	
141-96	32510-32518	Analysis	_	
141-97	32518-32519	:	_	
141-98	32520-32525	Leave	_	
141-99	32526-32529	One	_	
141-100	32530-32537	Subject	_	
141-101	32538-32541	Out	_	
141-102	32542-32545	The	_	
141-103	32546-32557	Development	_	
141-104	32558-32560	of	_	
141-105	32561-32562	a	_	
141-106	32563-32570	Cocaine	_	
141-107	32571-32578	Craving	_	
141-108	32579-32592	Questionnaire	_	
141-109	32593-32602	Bootstrap	_	
141-110	32603-32610	Methods	_	
141-111	32611-32614	for	_	
141-112	32615-32623	Standard	_	
141-113	32624-32630	Errors	_	
141-114	32630-32631	,	_	
141-115	32632-32642	Confidence	_	
141-116	32643-32652	Intervals	_	
141-117	32652-32653	,	_	
141-118	32654-32657	and	_	
141-119	32658-32663	Other	_	
141-120	32664-32672	Measures	_	
141-121	32673-32675	of	_	
141-122	32676-32687	Statistical	_	
141-123	32688-32696	Accuracy	_	
141-124	32698-32702	From	_	
141-125	32703-32716	Reinforcement	_	
141-126	32717-32725	Learning	_	
141-127	32726-32732	Models	_	
141-128	32733-32735	to	_	
141-129	32736-32747	Psychiatric	_	
141-130	32748-32751	and	_	
141-131	32752-32764	Neurological	_	
141-132	32765-32774	Disorders	_	
141-133	32775-32788	Computational	_	
141-134	32789-32799	Psychiatry	_	
141-135	32799-32800	:	_	
141-136	32801-32804	the	_	
141-137	32805-32810	Brain	_	
141-138	32811-32813	as	_	
141-139	32814-32815	a	_	
141-140	32816-32826	Phantastic	_	
141-141	32827-32832	organ	_	
141-142	32833-32846	Computational	_	
141-143	32847-32855	Nosology	_	
141-144	32856-32859	and	_	
141-145	32860-32869	Precision	_	
141-146	32870-32880	Psychiatry	_	
141-147	32881-32890	Addiction	_	
141-148	32891-32893	as	_	
141-149	32894-32895	a	_	
141-150	32896-32909	Computational	_	
141-151	32910-32917	Process	_	
141-152	32918-32922	Gone	_	
141-153	32923-32927	Awry	_	
141-154	32928-32937	Potential	_	
141-155	32938-32953	Vulnerabilities	_	
141-156	32954-32956	of	_	
141-157	32957-32965	Neuronal	_	
141-158	32966-32972	Reward	_	
141-159	32972-32973	,	_	
141-160	32974-32978	Risk	_	
141-161	32978-32979	,	_	
141-162	32980-32983	and	_	
141-163	32984-32992	Decision	_	
141-164	32993-33003	Mechanisms	_	
141-165	33004-33006	to	_	
141-166	33007-33016	Addictive	_	
141-167	33017-33022	Drugs	_	
141-168	33023-33031	Dopamine	_	
141-169	33032-33042	Prediction	_	
141-170	33043-33049	Errors	_	
141-171	33050-33052	in	_	
141-172	33053-33059	Reward	_	
141-173	33060-33068	Learning	_	
141-174	33069-33072	and	_	
141-175	33073-33082	Addiction	_	
141-176	33082-33083	:	_	
141-177	33084-33088	From	_	
141-178	33089-33095	Theory	_	
141-179	33096-33098	to	_	
141-180	33099-33105	Neural	_	
141-181	33106-33115	Circuitry	_	
141-182	33116-33126	Mechanisms	_	
141-183	33127-33137	Underlying	_	
141-184	33138-33155	Dopamine-Mediated	_	
141-185	33156-33162	Reward	_	
141-186	33163-33167	Bias	_	
141-187	33168-33170	in	_	
141-188	33171-33181	Compulsive	_	
141-189	33182-33191	Behaviors	_	
141-190	33192-33196	Mind	_	
141-191	33197-33204	Matters	_	
141-192	33204-33205	:	_	
141-193	33206-33213	Placebo	_	
141-194	33214-33222	Enhances	_	
141-195	33223-33229	Reward	_	
141-196	33230-33238	Learning	_	
141-197	33239-33241	in	_	
141-198	33242-33251	Parkinson	_	
141-199	33251-33252	’	_	
141-200	33252-33253	s	_	
141-201	33254-33261	Disease	_	
141-202	33262-33270	Critical	_	
141-203	33271-33276	Roles	_	
141-204	33277-33280	for	_	
141-205	33281-33289	Anterior	_	
141-206	33290-33296	Insula	_	
141-207	33297-33300	and	_	
141-208	33301-33307	Dorsal	_	
141-209	33308-33316	Striatum	_	
141-210	33317-33319	in	_	
141-211	33320-33336	Punishment-Based	_	
141-212	33337-33346	Avoidance	_	
141-213	33347-33355	Learning	_	
141-214	33356-33368	Differential	_	
141-215	33369-33377	encoding	_	
141-216	33378-33380	of	_	
141-217	33381-33387	losses	_	
141-218	33388-33391	and	_	
141-219	33392-33397	gains	_	
141-220	33398-33400	in	_	
141-221	33401-33404	the	_	
141-222	33405-33410	human	_	
141-223	33411-33419	striatum	_	
141-224	33420-33428	Striatal	_	
141-225	33429-33431	D1	_	
141-226	33432-33435	and	_	
141-227	33436-33438	D2	_	
141-228	33439-33448	Signaling	_	
141-229	33449-33463	Differentially	_	
141-230	33464-33471	Predict	_	
141-231	33472-33480	Learning	_	
141-232	33481-33485	from	_	
141-233	33486-33494	Positive	_	
141-234	33495-33498	and	_	
141-235	33499-33507	Negative	_	
141-236	33508-33516	Outcomes	_	
141-237	33517-33520	The	_	
141-238	33521-33525	Good	_	
141-239	33525-33526	,	_	
141-240	33527-33530	the	_	
141-241	33531-33534	Bad	_	
141-242	33535-33538	and	_	
141-243	33539-33542	the	_	
141-244	33543-33548	Brain	_	
141-245	33548-33549	:	_	
141-246	33550-33556	Neural	_	
141-247	33557-33567	Correlates	_	
141-248	33568-33570	of	_	
141-249	33571-33581	Appetitive	_	
141-250	33582-33585	and	_	
141-251	33586-33594	Aversive	_	
141-252	33595-33601	Values	_	
141-253	33602-33612	Underlying	_	
141-254	33613-33621	Decision	_	
141-255	33622-33628	Making	_	
141-256	33629-33636	Carrots	_	
141-257	33637-33640	and	_	
141-258	33641-33647	sticks	_	
141-259	33648-33652	fail	_	
141-260	33653-33655	to	_	
141-261	33656-33662	change	_	
141-262	33663-33671	behavior	_	
141-263	33672-33674	in	_	
141-264	33675-33682	cocaine	_	
141-265	33683-33692	addiction	_	
141-266	33693-33705	Experimental	_	
141-267	33706-33712	design	_	
141-268	33713-33716	and	_	
141-269	33717-33735	cocaine-modulation	_	
141-270	33736-33738	of	_	
141-271	33739-33747	learning	_	
141-272	33747-33748	.	_	

#Text=A) Participants performed a probabilistic loss-learning task wherein they made a series of choices between two options and were shown the outcome of each choice.
142-1	33749-33750	A	_	
142-2	33750-33751	)	_	
142-3	33752-33764	Participants	_	
142-4	33765-33774	performed	_	
142-5	33775-33776	a	_	
142-6	33777-33790	probabilistic	_	
142-7	33791-33804	loss-learning	_	
142-8	33805-33809	task	_	
142-9	33810-33817	wherein	_	
142-10	33818-33822	they	_	
142-11	33823-33827	made	_	
142-12	33828-33829	a	_	
142-13	33830-33836	series	_	
142-14	33837-33839	of	_	
142-15	33840-33847	choices	_	
142-16	33848-33855	between	_	
142-17	33856-33859	two	_	
142-18	33860-33867	options	_	
142-19	33868-33871	and	_	
142-20	33872-33876	were	_	
142-21	33877-33882	shown	_	
142-22	33883-33886	the	_	
142-23	33887-33894	outcome	_	
142-24	33895-33897	of	_	
142-25	33898-33902	each	_	
142-26	33903-33909	choice	_	
142-27	33909-33910	.	_	

#Text=In this example, the selected option has a 75% chance of losing $0.25 and a 25% chance of losing $0.75 and is the ‘better’ of the two options (less loss).
143-1	33911-33913	In	_	
143-2	33914-33918	this	_	
143-3	33919-33926	example	_	
143-4	33926-33927	,	_	
143-5	33928-33931	the	_	
143-6	33932-33940	selected	_	
143-7	33941-33947	option	_	
143-8	33948-33951	has	_	
143-9	33952-33953	a	_	
143-10	33954-33957	75%	_	
143-11	33958-33964	chance	_	
143-12	33965-33967	of	_	
143-13	33968-33974	losing	_	
143-14	33975-33980	$0.25	_	
143-15	33981-33984	and	_	
143-16	33985-33986	a	_	
143-17	33987-33990	25%	_	
143-18	33991-33997	chance	_	
143-19	33998-34000	of	_	
143-20	34001-34007	losing	_	
143-21	34008-34013	$0.75	_	
143-22	34014-34017	and	_	
143-23	34018-34020	is	_	
143-24	34021-34024	the	_	
143-25	34025-34026	‘	_	
143-26	34026-34032	better	_	
143-27	34032-34033	’	_	
143-28	34034-34036	of	_	
143-29	34037-34040	the	_	
143-30	34041-34044	two	_	
143-31	34045-34052	options	_	
143-32	34053-34054	(	_	
143-33	34054-34058	less	_	
143-34	34059-34063	loss	_	
143-35	34063-34064	)	_	
143-36	34064-34065	.	_	

#Text=Participants completed trials until learning occurred or up to 36 trials per block.
144-1	34066-34078	Participants	_	
144-2	34079-34088	completed	_	
144-3	34089-34095	trials	_	
144-4	34096-34101	until	_	
144-5	34102-34110	learning	_	
144-6	34111-34119	occurred	_	
144-7	34120-34122	or	_	
144-8	34123-34125	up	_	
144-9	34126-34128	to	_	
144-10	34129-34131	36	_	
144-11	34132-34138	trials	_	
144-12	34139-34142	per	_	
144-13	34143-34148	block	_	
144-14	34148-34149	.	_	

#Text=B) The reinforcement learning model incorporated positive and negative prediction errors (δ+ and δ-, respectively) which updated the subsequent expected value (Q) with separately estimated learning rates (α+ and x- respectively).
145-1	34150-34151	B	_	
145-2	34151-34152	)	_	
145-3	34153-34156	The	_	
145-4	34157-34170	reinforcement	_	
145-5	34171-34179	learning	_	
145-6	34180-34185	model	_	
145-7	34186-34198	incorporated	_	
145-8	34199-34207	positive	_	
145-9	34208-34211	and	_	
145-10	34212-34220	negative	_	
145-11	34221-34231	prediction	_	
145-12	34232-34238	errors	_	
145-13	34239-34240	(	_	
145-14	34240-34241	δ	_	
145-15	34241-34242	+	_	
145-16	34243-34246	and	_	
145-17	34247-34248	δ	_	
145-18	34248-34249	-	_	
145-19	34249-34250	,	_	
145-20	34251-34263	respectively	_	
145-21	34263-34264	)	_	
145-22	34265-34270	which	_	
145-23	34271-34278	updated	_	
145-24	34279-34282	the	_	
145-25	34283-34293	subsequent	_	
145-26	34294-34302	expected	_	
145-27	34303-34308	value	_	
145-28	34309-34310	(	_	
145-29	34310-34311	Q	_	
145-30	34311-34312	)	_	
145-31	34313-34317	with	_	
145-32	34318-34328	separately	_	
145-33	34329-34338	estimated	_	
145-34	34339-34347	learning	_	
145-35	34348-34353	rates	_	
145-36	34354-34355	(	_	
145-37	34355-34356	α	_	
145-38	34356-34357	+	_	
145-39	34358-34361	and	_	
145-40	34362-34363	x	_	
145-41	34363-34364	-	_	
145-42	34365-34377	respectively	_	
145-43	34377-34378	)	_	
145-44	34378-34379	.	_	

#Text=Trial-by-trial prediction errors are computed as the difference between the outcome and expected value (R - Q).
146-1	34380-34394	Trial-by-trial	_	
146-2	34395-34405	prediction	_	
146-3	34406-34412	errors	_	
146-4	34413-34416	are	_	
146-5	34417-34425	computed	_	
146-6	34426-34428	as	_	
146-7	34429-34432	the	_	
146-8	34433-34443	difference	_	
146-9	34444-34451	between	_	
146-10	34452-34455	the	_	
146-11	34456-34463	outcome	_	
146-12	34464-34467	and	_	
146-13	34468-34476	expected	_	
146-14	34477-34482	value	_	
146-15	34483-34484	(	_	
146-16	34484-34485	R	_	
146-17	34486-34487	-	_	
146-18	34488-34489	Q	_	
146-19	34489-34490	)	_	
146-20	34490-34491	.	_	

#Text=C) The model predicted probability of selecting the better option was a good fit with both C- and C+ participants’ actual behavior (% better option selected across subjects).
147-1	34492-34493	C	_	
147-2	34493-34494	)	_	
147-3	34495-34498	The	_	
147-4	34499-34504	model	_	
147-5	34505-34514	predicted	_	
147-6	34515-34526	probability	_	
147-7	34527-34529	of	_	
147-8	34530-34539	selecting	_	
147-9	34540-34543	the	_	
147-10	34544-34550	better	_	
147-11	34551-34557	option	_	
147-12	34558-34561	was	_	
147-13	34562-34563	a	_	
147-14	34564-34568	good	_	
147-15	34569-34572	fit	_	
147-16	34573-34577	with	_	
147-17	34578-34582	both	_	
147-18	34583-34584	C	_	
147-19	34584-34585	-	_	
147-20	34586-34589	and	_	
147-21	34590-34591	C	_	
147-22	34591-34592	+	_	
147-23	34593-34605	participants	_	
147-24	34605-34606	’	_	
147-25	34607-34613	actual	_	
147-26	34614-34622	behavior	_	
147-27	34623-34624	(	_	
147-28	34624-34625	%	_	
147-29	34626-34632	better	_	
147-30	34633-34639	option	_	
147-31	34640-34648	selected	_	
147-32	34649-34655	across	_	
147-33	34656-34664	subjects	_	
147-34	34664-34665	)	_	
147-35	34665-34666	.	_	

#Text=Model prediction and actual selection for participants in the C- (blue) and C+ (red) drug-use states were similar (no difference of average log likelihood per trial in a paired comparison across states; t(17) = 1.47, p = 0.14).
148-1	34667-34672	Model	_	
148-2	34673-34683	prediction	_	
148-3	34684-34687	and	_	
148-4	34688-34694	actual	_	
148-5	34695-34704	selection	_	
148-6	34705-34708	for	_	
148-7	34709-34721	participants	_	
148-8	34722-34724	in	_	
148-9	34725-34728	the	_	
148-10	34729-34730	C	_	
148-11	34730-34731	-	_	
148-12	34732-34733	(	_	
148-13	34733-34737	blue	_	
148-14	34737-34738	)	_	
148-15	34739-34742	and	_	
148-16	34743-34744	C	_	
148-17	34744-34745	+	_	
148-18	34746-34747	(	_	
148-19	34747-34750	red	_	
148-20	34750-34751	)	_	
148-21	34752-34760	drug-use	_	
148-22	34761-34767	states	_	
148-23	34768-34772	were	_	
148-24	34773-34780	similar	_	
148-25	34781-34782	(	_	
148-26	34782-34784	no	_	
148-27	34785-34795	difference	_	
148-28	34796-34798	of	_	
148-29	34799-34806	average	_	
148-30	34807-34810	log	_	
148-31	34811-34821	likelihood	_	
148-32	34822-34825	per	_	
148-33	34826-34831	trial	_	
148-34	34832-34834	in	_	
148-35	34835-34836	a	_	
148-36	34837-34843	paired	_	
148-37	34844-34854	comparison	_	
148-38	34855-34861	across	_	
148-39	34862-34868	states	_	
148-40	34868-34869	;	_	
148-41	34870-34871	t	_	
148-42	34871-34872	(	_	
148-43	34872-34874	17	_	
148-44	34874-34875	)	_	
148-45	34876-34877	=	_	
148-46	34878-34882	1.47	_	
148-47	34882-34883	,	_	
148-48	34884-34885	p	_	
148-49	34886-34887	=	_	
148-50	34888-34892	0.14	_	
148-51	34892-34893	)	_	
148-52	34893-34894	.	_	

#Text=D) In both states of drug use, individuals showed learning, improving in choosing the better option as trials progressed.
149-1	34895-34896	D	_	
149-2	34896-34897	)	_	
149-3	34898-34900	In	_	
149-4	34901-34905	both	_	
149-5	34906-34912	states	_	
149-6	34913-34915	of	_	
149-7	34916-34920	drug	_	
149-8	34921-34924	use	_	
149-9	34924-34925	,	_	
149-10	34926-34937	individuals	_	
149-11	34938-34944	showed	_	
149-12	34945-34953	learning	_	
149-13	34953-34954	,	_	
149-14	34955-34964	improving	_	
149-15	34965-34967	in	_	
149-16	34968-34976	choosing	_	
149-17	34977-34980	the	_	
149-18	34981-34987	better	_	
149-19	34988-34994	option	_	
149-20	34995-34997	as	_	
149-21	34998-35004	trials	_	
149-22	35005-35015	progressed	_	
149-23	35015-35016	.	_	

#Text=C- relative to C+ individuals showed diminished overall accuracy (t(17) = 2.62, p = 0.01).
150-1	35017-35018	C	_	
150-2	35018-35019	-	_	
150-3	35020-35028	relative	_	
150-4	35029-35031	to	_	
150-5	35032-35033	C	_	
150-6	35033-35034	+	_	
150-7	35035-35046	individuals	_	
150-8	35047-35053	showed	_	
150-9	35054-35064	diminished	_	
150-10	35065-35072	overall	_	
150-11	35073-35081	accuracy	_	
150-12	35082-35083	(	_	
150-13	35083-35084	t	_	
150-14	35084-35085	(	_	
150-15	35085-35087	17	_	
150-16	35087-35088	)	_	
150-17	35089-35090	=	_	
150-18	35091-35095	2.62	_	
150-19	35095-35096	,	_	
150-20	35097-35098	p	_	
150-21	35099-35100	=	_	
150-22	35101-35105	0.01	_	
150-23	35105-35106	)	_	
150-24	35106-35107	.	_	

#Text=E) Bootstrapped group estimates for positive learning rate (α+), negative learning rate (α-), and inverse temperature (β) suggested higher α+ and lower β during cocaine deprivation.
151-1	35108-35109	E	_	
151-2	35109-35110	)	_	
151-3	35111-35123	Bootstrapped	_	
151-4	35124-35129	group	_	
151-5	35130-35139	estimates	_	
151-6	35140-35143	for	_	
151-7	35144-35152	positive	_	
151-8	35153-35161	learning	_	
151-9	35162-35166	rate	_	
151-10	35167-35168	(	_	
151-11	35168-35169	α	_	
151-12	35169-35170	+	_	
151-13	35170-35171	)	_	
151-14	35171-35172	,	_	
151-15	35173-35181	negative	_	
151-16	35182-35190	learning	_	
151-17	35191-35195	rate	_	
151-18	35196-35197	(	_	
151-19	35197-35198	α	_	
151-20	35198-35199	-	_	
151-21	35199-35200	)	_	
151-22	35200-35201	,	_	
151-23	35202-35205	and	_	
151-24	35206-35213	inverse	_	
151-25	35214-35225	temperature	_	
151-26	35226-35227	(	_	
151-27	35227-35228	β	_	
151-28	35228-35229	)	_	
151-29	35230-35239	suggested	_	
151-30	35240-35246	higher	_	
151-31	35247-35248	α	_	
151-32	35248-35249	+	_	
151-33	35250-35253	and	_	
151-34	35254-35259	lower	_	
151-35	35260-35261	β	_	
151-36	35262-35268	during	_	
151-37	35269-35276	cocaine	_	
151-38	35277-35288	deprivation	_	
151-39	35288-35289	.	_	

#Text=F) To clarify whether the drug-state modulation of α+ and/or β was associated with the cocaine- state differences in model-free behavioral performance (panel d), we simulated behavioral choices iterating through the observed ranges of α+ and β parameter values and show that increasing α+ was associated with diminished total earnings, while performance did not vary with changes in β.
152-1	35290-35291	F	_	
152-2	35291-35292	)	_	
152-3	35293-35295	To	_	
152-4	35296-35303	clarify	_	
152-5	35304-35311	whether	_	
152-6	35312-35315	the	_	
152-7	35316-35326	drug-state	_	
152-8	35327-35337	modulation	_	
152-9	35338-35340	of	_	
152-10	35341-35342	α	_	
152-11	35342-35343	+	_	
152-12	35344-35347	and	_	
152-13	35347-35348	/	_	
152-14	35348-35350	or	_	
152-15	35351-35352	β	_	
152-16	35353-35356	was	_	
152-17	35357-35367	associated	_	
152-18	35368-35372	with	_	
152-19	35373-35376	the	_	
152-20	35377-35384	cocaine	_	
152-21	35384-35385	-	_	
152-22	35386-35391	state	_	
152-23	35392-35403	differences	_	
152-24	35404-35406	in	_	
152-25	35407-35417	model-free	_	
152-26	35418-35428	behavioral	_	
152-27	35429-35440	performance	_	
152-28	35441-35442	(	_	
152-29	35442-35447	panel	_	
152-30	35448-35449	d	_	
152-31	35449-35450	)	_	
152-32	35450-35451	,	_	
152-33	35452-35454	we	_	
152-34	35455-35464	simulated	_	
152-35	35465-35475	behavioral	_	
152-36	35476-35483	choices	_	
152-37	35484-35493	iterating	_	
152-38	35494-35501	through	_	
152-39	35502-35505	the	_	
152-40	35506-35514	observed	_	
152-41	35515-35521	ranges	_	
152-42	35522-35524	of	_	
152-43	35525-35526	α	_	
152-44	35526-35527	+	_	
152-45	35528-35531	and	_	
152-46	35532-35533	β	_	
152-47	35534-35543	parameter	_	
152-48	35544-35550	values	_	
152-49	35551-35554	and	_	
152-50	35555-35559	show	_	
152-51	35560-35564	that	_	
152-52	35565-35575	increasing	_	
152-53	35576-35577	α	_	
152-54	35577-35578	+	_	
152-55	35579-35582	was	_	
152-56	35583-35593	associated	_	
152-57	35594-35598	with	_	
152-58	35599-35609	diminished	_	
152-59	35610-35615	total	_	
152-60	35616-35624	earnings	_	
152-61	35624-35625	,	_	
152-62	35626-35631	while	_	
152-63	35632-35643	performance	_	
152-64	35644-35647	did	_	
152-65	35648-35651	not	_	
152-66	35652-35656	vary	_	
152-67	35657-35661	with	_	
152-68	35662-35669	changes	_	
152-69	35670-35672	in	_	
152-70	35673-35674	β	_	
152-71	35674-35675	.	_	

#Text=Cocaine-use status modulates neural learning signals and reveals increased positive prediction error signaling during deprivation.
153-1	35676-35687	Cocaine-use	_	
153-2	35688-35694	status	_	
153-3	35695-35704	modulates	_	
153-4	35705-35711	neural	_	
153-5	35712-35720	learning	_	
153-6	35721-35728	signals	_	
153-7	35729-35732	and	_	
153-8	35733-35740	reveals	_	
153-9	35741-35750	increased	_	
153-10	35751-35759	positive	_	
153-11	35760-35770	prediction	_	
153-12	35771-35776	error	_	
153-13	35777-35786	signaling	_	
153-14	35787-35793	during	_	
153-15	35794-35805	deprivation	_	
153-16	35805-35806	.	_	

#Text=A) Positive prediction error signal (δ+) was found in the right striatum for cocaine-deprived participants (C-; peak voxel at T = 5.33; cluster FWE corrected p = 0.005; thresholded at T = 2.9 for visualization, see Table S2A).
154-1	35807-35808	A	_	
154-2	35808-35809	)	_	
154-3	35810-35818	Positive	_	
154-4	35819-35829	prediction	_	
154-5	35830-35835	error	_	
154-6	35836-35842	signal	_	
154-7	35843-35844	(	_	
154-8	35844-35845	δ	_	
154-9	35845-35846	+	_	
154-10	35846-35847	)	_	
154-11	35848-35851	was	_	
154-12	35852-35857	found	_	
154-13	35858-35860	in	_	
154-14	35861-35864	the	_	
154-15	35865-35870	right	_	
154-16	35871-35879	striatum	_	
154-17	35880-35883	for	_	
154-18	35884-35900	cocaine-deprived	_	
154-19	35901-35913	participants	_	
154-20	35914-35915	(	_	
154-21	35915-35916	C	_	
154-22	35916-35917	-	_	
154-23	35917-35918	;	_	
154-24	35919-35923	peak	_	
154-25	35924-35929	voxel	_	
154-26	35930-35932	at	_	
154-27	35933-35934	T	_	
154-28	35935-35936	=	_	
154-29	35937-35941	5.33	_	
154-30	35941-35942	;	_	
154-31	35943-35950	cluster	_	
154-32	35951-35954	FWE	_	
154-33	35955-35964	corrected	_	
154-34	35965-35966	p	_	
154-35	35967-35968	=	_	
154-36	35969-35974	0.005	_	
154-37	35974-35975	;	_	
154-38	35976-35987	thresholded	_	
154-39	35988-35990	at	_	
154-40	35991-35992	T	_	
154-41	35993-35994	=	_	
154-42	35995-35998	2.9	_	
154-43	35999-36002	for	_	
154-44	36003-36016	visualization	_	
154-45	36016-36017	,	_	
154-46	36018-36021	see	_	
154-47	36022-36027	Table	_	
154-48	36028-36031	S2A	_	
154-49	36031-36032	)	_	
154-50	36032-36033	.	_	

#Text=No significant neural δ+ signals were found for participants using cocaine as usual (C+).
155-1	36034-36036	No	_	
155-2	36037-36048	significant	_	
155-3	36049-36055	neural	_	
155-4	36056-36057	δ	_	
155-5	36057-36058	+	_	
155-6	36059-36066	signals	_	
155-7	36067-36071	were	_	
155-8	36072-36077	found	_	
155-9	36078-36081	for	_	
155-10	36082-36094	participants	_	
155-11	36095-36100	using	_	
155-12	36101-36108	cocaine	_	
155-13	36109-36111	as	_	
155-14	36112-36117	usual	_	
155-15	36118-36119	(	_	
155-16	36119-36120	C	_	
155-17	36120-36121	+	_	
155-18	36121-36122	)	_	
155-19	36122-36123	.	_	

#Text=Neither C- nor C+ participants showed significant neural responses to negative prediction errors (δ-).
156-1	36124-36131	Neither	_	
156-2	36132-36133	C	_	
156-3	36133-36134	-	_	
156-4	36135-36138	nor	_	
156-5	36139-36140	C	_	
156-6	36140-36141	+	_	
156-7	36142-36154	participants	_	
156-8	36155-36161	showed	_	
156-9	36162-36173	significant	_	
156-10	36174-36180	neural	_	
156-11	36181-36190	responses	_	
156-12	36191-36193	to	_	
156-13	36194-36202	negative	_	
156-14	36203-36213	prediction	_	
156-15	36214-36220	errors	_	
156-16	36221-36222	(	_	
156-17	36222-36223	δ	_	
156-18	36223-36224	-	_	
156-19	36224-36225	)	_	
156-20	36225-36226	.	_	

#Text=See also Figure S2A and Table S2D for C- > C+ contrasts that further show ‘deprivation- enhancement’ of learning signals.
157-1	36227-36230	See	_	
157-2	36231-36235	also	_	
157-3	36236-36242	Figure	_	
157-4	36243-36246	S2A	_	
157-5	36247-36250	and	_	
157-6	36251-36256	Table	_	
157-7	36257-36260	S2D	_	
157-8	36261-36264	for	_	
157-9	36265-36266	C	_	
157-10	36266-36267	-	_	
157-11	36268-36269	>	_	
157-12	36270-36271	C	_	
157-13	36271-36272	+	_	
157-14	36273-36282	contrasts	_	
157-15	36283-36287	that	_	
157-16	36288-36295	further	_	
157-17	36296-36300	show	_	
157-18	36301-36302	‘	_	
157-19	36302-36313	deprivation	_	
157-20	36313-36314	-	_	
157-21	36315-36326	enhancement	_	
157-22	36326-36327	’	_	
157-23	36328-36330	of	_	
157-24	36331-36339	learning	_	
157-25	36340-36347	signals	_	
157-26	36347-36348	.	_	

#Text=B) Deprivation-enhancement of positive learning rate (α+) was correlated with deprivation-enhancement of positive prediction error (δ+) in the striatum (C-> C+ for α+ and neural C- > C+ for δ+; left striatum peak at T = 7.20, Right striatum peak at T = 5.61; both p < 0.0001; thresholded at T = 2.9 with striatum mask for visualization, see Table S2C).
158-1	36349-36350	B	_	
158-2	36350-36351	)	_	
158-3	36352-36375	Deprivation-enhancement	_	
158-4	36376-36378	of	_	
158-5	36379-36387	positive	_	
158-6	36388-36396	learning	_	
158-7	36397-36401	rate	_	
158-8	36402-36403	(	_	
158-9	36403-36404	α	_	
158-10	36404-36405	+	_	
158-11	36405-36406	)	_	
158-12	36407-36410	was	_	
158-13	36411-36421	correlated	_	
158-14	36422-36426	with	_	
158-15	36427-36450	deprivation-enhancement	_	
158-16	36451-36453	of	_	
158-17	36454-36462	positive	_	
158-18	36463-36473	prediction	_	
158-19	36474-36479	error	_	
158-20	36480-36481	(	_	
158-21	36481-36482	δ	_	
158-22	36482-36483	+	_	
158-23	36483-36484	)	_	
158-24	36485-36487	in	_	
158-25	36488-36491	the	_	
158-26	36492-36500	striatum	_	
158-27	36501-36502	(	_	
158-28	36502-36503	C	_	
158-29	36503-36504	-	_	
158-30	36504-36505	>	_	
158-31	36506-36507	C	_	
158-32	36507-36508	+	_	
158-33	36509-36512	for	_	
158-34	36513-36514	α	_	
158-35	36514-36515	+	_	
158-36	36516-36519	and	_	
158-37	36520-36526	neural	_	
158-38	36527-36528	C	_	
158-39	36528-36529	-	_	
158-40	36530-36531	>	_	
158-41	36532-36533	C	_	
158-42	36533-36534	+	_	
158-43	36535-36538	for	_	
158-44	36539-36540	δ	_	
158-45	36540-36541	+	_	
158-46	36541-36542	;	_	
158-47	36543-36547	left	_	
158-48	36548-36556	striatum	_	
158-49	36557-36561	peak	_	
158-50	36562-36564	at	_	
158-51	36565-36566	T	_	
158-52	36567-36568	=	_	
158-53	36569-36573	7.20	_	
158-54	36573-36574	,	_	
158-55	36575-36580	Right	_	
158-56	36581-36589	striatum	_	
158-57	36590-36594	peak	_	
158-58	36595-36597	at	_	
158-59	36598-36599	T	_	
158-60	36600-36601	=	_	
158-61	36602-36606	5.61	_	
158-62	36606-36607	;	_	
158-63	36608-36612	both	_	
158-64	36613-36614	p	_	
158-65	36615-36616	<	_	
158-66	36617-36623	0.0001	_	
158-67	36623-36624	;	_	
158-68	36625-36636	thresholded	_	
158-69	36637-36639	at	_	
158-70	36640-36641	T	_	
158-71	36642-36643	=	_	
158-72	36644-36647	2.9	_	
158-73	36648-36652	with	_	
158-74	36653-36661	striatum	_	
158-75	36662-36666	mask	_	
158-76	36667-36670	for	_	
158-77	36671-36684	visualization	_	
158-78	36684-36685	,	_	
158-79	36686-36689	see	_	
158-80	36690-36695	Table	_	
158-81	36696-36699	S2C	_	
158-82	36699-36700	)	_	
158-83	36700-36701	.	_	

#Text=C) Drug-state dependent (i.e., C- > C+) neural δ beta values were extracted for both δ+ and δ- from bilateral striatum and correlated with their corresponding deprivation-enhanced learning rates.
159-1	36702-36703	C	_	
159-2	36703-36704	)	_	
159-3	36705-36715	Drug-state	_	
159-4	36716-36725	dependent	_	
159-5	36726-36727	(	_	
159-6	36727-36730	i.e	_	
159-7	36730-36731	.	_	
159-8	36731-36732	,	_	
159-9	36733-36734	C	_	
159-10	36734-36735	-	_	
159-11	36736-36737	>	_	
159-12	36738-36739	C	_	
159-13	36739-36740	+	_	
159-14	36740-36741	)	_	
159-15	36742-36748	neural	_	
159-16	36749-36750	δ	_	
159-17	36751-36755	beta	_	
159-18	36756-36762	values	_	
159-19	36763-36767	were	_	
159-20	36768-36777	extracted	_	
159-21	36778-36781	for	_	
159-22	36782-36786	both	_	
159-23	36787-36788	δ	_	
159-24	36788-36789	+	_	
159-25	36790-36793	and	_	
159-26	36794-36795	δ	_	
159-27	36795-36796	-	_	
159-28	36797-36801	from	_	
159-29	36802-36811	bilateral	_	
159-30	36812-36820	striatum	_	
159-31	36821-36824	and	_	
159-32	36825-36835	correlated	_	
159-33	36836-36840	with	_	
159-34	36841-36846	their	_	
159-35	36847-36860	corresponding	_	
159-36	36861-36881	deprivation-enhanced	_	
159-37	36882-36890	learning	_	
159-38	36891-36896	rates	_	
159-39	36896-36897	.	_	

#Text=For positive learning rate, the degree of participants’ deprivation-enhancement was significantly associated with the degree of deprivation-enhancement of positive prediction error responses in the striatum (C- > C+ for α+ and neural C- > C+ for δ+;
#Text=Table S2C; r = 0.79, p < 0.01; 27).
160-1	36898-36901	For	_	
160-2	36902-36910	positive	_	
160-3	36911-36919	learning	_	
160-4	36920-36924	rate	_	
160-5	36924-36925	,	_	
160-6	36926-36929	the	_	
160-7	36930-36936	degree	_	
160-8	36937-36939	of	_	
160-9	36940-36952	participants	_	
160-10	36952-36953	’	_	
160-11	36954-36977	deprivation-enhancement	_	
160-12	36978-36981	was	_	
160-13	36982-36995	significantly	_	
160-14	36996-37006	associated	_	
160-15	37007-37011	with	_	
160-16	37012-37015	the	_	
160-17	37016-37022	degree	_	
160-18	37023-37025	of	_	
160-19	37026-37049	deprivation-enhancement	_	
160-20	37050-37052	of	_	
160-21	37053-37061	positive	_	
160-22	37062-37072	prediction	_	
160-23	37073-37078	error	_	
160-24	37079-37088	responses	_	
160-25	37089-37091	in	_	
160-26	37092-37095	the	_	
160-27	37096-37104	striatum	_	
160-28	37105-37106	(	_	
160-29	37106-37107	C	_	
160-30	37107-37108	-	_	
160-31	37109-37110	>	_	
160-32	37111-37112	C	_	
160-33	37112-37113	+	_	
160-34	37114-37117	for	_	
160-35	37118-37119	α	_	
160-36	37119-37120	+	_	
160-37	37121-37124	and	_	
160-38	37125-37131	neural	_	
160-39	37132-37133	C	_	
160-40	37133-37134	-	_	
160-41	37135-37136	>	_	
160-42	37137-37138	C	_	
160-43	37138-37139	+	_	
160-44	37140-37143	for	_	
160-45	37144-37145	δ	_	
160-46	37145-37146	+	_	
160-47	37146-37147	;	_	
160-48	37148-37153	Table	_	
160-49	37154-37157	S2C	_	
160-50	37157-37158	;	_	
160-51	37159-37160	r	_	
160-52	37161-37162	=	_	
160-53	37163-37167	0.79	_	
160-54	37167-37168	,	_	
160-55	37169-37170	p	_	
160-56	37171-37172	<	_	
160-57	37173-37177	0.01	_	
160-58	37177-37178	;	_	
160-59	37179-37181	27	_	
160-60	37181-37182	)	_	
160-61	37182-37183	.	_	

#Text=No relationship between drug-state modulation of negative learning rates and their associated neural prediction error signals was observed (C- > C+ for α-and neural C- > C+ for δ- ; r = −0.08, p = 0.72.
161-1	37184-37186	No	_	
161-2	37187-37199	relationship	_	
161-3	37200-37207	between	_	
161-4	37208-37218	drug-state	_	
161-5	37219-37229	modulation	_	
161-6	37230-37232	of	_	
161-7	37233-37241	negative	_	
161-8	37242-37250	learning	_	
161-9	37251-37256	rates	_	
161-10	37257-37260	and	_	
161-11	37261-37266	their	_	
161-12	37267-37277	associated	_	
161-13	37278-37284	neural	_	
161-14	37285-37295	prediction	_	
161-15	37296-37301	error	_	
161-16	37302-37309	signals	_	
161-17	37310-37313	was	_	
161-18	37314-37322	observed	_	
161-19	37323-37324	(	_	
161-20	37324-37325	C	_	
161-21	37325-37326	-	_	
161-22	37327-37328	>	_	
161-23	37329-37330	C	_	
161-24	37330-37331	+	_	
161-25	37332-37335	for	_	
161-26	37336-37341	α-and	_	
161-27	37342-37348	neural	_	
161-28	37349-37350	C	_	
161-29	37350-37351	-	_	
161-30	37352-37353	>	_	
161-31	37354-37355	C	_	
161-32	37355-37356	+	_	
161-33	37357-37360	for	_	
161-34	37361-37362	δ	_	
161-35	37362-37363	-	_	
161-36	37364-37365	;	_	
161-37	37366-37367	r	_	
161-38	37368-37369	=	_	
161-39	37370-37371	−	_	
161-40	37371-37375	0.08	_	
161-41	37375-37376	,	_	
161-42	37377-37378	p	_	
161-43	37379-37380	=	_	
161-44	37381-37385	0.72	_	
161-45	37385-37386	.	_	

#Text=Beta value differences (C- > C+, whole brain normalized) are plotted.
162-1	37387-37391	Beta	_	
162-2	37392-37397	value	_	
162-3	37398-37409	differences	_	
162-4	37410-37411	(	_	
162-5	37411-37412	C	_	
162-6	37412-37413	-	_	
162-7	37414-37415	>	_	
162-8	37416-37417	C	_	
162-9	37417-37418	+	_	
162-10	37418-37419	,	_	
162-11	37420-37425	whole	_	
162-12	37426-37431	brain	_	
162-13	37432-37442	normalized	_	
162-14	37442-37443	)	_	
162-15	37444-37447	are	_	
162-16	37448-37455	plotted	_	
162-17	37455-37456	.	_	

#Text=During cocaine deprivation, neural positive prediction error signals mediate relationship between chronicity of drug use and desire to use cocaine.
163-1	37457-37463	During	_	
163-2	37464-37471	cocaine	_	
163-3	37472-37483	deprivation	_	
163-4	37483-37484	,	_	
163-5	37485-37491	neural	_	
163-6	37492-37500	positive	_	
163-7	37501-37511	prediction	_	
163-8	37512-37517	error	_	
163-9	37518-37525	signals	_	
163-10	37526-37533	mediate	_	
163-11	37534-37546	relationship	_	
163-12	37547-37554	between	_	
163-13	37555-37565	chronicity	_	
163-14	37566-37568	of	_	
163-15	37569-37573	drug	_	
163-16	37574-37577	use	_	
163-17	37578-37581	and	_	
163-18	37582-37588	desire	_	
163-19	37589-37591	to	_	
163-20	37592-37595	use	_	
163-21	37596-37603	cocaine	_	
163-22	37603-37604	.	_	

#Text=In deprived cocaine dependent individuals (C-): A) Positive prediction error signal (normalized δ+) in striatum is associated with greater desire to use cocaine (r = 0.70, p < 0.01), longer history of cocaine use predicted increased neural prediction error signal (normalized δ+; r = 0.64, p < 0.01), and longer history of cocaine use predicted higher desire to use cocaine (r = 0.61, p < 0.01).
164-1	37605-37607	In	_	
164-2	37608-37616	deprived	_	
164-3	37617-37624	cocaine	_	
164-4	37625-37634	dependent	_	
164-5	37635-37646	individuals	_	
164-6	37647-37648	(	_	
164-7	37648-37649	C	_	
164-8	37649-37650	-	_	
164-9	37650-37651	)	_	
164-10	37651-37652	:	_	
164-11	37653-37654	A	_	
164-12	37654-37655	)	_	
164-13	37656-37664	Positive	_	
164-14	37665-37675	prediction	_	
164-15	37676-37681	error	_	
164-16	37682-37688	signal	_	
164-17	37689-37690	(	_	
164-18	37690-37700	normalized	_	
164-19	37701-37702	δ	_	
164-20	37702-37703	+	_	
164-21	37703-37704	)	_	
164-22	37705-37707	in	_	
164-23	37708-37716	striatum	_	
164-24	37717-37719	is	_	
164-25	37720-37730	associated	_	
164-26	37731-37735	with	_	
164-27	37736-37743	greater	_	
164-28	37744-37750	desire	_	
164-29	37751-37753	to	_	
164-30	37754-37757	use	_	
164-31	37758-37765	cocaine	_	
164-32	37766-37767	(	_	
164-33	37767-37768	r	_	
164-34	37769-37770	=	_	
164-35	37771-37775	0.70	_	
164-36	37775-37776	,	_	
164-37	37777-37778	p	_	
164-38	37779-37780	<	_	
164-39	37781-37785	0.01	_	
164-40	37785-37786	)	_	
164-41	37786-37787	,	_	
164-42	37788-37794	longer	_	
164-43	37795-37802	history	_	
164-44	37803-37805	of	_	
164-45	37806-37813	cocaine	_	
164-46	37814-37817	use	_	
164-47	37818-37827	predicted	_	
164-48	37828-37837	increased	_	
164-49	37838-37844	neural	_	
164-50	37845-37855	prediction	_	
164-51	37856-37861	error	_	
164-52	37862-37868	signal	_	
164-53	37869-37870	(	_	
164-54	37870-37880	normalized	_	
164-55	37881-37882	δ	_	
164-56	37882-37883	+	_	
164-57	37883-37884	;	_	
164-58	37885-37886	r	_	
164-59	37887-37888	=	_	
164-60	37889-37893	0.64	_	
164-61	37893-37894	,	_	
164-62	37895-37896	p	_	
164-63	37897-37898	<	_	
164-64	37899-37903	0.01	_	
164-65	37903-37904	)	_	
164-66	37904-37905	,	_	
164-67	37906-37909	and	_	
164-68	37910-37916	longer	_	
164-69	37917-37924	history	_	
164-70	37925-37927	of	_	
164-71	37928-37935	cocaine	_	
164-72	37936-37939	use	_	
164-73	37940-37949	predicted	_	
164-74	37950-37956	higher	_	
164-75	37957-37963	desire	_	
164-76	37964-37966	to	_	
164-77	37967-37970	use	_	
164-78	37971-37978	cocaine	_	
164-79	37979-37980	(	_	
164-80	37980-37981	r	_	
164-81	37982-37983	=	_	
164-82	37984-37988	0.61	_	
164-83	37988-37989	,	_	
164-84	37990-37991	p	_	
164-85	37992-37993	<	_	
164-86	37994-37998	0.01	_	
164-87	37998-37999	)	_	
164-88	37999-38000	.	_	

#Text=B) Following these correlational results, a mediation analysis found that the relationship between individuals’ years of cocaine use and their desire to use while deprived (path c: β = 0.09, p < 0.01) was fully mediated by individuals’ deprivation-enhanced neural δ+ signal (path a: β = 0.06, p = 0.04; path b: β = 0.66, p = 0.01; path c’: β = 0.05, p = 0.07; mediation effect a*b: 95% CI 0.0008–0.0953).
165-1	38001-38002	B	_	
165-2	38002-38003	)	_	
165-3	38004-38013	Following	_	
165-4	38014-38019	these	_	
165-5	38020-38033	correlational	_	
165-6	38034-38041	results	_	
165-7	38041-38042	,	_	
165-8	38043-38044	a	_	
165-9	38045-38054	mediation	_	
165-10	38055-38063	analysis	_	
165-11	38064-38069	found	_	
165-12	38070-38074	that	_	
165-13	38075-38078	the	_	
165-14	38079-38091	relationship	_	
165-15	38092-38099	between	_	
165-16	38100-38111	individuals	_	
165-17	38111-38112	’	_	
165-18	38113-38118	years	_	
165-19	38119-38121	of	_	
165-20	38122-38129	cocaine	_	
165-21	38130-38133	use	_	
165-22	38134-38137	and	_	
165-23	38138-38143	their	_	
165-24	38144-38150	desire	_	
165-25	38151-38153	to	_	
165-26	38154-38157	use	_	
165-27	38158-38163	while	_	
165-28	38164-38172	deprived	_	
165-29	38173-38174	(	_	
165-30	38174-38178	path	_	
165-31	38179-38180	c	_	
165-32	38180-38181	:	_	
165-33	38182-38183	β	_	
165-34	38184-38185	=	_	
165-35	38186-38190	0.09	_	
165-36	38190-38191	,	_	
165-37	38192-38193	p	_	
165-38	38194-38195	<	_	
165-39	38196-38200	0.01	_	
165-40	38200-38201	)	_	
165-41	38202-38205	was	_	
165-42	38206-38211	fully	_	
165-43	38212-38220	mediated	_	
165-44	38221-38223	by	_	
165-45	38224-38235	individuals	_	
165-46	38235-38236	’	_	
165-47	38237-38257	deprivation-enhanced	_	
165-48	38258-38264	neural	_	
165-49	38265-38266	δ	_	
165-50	38266-38267	+	_	
165-51	38268-38274	signal	_	
165-52	38275-38276	(	_	
165-53	38276-38280	path	_	
165-54	38281-38282	a	_	
165-55	38282-38283	:	_	
165-56	38284-38285	β	_	
165-57	38286-38287	=	_	
165-58	38288-38292	0.06	_	
165-59	38292-38293	,	_	
165-60	38294-38295	p	_	
165-61	38296-38297	=	_	
165-62	38298-38302	0.04	_	
165-63	38302-38303	;	_	
165-64	38304-38308	path	_	
165-65	38309-38310	b	_	
165-66	38310-38311	:	_	
165-67	38312-38313	β	_	
165-68	38314-38315	=	_	
165-69	38316-38320	0.66	_	
165-70	38320-38321	,	_	
165-71	38322-38323	p	_	
165-72	38324-38325	=	_	
165-73	38326-38330	0.01	_	
165-74	38330-38331	;	_	
165-75	38332-38336	path	_	
165-76	38337-38338	c	_	
165-77	38338-38339	’	_	
165-78	38339-38340	:	_	
165-79	38341-38342	β	_	
165-80	38343-38344	=	_	
165-81	38345-38349	0.05	_	
165-82	38349-38350	,	_	
165-83	38351-38352	p	_	
165-84	38353-38354	=	_	
165-85	38355-38359	0.07	_	
165-86	38359-38360	;	_	
165-87	38361-38370	mediation	_	
165-88	38371-38377	effect	_	
165-89	38378-38379	a	_	
165-90	38379-38380	*	_	
165-91	38380-38381	b	_	
165-92	38381-38382	:	_	
165-93	38383-38386	95%	_	
165-94	38387-38389	CI	_	
165-95	38390-38396	0.0008	_	
165-96	38396-38397	–	_	
165-97	38397-38403	0.0953	_	
165-98	38403-38404	)	_	
165-99	38404-38405	.	_	

#Text=A) Participant Characteristics\t \t
#Text=Variable - Mean (SD)\tCocaine Dependent Individuals (N = 22)\t \t\t \tAge\t45.7 (7.0)\t \tEducation - Years\t12.9 (1.0)\t \tWTAR*\t98.4 (10.8)\t \tYears of Cocaine Use\t17.6 (7.9)\t \t
#Text=B) Participant self-reported craving\t \t
#Text=Drug Use Information - Mean (SE)\tDeprived (C-)\tUsing As Usual (C+)\t \t\t \tEstimated Cocaine Intake Last 48 hours\t0g (0)\t15g (0.5)\t \tCCQ** Grand total\t137.9 (8.7)\t145.3 (8.7)\t \tCCQ Anticipated Positive Outcome\t2.4 (0.3)\t2.7 (0.3)\t \tCCQ Desire to Use\t3.2 (0.2)\t3.4 (0.2)\t \tCCQ Intention to Use\t3.0 (0.3)\t3.0 (0.3)\t \tCCQ Anticipated Withdrawal Relief\t3.9 (0.4)\t3.5 (0.4)\t \tCCQ No Control\t3.8 (0.4)\t3.5 (0.4)\t \t
#Text=Wechsler Test of Adult Reading (Standardized Score Representing Verbal IQ)
#Text=Cocaine Craving Questionnaire (grand total composed of total raw score from each individual item; subscales are averaged across items)
166-1	38406-38407	A	_	
166-2	38407-38408	)	_	
166-3	38409-38420	Participant	_	
166-4	38421-38436	Characteristics	_	
166-5	38440-38448	Variable	_	
166-6	38449-38450	-	_	
166-7	38451-38455	Mean	_	
166-8	38456-38457	(	_	
166-9	38457-38459	SD	_	
166-10	38459-38460	)	_	
166-11	38461-38468	Cocaine	_	
166-12	38469-38478	Dependent	_	
166-13	38479-38490	Individuals	_	
166-14	38491-38492	(	_	
166-15	38492-38493	N	_	
166-16	38494-38495	=	_	
166-17	38496-38498	22	_	
166-18	38498-38499	)	_	
166-19	38505-38508	Age	_	
166-20	38509-38513	45.7	_	
166-21	38514-38515	(	_	
166-22	38515-38518	7.0	_	
166-23	38518-38519	)	_	
166-24	38522-38531	Education	_	
166-25	38532-38533	-	_	
166-26	38534-38539	Years	_	
166-27	38540-38544	12.9	_	
166-28	38545-38546	(	_	
166-29	38546-38549	1.0	_	
166-30	38549-38550	)	_	
166-31	38553-38557	WTAR	_	
166-32	38557-38558	*	_	
166-33	38559-38563	98.4	_	
166-34	38564-38565	(	_	
166-35	38565-38569	10.8	_	
166-36	38569-38570	)	_	
166-37	38573-38578	Years	_	
166-38	38579-38581	of	_	
166-39	38582-38589	Cocaine	_	
166-40	38590-38593	Use	_	
166-41	38594-38598	17.6	_	
166-42	38599-38600	(	_	
166-43	38600-38603	7.9	_	
166-44	38603-38604	)	_	
166-45	38608-38609	B	_	
166-46	38609-38610	)	_	
166-47	38611-38622	Participant	_	
166-48	38623-38636	self-reported	_	
166-49	38637-38644	craving	_	
166-50	38648-38652	Drug	_	
166-51	38653-38656	Use	_	
166-52	38657-38668	Information	_	
166-53	38669-38670	-	_	
166-54	38671-38675	Mean	_	
166-55	38676-38677	(	_	
166-56	38677-38679	SE	_	
166-57	38679-38680	)	_	
166-58	38681-38689	Deprived	_	
166-59	38690-38691	(	_	
166-60	38691-38692	C	_	
166-61	38692-38693	-	_	
166-62	38693-38694	)	_	
166-63	38695-38700	Using	_	
166-64	38701-38703	As	_	
166-65	38704-38709	Usual	_	
166-66	38710-38711	(	_	
166-67	38711-38712	C	_	
166-68	38712-38713	+	_	
166-69	38713-38714	)	_	
166-70	38720-38729	Estimated	_	
166-71	38730-38737	Cocaine	_	
166-72	38738-38744	Intake	_	
166-73	38745-38749	Last	_	
166-74	38750-38752	48	_	
166-75	38753-38758	hours	_	
166-76	38759-38761	0g	_	
166-77	38762-38763	(	_	
166-78	38763-38764	0	_	
166-79	38764-38765	)	_	
166-80	38766-38769	15g	_	
166-81	38770-38771	(	_	
166-82	38771-38774	0.5	_	
166-83	38774-38775	)	_	
166-84	38778-38781	CCQ	_	
166-85	38781-38782	*	_	
166-86	38782-38783	*	_	
166-87	38784-38789	Grand	_	
166-88	38790-38795	total	_	
166-89	38796-38801	137.9	_	
166-90	38802-38803	(	_	
166-91	38803-38806	8.7	_	
166-92	38806-38807	)	_	
166-93	38808-38813	145.3	_	
166-94	38814-38815	(	_	
166-95	38815-38818	8.7	_	
166-96	38818-38819	)	_	
166-97	38822-38825	CCQ	_	
166-98	38826-38837	Anticipated	_	
166-99	38838-38846	Positive	_	
166-100	38847-38854	Outcome	_	
166-101	38855-38858	2.4	_	
166-102	38859-38860	(	_	
166-103	38860-38863	0.3	_	
166-104	38863-38864	)	_	
166-105	38865-38868	2.7	_	
166-106	38869-38870	(	_	
166-107	38870-38873	0.3	_	
166-108	38873-38874	)	_	
166-109	38877-38880	CCQ	_	
166-110	38881-38887	Desire	_	
166-111	38888-38890	to	_	
166-112	38891-38894	Use	_	
166-113	38895-38898	3.2	_	
166-114	38899-38900	(	_	
166-115	38900-38903	0.2	_	
166-116	38903-38904	)	_	
166-117	38905-38908	3.4	_	
166-118	38909-38910	(	_	
166-119	38910-38913	0.2	_	
166-120	38913-38914	)	_	
166-121	38917-38920	CCQ	_	
166-122	38921-38930	Intention	_	
166-123	38931-38933	to	_	
166-124	38934-38937	Use	_	
166-125	38938-38941	3.0	_	
166-126	38942-38943	(	_	
166-127	38943-38946	0.3	_	
166-128	38946-38947	)	_	
166-129	38948-38951	3.0	_	
166-130	38952-38953	(	_	
166-131	38953-38956	0.3	_	
166-132	38956-38957	)	_	
166-133	38960-38963	CCQ	_	
166-134	38964-38975	Anticipated	_	
166-135	38976-38986	Withdrawal	_	
166-136	38987-38993	Relief	_	
166-137	38994-38997	3.9	_	
166-138	38998-38999	(	_	
166-139	38999-39002	0.4	_	
166-140	39002-39003	)	_	
166-141	39004-39007	3.5	_	
166-142	39008-39009	(	_	
166-143	39009-39012	0.4	_	
166-144	39012-39013	)	_	
166-145	39016-39019	CCQ	_	
166-146	39020-39022	No	_	
166-147	39023-39030	Control	_	
166-148	39031-39034	3.8	_	
166-149	39035-39036	(	_	
166-150	39036-39039	0.4	_	
166-151	39039-39040	)	_	
166-152	39041-39044	3.5	_	
166-153	39045-39046	(	_	
166-154	39046-39049	0.4	_	
166-155	39049-39050	)	_	
166-156	39054-39062	Wechsler	_	
166-157	39063-39067	Test	_	
166-158	39068-39070	of	_	
166-159	39071-39076	Adult	_	
166-160	39077-39084	Reading	_	
166-161	39085-39086	(	_	
166-162	39086-39098	Standardized	_	
166-163	39099-39104	Score	_	
166-164	39105-39117	Representing	_	
166-165	39118-39124	Verbal	_	
166-166	39125-39127	IQ	_	
166-167	39127-39128	)	_	
166-168	39129-39136	Cocaine	_	
166-169	39137-39144	Craving	_	
166-170	39145-39158	Questionnaire	_	
166-171	39159-39160	(	_	
166-172	39160-39165	grand	_	
166-173	39166-39171	total	_	
166-174	39172-39180	composed	_	
166-175	39181-39183	of	_	
166-176	39184-39189	total	_	
166-177	39190-39193	raw	_	
166-178	39194-39199	score	_	
166-179	39200-39204	from	_	
166-180	39205-39209	each	_	
166-181	39210-39220	individual	_	
166-182	39221-39225	item	_	
166-183	39225-39226	;	_	
166-184	39227-39236	subscales	_	
166-185	39237-39240	are	_	
166-186	39241-39249	averaged	_	
166-187	39250-39256	across	_	
166-188	39257-39262	items	_	
166-189	39262-39263	)	_	
